Document:

EX-10.16

 Exhibit 10.16 

FERRING INTERNATIONAL CENTER SA 

and 
 I-MAB 
  
  

 
  

LICENSE AND SUBLICENSE AGREEMENT 

  
 1 

 INDEX 
  

			
	1.	 	DEFINITIONS
		
	2.	 	GRANT OF RIGHTS
		
	3.	 	DEVELOPMENT
		
	4.	 	GOVERNANCE; JOINT STEERING COMMITTEE
		
	5.	 	EXCHANGE OF INFORMATION
		
	6.	 	COMMERCIALISATION
		
	7.	 	PAYMENTS AND FEES
		
	8.	 	INTELLECTUAL PROPERTY
		
	9.	 	TERM AND TERMINATION
		
	10	 	CONSEQUENCE OF TERMINATION
		
	11.	 	ACCRUED RIGHTS; SURVIVING OBLIGATIONS
		
	12.	 	GENERAL PERFORMANCE STANDARDS
		
	13.	 	MANUFACTURE AND SUPPLY
		
	14.	 	WARRANTIES, REPRESENTATIONS, INDEMNIFICATION AND INSURANCE
		
	15.	 	ASSIGNMENT
		
	16.	 	INDEPENDENT CONTRACTORS
		
	17.	 	NOTICES
		
	18.	 	ENTIRE AGREEMENT; WAIVER
		
	19.	 	SEVERABILITY
		
	20.	 	FURTHER ASSURANCE AND REGISTRATION
		
	21.	 	GOVERNING LAW; RELIEF
		
	22.	 	FORCE MAJEURE
		
	23.	 	DISPUTE RESOLUTION
		
	24.	 	EXECUTION IN COUNTERPARTS

  
 2 

 THIS LICENSE AND SUBLICENSE AGREEMENT (this “Agreement”) is effective as of 4th of November 2016 (the “Effective Date”), and is by and between FERRING INTERNATIONAL CENTER SA, a company organised and existing under the laws of Switzerland and having its
principal place of business at *** (“Ferring”) and I-MAB, a company organised and existing under the laws of Cayman Islands and having its principal place of business at ***, (“I-MAB”). Each party individually may be referred to herein as a “Party” and collectively both parties may be referred to herein as the “Parties.” 

PREAMBLE 
 WHEREAS, Ferring has an
exclusive license to certain Sublicensed Intellectual Property (as later defined herein) and has the right to grant sublicenses under the Sublicensed Intellectual Property with respect to the Licensed Compound and the Licensed Product (each as later
defined herein); 
 WHEREAS, Ferring also possesses certain Ferring Intellectual Property and Know-How (as later
defined herein) and has the right to grant licenses to the Ferring Intellectual Property and Know-How with respect to the Licensed Compound and the Licensed Product; and 

WHEREAS, Ferring wishes to grant to I-MAB, and I-MAB wishes to accept, a
license or a sublicense to its interests in the Ferring Intellectual Property and Sublicensed Intellectual Property, respectively, and a license to its Know-How to research, commercially develop, make, have
made, import, use, sell, dispose of, offer to sell or dispose of the Licensed Product through a diligent program of exploiting the Ferring Intellectual Property and Sublicensed Intellectual Property and
Know-How in the Territory and Optional Territory (if applicable) in accordance with the terms and conditions set forth below. 

  
 3 

 NOW THEREFORE, in consideration of the covenants and obligations expressed below, and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 
  

	1.	 DEFINITIONS 

For the purpose of this Agreement, the following words and phrases shall have the following meanings: 

 

	1.1	 “I-MAB Improvements” means any and all changes,
developments, enhancements, modifications, additions, or improvements to the Sublicensed Intellectual Property and/or Licensed Ferring Intellectual Property and Know-How made by or on behalf of I-MAB or its Affiliates or Sub-licensees or Sub-Sublicensees. 

 

	1.2	 “I-MAB IP” means
Know-How and Intellectual Property that is conceived, discovered, developed or otherwise made by or on behalf of I-MAB or its Affiliates or its Sub-licensees or Sub-Sublicensees under, or in connection with, this Agreement or otherwise related to the Licensed Compound or Licensed Product. I-MAB IP shall include I-MAB Improvements. 

  

	1.3	 “Adverse Event” means any untoward medical occurrence in a patient or an investigation subject
who has been administered the Licensed Product and which does not necessarily have to have a causal relationship with the exposure or use of the Licensed Product. For purposes of this Agreement, Adverse Event includes all noxious and unintended
response or symptom to the Licensed Product related to any dose of the Licensed Product, and any adverse reaction, the nature or severity of which is inconsistent with the applicable Licensed Product information. 

 

	1.4	 “Affiliate” means, with respect to a Person, any other Person that, directly or indirectly,
through one or more intermediaries, controls, is controlled by or is under common control with such Person. For purposes of this definition, “control” and, with correlative meanings, the terms “controlled by” and
“under common control with” means: (a) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership of voting securities, by contract relating to
voting rights or corporate governance, or otherwise; or (b) the ownership, directly or indirectly, of more than 50% of the voting securities or other ownership interest of a business entity (or, with respect to a limited partnership or other
similar entity, its general partner or controlling entity). 

  
 4 

	1.5	 “Applicable Law” means any and all applicable laws, statutes, orders, rules, regulations,
directives and guidelines that have legal effect, whether local, national, international or otherwise, existing from time to time, including any rules, regulations, guidelines or other requirements of the Regulatory Authorities.

  

	1.6	 “Business Day” means a day, other than a Saturday, Sunday, or public holiday on which banking
institutions are not authorized or required to close in China. 

  

	1.7	 “Calendar Quarter” means each successive period of three calendar months commencing on
January 1, April 1, July 1 and October 1. 

  

	1.8	 “Calendar Year” means each successive period of 12 calendar months commencing on
January 1 and ending on December 31. 

  

	1.9	 “CFDA” means the China Food and Drug Administration. 

 

	1.10	 “China” or “PRC” means the People’s Republic of China, which, for purposes of
this Agreement, excludes the Hong Kong Special Administrative Region (“Hong Kong”), the Macau Special Administrative Region, and Taiwan. 

  

	1.11	 “Clinical Data” means all data, reports and results with respect to the Licensed Compound and
the Licensed Product made, collected or otherwise generated under, or in connection with, the Clinical Studies. 

  

	1.12	 “Clinical Studies” or “Clinical Study” means human clinical trials for the
Licensed Product and any other tests and studies for the Licensed Product in human subjects. 

  

	1.13	 “Commercialization” means, with respect to the Licensed Product, any and all activities
(whether before or after Regulatory Approval) directed to the marketing, promotion, distribution and sale of the Licensed Product in the Field in the Territory or the Optional Territory (if applicable) after Regulatory Approval for commercial sale
has been obtained, including pre-launch and post-launch marketing, promoting, distributing, offering to commercially sell and commercially selling the Licensed Product, importing, exporting or transporting the
Licensed Product for commercial sale, conducting Clinical Studies that are not required to obtain or maintain Regulatory Approval for the Licensed Product for an indication, which may include epidemiological studies, modeling and pharmacoeconomic
studies, post-marketing surveillance studies, investigator sponsored studies and health economics studies and regulatory affairs (including interacting with Regulatory Authorities) with respect to the foregoing. When used as a verb,
“Commercializing” means to engage in Commercialization and “Commercialize” and “Commercialized” shall have corresponding meanings. 

  
 5 

	1.14	 “Development” means, with respect to the Licensed Product and Licensed Compound, all
activities related to research, preclinical and other non-clinical testing, test method development and stability testing, toxicology, formulation, Manufacture Process Development, Clinical Studies, including
Manufacturing in support thereof (but excluding any commercial Manufacturing), statistical analysis and report writing, the preparation and submission of Drug Approval Applications, regulatory affairs with respect to the foregoing and all other
activities necessary or reasonably useful or otherwise requested or required by a Regulatory Authority as a condition or in support of obtaining or maintaining a Regulatory Approval for such Licensed Product. When used as a verb,
“Develop” means to engage in Development. 

  

	1.15	 “Development Plan” means the plan for the Development of the Licensed Product as described in
Section 3.2, as updated from time to time pursuant to Section 3.2. 

  

	1.16	 “Dollars” or “$” means the United States Dollars. 

 

	1.17	 “Drug Approval Application” means: (i) the clinical trial application for new drugs (新药临床试验申请); (ii) the application for new drug certificate
(新药证书申请); and (iii) the drug approval number application
(药品批准文号申请), collectively, each as set forth in the PRC Pharmaceutical Administration Law, as may be amended from time to time (including
all additions, supplements, extensions and modifications thereto), or any corresponding foreign application in the Territory or the Optional Territory (if applicable). 

  
 6 

	1.18	 “Effective Date” means the date as of which this Agreement is effective which shall be the
date first written above. 

  

	1.19	 “Exploit” means, with respect to the Licensed Compound and/or the Licensed Product, to make,
have made, import, use, sell or offer for sale, including to research, Develop, Commercialize, register, Manufacture, have Manufactured, hold or keep (whether for disposal or otherwise), have used, export within the Territory or Optional Territory
(if applicable), transport, distribute, promote, market or have sold or otherwise dispose of the Licensed Product and “Exploitation” means the act of Exploiting the Licensed Product. 

 

	1.20	 “Ferring Improvements” means any and all changes, developments, enhancements, modifications,
additions, or improvements to the Sublicensed Intellectual Property and/or the Licensed Ferring Intellectual Property and Know-How made by or on behalf of Ferring or its Affiliates. 

 

	1.21	 “Ferring Intellectual Property” means the patent applications (until such time as such
applications or any of them are denied, abandoned or issued into patents) listed in Schedule B1 hereof and future patents and patent applications covering the Licensed Compound or Licensed Product, along with any future patents and patent
applications including continuations, divisionals and reissues as part of patents and extensions thereof including supplementary protection certificates and their equivalent. Ferring Intellectual Property includes Ferring Improvements. Schedule B1
shall be updated from time-to-time to reflect any new Ferring Intellectual Property, including Ferring Improvements. 

 

	1.22	 “Field” means any indication for medicinal use in humans, including rheumatoid arthritis.

  

	1.23	 “First Commercial Sale” means, with respect to the Licensed Product, the first sale by I-MAB, its Affiliates, Sublicensees or Sub-sublicensees, as applicable, to a Third Party of the Licensed Product in a country in the Territory or Optional Territory (if
applicable) after all required marketing and pricing or reimbursement approvals have been granted by the applicable Regulatory Authority for such country. 

  
 7 

	1.24	 “Force Majeure” means any significant unexpected event that is beyond the reasonable control
of a Party for which such Party cannot reasonably have been expected to have taken account as of the Effective Date, which significantly delays the Development Program set out in Appendix B and including, but without prejudice to the
foregoing generality, events resulting from an act of God, lightning, fire, flood, earthquake, accumulation of snow or ice, lack of water arising from weather or environmental problems, strike, lock-out or
other industrial disturbance, act of the public enemy, war declared or undeclared; threat of war; terrorist act; blockade, revolution, riot, insurrection, civil commotion, public demonstration, sabotage, act of vandalism, prevention from or
hindrance in obtaining any raw materials, energy or other supplies, explosion, fault or failure of plant or machinery (which could not have been prevented by good industry practice); government restraint, act of legislature or a directive or
requirement of the competent authority affecting a Party or its subcontractor providing that such Party or its subcontractor’s lack of funds shall not be interpreted as a cause beyond such Party’s reasonable control. 

 

	1.25	 “IND” means an Investigational New Drug Application submitted under the United States Federal
Food, Drug, and Cosmetic Act, as amended, and the rules and regulations promulgated thereunder (the “FD&C Act”), or an analogous application or submission with any analogous agency or Regulatory Authority outside of the
United States for the purposes of obtaining permission to conduct clinical trials. 

  

	1.26	 “Information” means any and all 

 

	(a)	 information relating to the business affairs, finances or commercial interests of a Party which is disclosed
pursuant to this Agreement in whatever form; 

  

	(b)	 Know-How; 

 

	(c)	 samples of Materials provided for testing; 

 

	(d)	 results of any tests performed with samples of Materials; 

 

	(e)	 such other written information whether provided in printed, hand-written, electronic or any other form, either
Party deems confidential that is provided to the other Party in writing pursuant to this Agreement. 

  
 8 

	1.27	 “Intellectual Property” means, collectively, all intellectual property rights (whether or not
patented or patentable) related to the purpose of this Agreement including, but not limited to, algorithms, approvals, certifications, chemical compounds, conceptual expressions, copyrights, trademarks, data, designs, formulae, inventions, patents,
patent rights, and prototypes. 

  

	1.28	 “Know-How” means technical and other information of
either Party that is not in the public domain, including information comprising or relating to concepts, discoveries, data, designs, formulae, ideas, information relating to Materials, inventions, methods, models, assays, research and/or development
plans, procedures, designs for experiments and tests and results of experimentation and tests (including results of research or development), processes (including manufacturing processes, specifications and techniques), laboratory records, chemical,
pharmacological, toxicological, clinical, analytical and quality control data, trial data, case report forms, data analyses, reports or summaries. 

  

	1.29	 “Korea” means the Republic of Korea. 

 

	1.30	 “Licensed Compound” means FE301, i.e., SGP130Fc fusion protein, an interleukin-6 inhibitor. 

  

	1.31	 “Licensed Know-How” means the Know-How contained or disclosed in the documents set forth on Schedule A, but excluding any Know-How to the extent claimed or covered by published patents or patent
applications of the Ferring Intellectual Property and Sublicensed Intellectual Property. 

  

	1.32	 “Licensed Product” means all pharmaceutical formulations in finished packaged form containing
the Licensed Compound covered by any patent or patent application as set out in Schedule B hereto and/or uses any other Ferring Intellectual Property or Sublicensed Intellectual Property or Know-How,
for use in the Field. 

  

	1.33	 “Manufacture” and “Manufacturing” mean, with respect to the Licensed
Compound and Licensed Product, all activities related to the production, manufacture, processing, filling, finishing, packaging, labeling, shipping, holding, Manufacture Process Development, stability testing, quality assurance or quality control of
the Licensed Product or any intermediate thereof. 

  
 9 

	1.34	 “Manufacturing Process” means the process used to manufacture the Licensed Compound and the
Licensed Product, including but not limited to the cell line that stably expresses the Licensed Compound, the process to grow the cell line in large scale incubators, the large-scale process to purify the Licensed Compound, and other activities
provided in 1.32. 

  

	1.35	 “Manufacture Process Development” means the process development, process qualification and
validation and scale-up of the process to manufacture the Licensed Compound and Licensed Product and analytic development and product characterization with respect thereto. 

 

	1.36	 “NDA” means a New Drug Application (which, for purposes of this Agreement, includes a
Biologics License Application) submitted to the United States Food and Drug Administration or any successor agency thereto (“FDA”) in accordance with the FD&C Act with respect to a pharmaceutical product (including all
additions, supplements, extensions and modifications thereto), or any other analogous application or submission with any Regulatory Authority in the Territory or the Optional Territory (if applicable), including, with respect to China, a Marketing
Authorization Application filed with the CFDA. 

  

	1.37	 “Net Sales” means, for any period, the gross amount invoiced by
I-MAB, its Sublicensees or any of its or their respective Affiliates for the sale of the Licensed Product (the “Invoiced Sales”), less deductions for: (a) normal and customary
trade, quantity and cash discounts and sales returns and allowances, including those granted on account of price adjustments, billing errors, rejected goods, damaged goods and returns, and chargebacks; (b) freight, postage, shipping and
insurance expenses to the extent that such items are included in the gross amount invoiced; (c) sales taxes and other governmental charges (including value added tax) to the extent billed separately on the invoice and actually paid in
connection with the sale but only to the extent actually included in gross sales; and (d) rebates and similar payments made with respect to sales paid for by any Regulatory Authority. Any of the deductions listed above that involves a payment
by I-MAB, its Sublicensees or any of its or their respective Affiliates shall be taken as a deduction in the Calendar Quarter in which the payment is accrued by such entity. The methodology for calculating (a)
- (d), on a country-by-country basis, shall conform to International Financial Reporting Standards consistently applied by I-MAB.
For purposes of determining the Net Sales, the Licensed Product shall be deemed to be sold when invoiced and a “sale” shall not include transfers or dispositions of the Licensed Product for
pre-clinical or clinical purposes or as samples, in each case, whether supplied without charge or not. 

  
 10 

 In the case of pharmacy incentive programs, hospital performance incentive programs,
chargebacks, disease management programs, similar programs or discounts on portfolio product offerings for the Licensed Product, all rebates, discounts and other forms of reimbursements shall be allocated on the basis on which such rebates,
discounts and other forms of reimbursements were actually granted or, if such basis cannot be determined, in accordance with I-MAB’s, its Sublicensees’ or its or their respective Affiliates’
existing allocation method. 
 I-MAB’s or any of its Sublicensees’ or its or their
respective Affiliates’ transfer of the Licensed Product to an Affiliate or Sublicensee shall not result in any Net Sales. In addition, Net Sales shall not include the sales of any Licensed Product to be used in clinical trials, for research or
other non-commercial purposes, or supplied as commercial samples or as charitable or humanitarian donations (whether supplied without charge, at a substantial discount or otherwise). 

 

	1.38	 “Optional Territory” means countries of North America (i.e., Canada, the United States and
Mexico) and the European Union and Japan to be mutually agreed in writing by the Parties within thirty (30) days of receipt of notice from I-MAB that it wishes to exercize its option right to obtain an
exclusive license to the Optional Territory, cf. Clause 2.2 below. For the purposes of this Agreement, the United Kingdom shall be considered a member state of the European Union, even if it exits the European Union during the Term.

  

	1.39	 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department
or agency of a government. 

  
 11 

	1.40	 “Phase IB” means an initial Clinical Study that assesses safety and tolerability, as well as
the pharmacokinetic and pharmacodynamic responses of the Licensed Product at multiple doses in the Asian rheumatoid arthritis patient population, as further described in the Development Plan. 

 

	1.41	 “Phase II Clinical Trial” means that certain Clinical Study, the principal purpose of which is
to determine safety and efficacy of the Licensed Product in the target patient population or a similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to Applicable Law or otherwise, including the Phase II
clinical trial referred to in Article 31 of the Provisions for Drug Registration Administration, promulgated by the CFDA and as may be amended from time to time. 

 

	1.42	 “Phase IIA” means that part of the Phase II Clinical Trial designed to assess dosing
requirements and efficacy of the Licensed Product. For the purposes of this Agreement, “completion of Phase IIA” means that stage of the Phase II Clinical Trial when the efficacy of the Licensed Product as specified in the
Development Plan has been observed and properly recorded. 

  

	1.43	 “Reasonable Commercial Efforts” means with respect to the Development and Commercialization of
the Licensed Product, the level of efforts and resources that are consistent to those efforts and resources commonly used by a similarly situated company in the pharmaceutical industry for comparable products with similar commercial and scientific
potential at a similar stage in their lifecycle, taking into consideration their safety, efficacy, their cost to develop, the competitiveness of alternative products in or reasonably anticipated to enter the marketplace, their proprietary position,
the likelihood of regulatory approval with appropriate and adequate labelling, their pricing, reimbursement, cost or productions, sales and marketing, any other reasonable commercial considerations and on a market by market basis.

  

	1.44	 “Recognised Agent” means a Third Party through which
I-MAB regularly distributes and sells its products in the Territory or Optional Territory (as applicable) where I-MAB has no Affiliate and where sales of I-MAB products are a very minor proportion of total worldwide I-MAB sales. 

  
 12 

	1.45	 “Regulatory Approval” means, with respect to the Licensed Product in a country in the
Territory or the Optional Territory (as applicable), any and all approvals, licenses, registrations or authorizations of any Regulatory Authority necessary to commercially market, promote, distribute or sell the Licensed Product in such country,
including, where applicable: (a) pricing or reimbursement approval in such country; (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or
authorization related thereto); and (c) labeling approval. 

  

	1.46	 “Regulatory Authority(ies)” means any national, multinational, state, provincial or local
regulatory agency, department, bureau or other governmental entity with authority over the testing, manufacture, use, storage, import, promotion, marketing and sale of a therapeutic product in the Territory and/or Optional Territory (as applicable)
necessary for the commercialization of the Licensed Product. 

  

	1.47	 “Regulatory Documentation” means all: (a) applications (including all INDs and Drug
Approval Applications), registrations, licenses, authorizations and approvals (including all Regulatory Approvals); (b) correspondence and reports submitted to or received from Regulatory Authorities (including minutes and official contact reports
relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all regulatory drug lists, advertising and promotion documents, Adverse Event files and complaint files; and (c) Clinical
Data and any other data contained in any of the foregoing, in each of ((a), (b) and (c)), relating to the Licensed Product. 

  

	1.48	 “RMB” means Renminbi, the official currency of the PRC. 

 

	1.49	 “Royalty Term” means the period beginning on the date of First Commercial Sale in any country
of the Territory and/or Optional Territory (as applicable) and expiring on a country by country basis: (i) fifteen (15) years from the date of launch; or (ii) on expiration of the last to expire patent rights of the Ferring Intellectual
Property or Sublicensed Intellectual Property in the Territory and/or Optional Territory (as applicable) that includes a Valid Claim covering the development, making, using or selling of the Licensed Compound or Licensed Product, whichever is later.

  
 13 

	1.50	 “Sublicensed Intellectual Property” means the patents and patent applications (until such time
as such applications or any of them are denied, abandoned or issued into patents) listed in Schedule B2 hereof and any future patents and patent applications including continuations, divisionals and reissues as part of patents and extensions thereof
including supplementary protection certificates and their equivalent and Know-How under which Ferring is licensed with the right to sublicense. 

 

	1.51	 “Sublicensee” means an Affiliate of I-MAB or a Third
Party that is granted a sublicense to Ferring Intellectual Property and Know-How by I-MAB in accordance with Section 2.3. 

 

	1.52	 “Sub-sublicensee” means an Affiliate of I-MAB or a Third Party that is granted a sub-sublicense to Sublicensed Intellectual Property by I-MAB in accordance with
Section 2.3 

  

	1.53	 “Territory” means China (including Hongkong, Macau), Taiwan and Korea. 

 

	1.54	 “Third Party” means any Person other than a Party to this Agreement and such Party’s
Affiliate. 

  

	1.55	 “Trademark” means any word, name, symbol, color, designation or device or any combination
thereof that functions as a source identifier, including any trademark, trade dress, service mark, trade name, brand name, logo or business symbol, whether or not registered, together with any goodwill associated therewith. 

 

	1.56	 “Valid Claim” means with respect to a particular country in the Territory or the Optional
Territory (as applicable): (a) any claim of an issued and unexpired patent in such country that: (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or governmental agency of competent jurisdiction that
is unappealable or unappealed within the time allowed for appeal; and (ii) has not been abandoned, disclaimed, denied or admitted to be invalid or unenforceable through reissue or disclaimer or otherwise in such country; or (b) any claim
of a pending patent application that has not been abandoned or finally disallowed without the possibility of appeal or re-filing of the application. 

  
 14 

	2.	 GRANT OF RIGHTS 

 

	2.1	 Territory. Ferring hereby grants to I-MAB: i) an exclusive
(including with regard to Ferring and its Affiliates, but excluding any non-exclusive license granted to Conaris by operation of the Development and License Agreement dated November 11, 2008) license,
with the right to grant sublicenses to Sublicensees in accordance with Section 2.3 in whole or in part, under Ferring Intellectual Property and Know-How; and ii) an exclusive (including with regard to
Ferring and its Affiliates) sublicense, with the right to grant sub-sublicenses to Sub-sublicensees in accordance with Section 2.3 in whole or in part, under
Sublicensed Intellectual Property, to research, develop, make, have made, import, use, sell and offer to sell the Licensed Compound and the Licensed Product in the Field in the Territory. 

 

	2.2	 Option Right of I-MAB to the Optional Territory (as applicable).
Ferring hereby grants to I-MAB: i) a non-exclusive option right to obtain an exclusive license, with the right to grant sublicenses to Sublicensees in accordance
with Section 2.3 in whole or in part, under Ferring Intellectual Property and Know-How; and ii) a non-exclusive option right to obtain an exclusive sublicense, with
the right to grant sub-sublicenses to Sub-sublicensees in accordance with Section 2.3 in whole or in part, under Sublicensed Intellectual Property, to research,
develop, make, have made, import, use, sell and offer to sell the Licensed Product in the Field in the mutually agreed upon countries in the Optional Territory, and for the avoidance of doubt Ferring shall retain the right to research, develop,
make, have made and use the Licensed Compound and/or Licensed Product in the Optional Territory for the purposes of this Agreement, including the right to grant sub-licenses to a Third Party. Ferring may
actively pursue to grant license and sublicense rights to one or more Third Party to research, develop, make, have made, import, use, sell and offer to sell the Licensed Compound and the Licensed Product in the Field in any country outside the
Territory, provided however that notwithstanding the aforementioned, Ferring shall not be entitled to grant any rights under the Ferring Intellectual Property and Sublicensed Intellectual Property to a Third Party without first providing written
notice of its intentions to do so of 30 (thirty) days to I-MAB, and in such event I-MAB shall be entitled to have a first right of refusal to exercise the option right
and to obtain exclusive license rights to the Optional Territory, subject to payment of the Initial Payment Covering the Optional Territory, cf. Clause 7.1.2 of this Agreement. If I-MAB notifies that it does
not want to obtain an exclusive license to the Optional Territory, such notice to be received by Ferring in writing within 30 (thirty) days after receipt of Ferring’s notice, cf. above, I-MAB foregoes of
the option right and Ferring shall be free to enter into the agreement with any Third Party. 

  
 15 

	2.3	 Sublicenses and Sub-sublicenses.
I-MAB shall have the right to grant sublicenses and/or sub-sublicenses (as applicable) to an Affiliate or a Third Party to research, develop, make, have made,
import, use, sell and offer to sell the Licensed Product in the Field in the Territory and the mutually agreed upon counties in the Optional Territory (as applicable, cf. Clause 2.2 above). Any sublicenses and/or
sub-sublicenses granted by I-MAB shall be subject to the terms and conditions of this Agreement. I-MAB shall inform Ferring in
writing of: i) the name and location of the Sublicensee and/or Sub-sublicensee; ii) the commercial terms in so far as required to provide Ferring with the requisite information for the purposes of section 7.5
below; and iii) the territory and indications included in the sublicense and/or sub-sublicense within thirty (30) days of the grant of the sublicense and/or
sub-sublicense. Ferring shall be entitled to request a copy of the agreements entered into with the respective sublicensees and/or sub-sublicensees.

  

	2.4	 Disclosure and Transfer. Ferring shall share with I-MAB or any
of its designees, as reasonably requested by I-MAB, the Regulatory Documentation in Ferrings’s control with respect to the Licensed Compound and the Licensed Product within sixty (60) days after the
Effective Date. 

  

	2.5	 Licensed Know-How Disclosure and Materials Transfer

 2.5.1 In General. Ferring shall deliver to I-MAB or any of its
designees, as reasonably requested by I-MAB: (a) within thirty (30) days after the Effective Date the Licensed Know-How set forth in Schedule A; and
(b) within thirty (30) days of a request made by I-MAB to Ferring, the agreed portion of the amount of Licensed Compound and the Licensed Product in Ferring’s inventory as described in Schedule
C, and all Manufacturing and batch records associated with the Materials in Ferring’s Control. I-MAB or its designee may inspect the received Materials, and shall notify Ferring in writing within a
reasonable period of time after the receipt thereof in the event it rejects the Materials. Upon and only upon acceptance of the Materials and subject to Section 13.1.2, I-MAB shall pay Ferring the book
value plus the Shipping Cost for the amount of Licensed Compound and/or the Licensed Product received. Notwithstanding anything in this Agreement to the contrary, I-MAB will have the right, effective upon the
Effective Date, to include Licensed Know-How in I-MAB’s Regulatory Documentation for filing or submission to, or correspondence or discussions with, Regulatory
Authorities, and the right to grant a sublicense under the foregoing right to a Sublicensee to include Licensed Know-How in the Sublicensee’s Regulatory Documentation for filing or submission to, or
correspondence or discussions with, Regulatory Authorities. 

  
 16 

 2.5.2 Assistance. During the Term, Ferring shall give
I-MAB and all Sublicensees and Sub-sublicensees reasonable access to Ferring personnel familiar with the Licensed Compound and the Licensed Product, including without
limitation personnel having knowledge, custody or expertise in connection with the Licensed Know-How, Clinical Data, Clinical Studies, formulation development, Regulatory Documentation and Manufacture Process
Development thereof The assistance referred to above will be provided to I-MAB and I-MAB’s designated experts by Ferring from its St. Prex headquarters and/or other
Ferring locations as determined by Ferring. Subject to advance agreement as to estimated amount, expenses incurred by Ferring in the provision of assistance at sites other than those mentioned above will be reimbursed by I-MAB or the I-MAB Sub-licensee, subject to provision of documented evidence. 

2.5.3 Delivery of Manufacturing Process. Within thirty (30) days of receipt of a written notice from
I-MAB of its readiness to initiate IND-enabling Clinical Studies, Ferring shall transfer to I-MAB or any of its designees at I-MAB’s cost, as directed by I-MAB, Ferring’s technology under Ferring’s Control for the commercial-scale Manufacturing process, to the extent the same has not been delivered to I-MAB in its entirety by the time such written notice is received by Ferring. If materials, know-how and Intellectual Property concerning the Manufacturing Process are owned
by and/or under the control of the Third Party, I-MAB shall be responsible itself for obtaining license rights to such materials, know-how and Intellectual Property from
the respective Third Party, and Ferring will use reasonable commercial efforts to assist I-MAB and the Third Party in such negotiations in order for I-MAB or its
designate to receive such materials, know-how and Intellectual Property within China. I-MAB shall not sublicense such material,
know-how and Intellectual Property without the Third Party’s written approval. 

  
 17 

 2.5.4 License to Clinical Data. I-MAB hereby
grants to Ferring a nonexclusive and royalty-free right and license to use all pre-clinical data and Clinical Data generated by I-MAB pursuant to this Agreement through
the Development of the License Compound and Licensed Product for any purpose outside the Territory and the Optional Territory (if applicable). 
  

	3.	 DEVELOPMENT 

  

	3.1	 In General. I-MAB shall use Reasonable Commercial Efforts to
Develop the Licensed Product in the Field in the Territory at its own cost and expense in accordance with the Development Plan and, subject to the exercise of the option right to receive a license in the Optional Territory, cf. Clause 2.2 above, in
the agreed upon countries in the Optional Territory (as applicable), Develop the Licensed Product in the Field in the Optional Territory (as applicable) at its own cost and expense in accordance with a supplemental development plan to be mutually
agreed upon by the Parties upon the completion of Phase IIA in the Territory, which shall be incorporated into and become a part of this Agreement. If, after good faith discussions the parties are not able to agree upon the supplemental development
plan, I-MAB’s position shall prevail. 

  

	3.2	 Development Plan. The initial Development Plan, which covers the period from the Effective Date through
completion of Phase IB, shall be jointly developed and agreed upon by the Parties within 45 days after the Effective Date, which shall then be incorporated into and become a part of this Agreement. Starting from the first quarter of 2017 and for
each Calendar Year or partial Calendar Year (as applicable) thereafter during the Term, I-MAB shall prepare an update to the Development Plan and submit such updated Development Plan to Ferring for its review.
Each update to the Development Plan shall set forth for the applicable Calendar Year or partial Calendar Year the Development objectives, the planned Clinical Studies and other Development activities and the contemplated timelines for the foregoing.
I-MAB shall manage the preparation of each such update so that it is submitted to Ferring for its review at least ninety (90) days prior to the end of the then-current Calendar Year. In addition, I-MAB may propose updates to the Development Plan to Ferring from time to time as appropriate in light of changed circumstances. If Ferring does not approve any element of an update to the Development Plan proposed
by I-MAB, then the Parties shall discuss in good faith Ferring’s concerns with respect thereto. If, after good faith discussions the parties are not able to agree upon the supplemental development plan,
I-MAB’s position shall prevail. 

  
 18 

	3.3	 Diligence. I-MAB shall use Reasonable Commercial Efforts to
Develop, obtain and maintain Regulatory Approvals for, the Licensed Product for use in the Field in the Territory and the Optional Territory (as applicable) in furtherance of the Development of the Licensed Product for the Field in the Territory and
the Optional Territory (as applicable). Ferring shall use Reasonable Commercial Efforts to perform activities assigned to it in the Development Plan and the supplemental development plan(s) (as applicable) in furtherance of the Development Plan of
the Licensed Product in the Field in the Territory and the Optional Territory (as applicable). 

  

	3.4	 Regulatory Matters. I-MAB shall have the right and
responsibility for preparing, obtaining and maintaining Drug Approval Applications and any other Regulatory Approvals, and for conducting communications with the Regulatory Authorities, for the Licensed Product in the Territory and the Optional
Territory (as applicable). All Regulatory Approvals relating to the Licensed Product with respect to the Territory and the Optional Territory (as applicable) shall be owned by, and shall be the sole property and held in the name of, I-MAB or its designated Affiliate. Ferring hereby shares with I-MAB all Regulatory Documentation in its control for the Licensed Compound and/or Licensed Product (including
any existing Regulatory Approvals) owned by Ferring and held in Ferring’s name in the Territory and Optional Territory (as applicable) as of the Effective Date. 

 

	3.5	 Subcontracting. I-MAB may freely subcontract the exercise of its
rights and the performance of its obligations under this Article 3; provided that I-MAB informs Ferring in writing the name of the third party contractor and provided that
I-MAB remains responsible to Ferring and its Affiliates, officers, servants or agents, for all activities sub-contracted and shall be responsible to, liable to and
indemnify Ferring in the same terms as according to this Agreement for any loss or damage attributable to any negligent act or omission or misconduct on the part such subcontractor, its Affiliates, its officers, servants or agents.

  
 19 

	3.6	 In the event that I-MAB elects for any reason not to continue with the
pre- clinical or clinical development of any Licensed Product in any and all indications or in any other way resolves not to make any further attempts aimed at commercializing any Licensed Product in a particular country of the Territory and/or
Optional Territory (as applicable), such election to be notified to Ferring as soon as practicably possible, the licenses and sublicenses in such country granted under this Agreement will be terminated and Ferring will receive from I-MAB an irrevocable, royalty free, unlimited and exclusive license to use in such country all I-MAB IP, Intellectual Property and
Know-How related thereto including but not limited to I-MAB Improvements and any I-MAB
Know-How related to the Licensed Compound and Licensed Product generated subsequent to the Effective Date. In addition, in such event, I-MAB shall provide to Ferring all
I-MAB IP, Intellectual Property, Information and Know-How related thereto including but not limited to I-MAB Improvements and any
Know-How related to the Licensed Product generated subsequent to the Effective Date. 

  

	4.	 GOVERNANCE; JOINT STEERING COMMITTEE 

 

	4.1	 Formation and Role. Within thirty (30) days after the Effective Date, the Parties shall establish a
Joint Steering Committee (the “Joint Steering Committee” or “JSC”) to oversee the Development and Commercialization of the Licensed Product under this Agreement. The JSC shall not have any power to bind either Party or to make
any tactical or day-to-day operational decisions with respect to either Party’s activities under this Agreement. 

 

	4.2	 Members. Each Party shall initially appoint two (2) representatives to the JSC, each of whom shall
be a senior officer of the applicable Party. The JSC may change its size from time to time by mutual written agreement of its members; however, at all times the JSC shall be comprised of equal members from each Party. Each Party may replace its
representatives at any time upon written notice to the other Party specifying the prior representative(s) and their replacement(s). Either Party may designate substitutes for its representatives if one (1) or more of such Party’s
designated representatives are unable to be present at a meeting. The JSC shall have two (2) co-chairpersons, and Ferring and I-MAB shall each have the right to
appoint one co-chairperson on an annual basis. The role of the co-chairpersons shall be to convene and preside at the meetings of the JSC and to ensure the preparation
of JSC meeting minutes, but the co-chairpersons shall have no additional powers or rights beyond those held by other JSC representatives. 

  
 20 

	4.3	 Meetings. The JSC shall meet at least one (1) time per Calendar Quarter during the Term unless the
Parties mutually agree in writing to a different frequency for such meetings. Either Party may also call a special meeting of the JSC (by videoconference or teleconference) by at least ten (10) Business Days prior written notice to the other
Party in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting, and such Party shall provide the JSC no later than ten (10) Business Days prior to the special meeting
with materials reasonably adequate to facilitate discussion of the issue. No later than ten (10) Business Days prior to any meeting of the JSC, the co-chairpersons of the JSC shall jointly prepare and
circulate an agenda for such meeting; provided, however, that either Party may propose additional topics to be included on such agenda, either prior to or in the course of such meeting, and such additional topic may be covered with the consent of
the other Party. The JSC may meet in person, by videoconference or by teleconference, provided, however, at least one (1) meeting per Calendar Year shall be in person unless the Parties mutually agree in writing to waive such requirement in
lieu of a videoconference or teleconference. In-person JSC meetings shall be held at locations in China and Europe alternately selected by I-MAB and by Ferring. Each
Party shall bear the expense of its respective JSC members’ participation in the JSC meetings. The JSC co-chairpersons shall jointly send draft meeting minutes to each member of the JSC for review and
approval within ten (10) Business Days after each JSC meeting. Such minutes shall be deemed approved unless one or more members of the JSC objects to the accuracy of such minutes within ten (10) Business Days of receipt.

  
 21 

	5.	 EXCHANGE OF INFORMATION 

 

	5.1	 Promptly after the Effective Date, I-MAB and Ferring shall meet to
discuss the scope and contents of a mutual exchange of Know-How relevant to the Development Plan, and shall, upon reaching agreement, promptly exchange such Know-How.
Thereafter each of the Parties shall periodically meet to discuss the exchange of any further Know-How which may become known to them and I-MAB shall inform Ferring by
written reports on a three times a year basis of its progress in preclinical and clinical development, the development of a commercial manufacturing process for the Licensed Compound and the Licensed Product and the progress of applications to the
Regulatory Authorities for clinical trials and commercial sale. 

  

	5.2	 During the term of this Agreement and for 10 (ten) years thereafter, irrespective of any termination earlier
than the expiration of the term of this Agreement neither Party shall reveal or disclose to any Third Party any Information received from the other Party or otherwise developed by either Party in the performance of activities in furtherance of this
Agreement or the existence of this Agreement and the collaboration between I-MAB and Ferring as set out herein, without first obtaining the written consent of that other Party, except as may be otherwise
provided herein, or: (a) for securing essential or desirable authorizations, privileges or rights from governmental agencies; (b) as required to be disclosed to a government agency; (c) as necessary to file or procure patent
applications relating to the Licensed Product pursuant to Section 8; or (d) to carry out any litigation concerning the Licensed Product. Consent or the reason for refusal shall be provided in a prompt and timely manner. This obligation of
confidentiality shall not apply to Know-How disclosed to Ferring in the case of termination by Ferring pursuant to Sections 9.2 or 9.3 or to such information that is or becomes a matter of public knowledge but
only in relation to such Know-How and Information that is specifically required by Ferring for the sole purpose of being able to commercialize the Licensed Product where Ferring has acquired such rights
pursuant to sections 9.2 or 9.3, or is already in the possession of the receiving Party, or is disclosed to the receiving Party by a Third Party having the right to do so, or is subsequently independently developed by employees or contractors of the
receiving Party or Affiliates thereof who have no knowledge of the confidential information disclosed. The Parties shall take reasonable measures to ensure that no unauthorized use or disclosure is made by others to whom access to such information
is granted. 

  
 22 

	5.3	 Nothing herein shall be construed as preventing either Party from disclosing any Information received
from the other Party to an Affiliate, Sublicensee, Sub-sublicensee, Recognised Agent or subcontractor of the receiving Party, provided that such Affiliate, Sublicensee,
Sub-sublicensee, Recognised Agent or subcontractor has undertaken a similar obligation of confidentiality with respect to the Information. 

 

	5.4	 In the event that a court or other legal or administrative tribunal directly or through an appointed
master, trustee or receiver assumes partial or complete control over the assets of a Party to this Agreement based on the insolvency or bankruptcy of such Party, the bankrupt or insolvent Party shall promptly notify the court or other tribunal:

  

	 	(i)	 that Information received from the other Party under this Agreement remains the property of the other Party;
and 

  

	 	(ii)	 of the confidentiality obligations under this Agreement. 

In addition, the bankrupt or insolvent Party shall, to the extent permitted by law, take all steps necessary or desirable to maintain the
confidentiality of the other Party’s Information and to ensure that the court, other tribunal or appointee maintains such Information in confidence in accordance with the terms of this Agreement. 

 

	5.5	 No public announcement or other disclosure to Third Parties concerning the structure or terms of this
Agreement or any work being carried out hereunder or the results of such work shall be made either directly or indirectly by any Party to this Agreement, except as may be legally required or as may be required for recording purposes, without first
obtaining the approval of the other Party and agreement upon the nature and text of such announcement or disclosure, which approval and agreement shall not be unreasonably withheld. The Party desiring to make any such public announcement or other
disclosure shall inform the other Party of the proposed announcement or disclosure in reasonably sufficient time prior to public release and shall provide the other Party with a written copy thereof to allow such other Party to comment upon such
announcements or disclosure; provided, however, that the contents of any public announcement, press release or similar publicity which has been reviewed and approved can be subsequently re-released by either
Party in any form without a requirement for re-approval provided the re-releasing Party advises the other Party prior to publication of the re-release and identifies the media in which it is to be published. 

  
 23 

	5.6	 Each Party agrees that it shall co-operate fully with the other
with respect to all disclosures regarding this Agreement to, or public disclosures as required by any other governmental or regulatory body, provided that the disclosing Party uses commercially reasonable efforts to seek confidential treatment for
any Information of either Party included in any such disclosure. 

  

	5.7	 Publications. Each Party recognizes that the publication of papers regarding Information and activities
under this Agreement, including oral presentations and abstracts, may be beneficial to both Parties, provided that such publications are subject to reasonable controls to protect confidential information. Accordingly, each Party shall have the right
to review and approve any paper proposed for publication by the other Party, including any oral presentation or abstract, that contains Clinical Data or pertains to results of Clinical Studies or includes other Information generated under this
Agreement or that otherwise includes confidential information of the other Party. Before any such paper is submitted for publication or an oral presentation is made, the publishing or presenting Party shall deliver a complete copy of the paper or
materials for oral presentation to the other Party at least sixty (60) days prior to submitting the paper to a publisher or making the presentation. The other Party shall review any such paper and give its comments to the publishing or
presenting Party within sixty (60) days after the delivery of such paper to such other Party. With respect to oral presentation materials and abstracts, the other Party shall make reasonable efforts to expedite review of such materials and
abstracts, and shall return such items as soon as reasonably practicable to the publishing or presenting Party with appropriate comments, if any, but in no event later than sixty (60) days after the date of delivery to such other Party. Failure
to respond within such sixty (60) days shall be deemed approval to publish or present. Notwithstanding the foregoing, the publishing or presenting Party shall comply with the other Party’s written request to: (a) delete references to
such other Party’s confidential information in any such paper or presentation; or (b) withhold publication of any such paper or any presentation of same for an additional one hundred twenty (120) days in order to permit the Parties to
obtain patent protection if either Party deems it necessary. Any publication shall include recognition of the contributions of the other Party according to standard practice for assigning scientific credit, either through authorship or
acknowledgement, as may be appropriate. Each Party shall use its respective Reasonable Commercial Efforts to cause investigators and institutions participating in clinical studies for the Licensed Product with which it contracts to agree to terms
substantially similar to those set forth in this Section 5.7, which efforts shall satisfy such Party’s obligations under this Section 5.7 with respect to such investigators and institutions. 

  
 24 

	5.8	 Nothing in this Agreement shall be construed as preventing or in any way inhibiting either Party from
complying with statutory and regulatory requirements governing the development, manufacture, use and sale or other distribution of the Licensed Product in any manner that it reasonably deems appropriate including, for example, by disclosing to
Regulatory Authorities Information or other information received from the other Party or Third Parties. 

  

	6.	 COMMERCIALISATION 

 

	6.1	 General. I-MAB shall use Reasonable Commercial Efforts to obtain
approval of the Regulatory Authorities and to promote, market, distribute and sell the Licensed Product in the Field in all countries of the Territory and/or Optional Territory (as applicable, cf. Clause 2.2 above), in each case at its own cost and
expense. Following receipt by I-MAB or its Affiliate, Sublicensee or Sub-sublicensee of marketing approval for the Licensed Product in a country or region of the
Territory and/or Optional Territory (as applicable), I-MAB shall start, and shall ensure that its Affiliate or its Sublicensee and/or its Sub-sublicensee start the
marketing and sales of the Licensed Product and to use its Reasonable Commercial Efforts to promote, market, distribute and sell the Licensed Product consistent with accepted pharmaceutical business practice and applicable legal requirements.

  
 25 

	6.2	 Sales and Distribution. I-MAB shall be responsible for:
(a) invoicing and booking sales; (b) establishing all terms of sale (including pricing and discounts); (c) warehousing and distributing; and (d) handling all returns, recalls and withdrawals, order processing, collection, inventory
and receivables, in each of (a) through (d), with respect to the Licensed Product in the Territory and the Optional Territory (as applicable). 

  

	6.3	 Product Trademarks. I-MAB shall have the right to determine the
Product Trademarks to be used with respect to the Licensed Product in the Field in the Territory and the Optional Territory (as applicable), and shall own all right, title and interest in and to the Product Trademarks. 

 

	6.4	 Markings. To the extent required by Applicable Law in a country in the Territory or the Optional
Territory (if applicable), the promotional materials, packaging and Product Labeling for the Licensed Product used by I-MAB, its Sublicensees, Sub-sublicensees or its or
their respective Affiliates in connection with the Licensed Product in such country shall contain the logo and corporate name of the manufacturer. 

  

	6.5	 Subcontracting. I-MAB may subcontract the Commercialization of
the Licensed Product in the Field in the Territory and the Optional Territory (if applicable); provided that any agreement pursuant to which I-MAB engages such subcontractor shall be consistent in all material
respects with this Agreement (where applicable) and provided that I-MAB informs Ferring in writing the name of the third party contractor and provided that I-MAB remains
responsible to Ferring and its Affiliates, officers, servants or agents, for all activities sub-contracted and shall be responsible to, liable to and indemnify Ferring in the same terms as according to this
Agreement for any loss or damage attributable to any negligent act or omission or misconduct on the part such subcontractor, its Affiliates, its officers, servants or agents. 

 

	6.6	 Meetings. At the request of Ferring, the Parties shall meet annually to discuss sales of the Licensed
Product in the Territory and/or Optional Territory (as applicable), and I-MAB shall inform Ferring of its marketing strategy for the Licensed Product. 

 

	6.7	 No Launch. In the event I-MAB shall decide not to launch any
Licensed Product in a particular country in the Territory and/or Optional Territory (as applicable), either by itself or through an Affiliate, a Recognised Agent, a Sublicense or a Sub-sublicensee, or Sub-contractor, I-MAB will immediately inform Ferring in writing of the reason for its decision and Ferring shall be entitled to unilaterally delete such country from the
Territory and/or Optional Territory (as applicable) without a notice period. In this case, I-MAB undertakes to transfer free of charge to Ferring any authorization to market a Licensed Product and its Product
Trademarks for such Licensed Product in such country that I-MAB may previously have acquired and to cooperate fully in the transfer of sales of such Licensed Product if any in such country to Ferring or to a
Third Party designated by Ferring and shall supply at cost Licensed Product or have it supplied to Ferring or its designee for such sale. 

  
 26 

	7.	 PAYMENTS AND FEES 

 

	7.1	 Initial Payments. 

7.1.1 Initial Payment Covering Territory. The initial non-refundable fee to be paid by I-MAB to Ferring for exclusivity in the Territory shall be Two Million Dollars ($2,000,000), payable within forty five (45) days after the Effective Date. 

7.1.2 Initial Payment Covering Optional Territory. Within sixty (60) days after the license grant by Ferring to I-MAB and the determination of the countries in the Optional Territory, cf. Clause 2.2 above, I-MAB shall pay Ferring Three Million Dollars ($3,000,000) as the initial non-refundable fee. 

  
 27 

	7.2	 Milestone Payments. 

7.2.1 Development Milestones in the Territory. I-MAB shall pay Ferring each of the following non-refundable, non-creditable milestone payments within sixty (60) days after the achievement of the corresponding Milestone Event. For clarity, each of the following
milestone payments shall be made only once and upon the first occurrence of the corresponding Milestone Event, regardless of the number of countries in which the Licensed Product achieves the applicable Milestone Event: 

 

			
	 Milestone Event
	  	 Milestone Payment

	Completion of Phase IB in the Territory	  	One Million Five Hundred Thousand Dollars ($1,500,000)
		
	Completion of Phase IIA study report in the Territory	  	Three Million Dollars ($3,000,000)
		
	NDA submission in the Territory	  	Five Million Dollars ($5,000,000)
		
	NDA approval in the Territory	  	Five Million Dollars ($5,000,000)

 7.2.2 Development Milestones in the Optional Territory. I-MAB
shall pay Ferring each of the following non-refundable, non-creditable milestone payments within sixty (60) days after the achievement of the corresponding
Milestone Event. For clarity, each of the following milestone payments shall be made only once and upon the first occurrence of the corresponding Milestone Event, regardless of the number of countries in which the Licensed Product achieves the
applicable Milestone Event: 
  

			
	 Milestone Event
	  	 Milestone Payment

	NDA submission in the United States	  	Ten Million Dollars ($10,000,000)
		
	NDA submission in the European Union	  	Five Million Dollars ($5,000,000)
		
	NDA approval in the United States	  	Ten Million Dollars ($10,000,000)
		
	NDA approval in the European Union	  	Five Million Dollars ($5,000,000)

 7.2.3 Determination that Milestone Events Have Occurred. I-MAB
shall notify Ferring promptly of the achievement of each Milestone Event. In the event that, notwithstanding the fact that I-MAB has not provided Ferring with such a notice, Ferring believes that any such
Milestone Event has been achieved, it shall so notify I-MAB in writing and the Parties shall promptly meet and discuss in good faith whether such Milestone Event has been achieved. Any dispute under this
Section 7.2.3 regarding whether or not a Milestone Event has been achieved shall be subject to resolution in accordance with Sections 21 and 23. 

  
 28 

	7.3	 Royalties. 

7.3.1 Royalty Rates in the Territory. In connection with the grant of the licenses and sublicenses under the Licensed Know-How and Sublicensed Intellectual Property in the Territory pursuant to Section 2.1, during the Royalty Term, I-MAB shall pay Ferring a
non-refundable, non-creditable royalty on Net Sales of the Licensed Product in the Territory in each Calendar Year (or partial Calendar Year), as follows, as calculated
by multiplying the applicable royalty rate in the table below by the corresponding amount of incremental Net Sales of all Licensed Products: 
  

					
	 That portion of Net Sales of the Licensed Product in the Territory in a

Calendar Year that is:
	  	Royalty Rate	 
	 Less than or equal to Five Hundred Million RMB (RMB500,000,000)
	  	 	6	% 
	 Greater than Five Hundred Million RMB (RMB500,000,000)
	  	 	8	% 

 7.3.2 Royalty Rates in the Optional Territory. In connection with the grant of the licenses and
sublicenses under the Licensed Know-How and Sublicensed Intellectual Property in the Optional Territory pursuant to Section 2.2, during the Royalty Term, I-MAB
shall pay Ferring a non-refundable, non-creditable royalty on Net Sales of the Licensed Product in the Optional Territory in each Calendar Year (or partial Calendar
Year), as follows, as calculated by multiplying the applicable royalty rate in the table below by the corresponding amount of incremental Net Sales of all Licensed Products: 
  

					
	 That portion of Net Sales of the Licensed Product in the Optional

Territory in a Calendar Year that is:
	  	Royalty Rate	 
	 Less than or equal to Five Hundred Million Dollars ($500,000,000)
	  	 	8	% 
	 Greater than Five Hundred Million Dollars ($500,000,000)
	  	 	10	% 

 7.3.3 Payment Dates and Reports. Royalty payments shall be made by
I-MAB within sixty (60) days after the end of each Calendar Quarter commencing with the Calendar Quarter in which the first day of the first Royalty Term for the first Licensed Product occurs. I-MAB shall also provide to Ferring, at the same time each such payment is made, a report showing: (a) the Net Sales of the Licensed Product by country in the Territory and the Optional Territory (as
applicable); (b) the basis for any deductions from Invoiced Sales to determine Net Sales; (c) the applicable royalty rates for the Licensed Product; (d) a calculation of the amount of royalty due to Ferring; and (e) the exchange rates
used in calculating any of the foregoing. 

  
 29 

	7.4	 Mode of Payment; Currency Conversion; Taxes. 

7.4.1 Mode of Payment. All payments to Ferring under this Agreement shall be made by wire transfer of Dollars in the requisite amount to
such bank account as Ferring may from time to time designate by notice to I-MAB. 
 7.4.2 Currency
Conversion. If any currency conversion shall be required in connection with any payment hereunder, such conversion shall be made by using the arithmetic mean of the exchange rates for the purchase of Dollars as published by the People’s
Bank of China, on the last Business Day of each month in the Calendar Quarter to which such payments relate. 
 7.4.3 Taxes. The
milestone and royalty payments and other amounts payable by I-MAB to Ferring pursuant to this Agreement (“Payments”) shall not be reduced on account of any taxes unless required by Applicable
Law. Ferring alone shall be responsible for paying any and all taxes incurred under this Agreement which it should be liable for under the tax law of the relevant jurisdiction. I-MAB shall deduct or withhold
from the Payments any taxes that it is required by Applicable Law to deduct or withhold. For the sake of clarity, any federal, state, county or municipal sales or use tax, excise, customs charges, duties or similar charge, or any other tax
assessment (other than that assessed against income), license, fee or other charge lawfully assessed or charged on the manufacture, sale or transportation of Materials sold pursuant to this Agreement or a separate supply agreement between the
Parties, shall be paid by Ferring. If Ferring is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, applicable withholding tax, it shall deliver to I-MAB or the
appropriate governmental authority (with the assistance of I-MAB to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable
rate of withholding or to relieve I-MAB of its obligation to withhold tax, and I-MAB shall apply the reduced rate of withholding, or dispense with withholding, as the
case may be; provided that I-MAB has received evidence, in a form reasonably satisfactory to I-MAB, of Ferring’s delivery of all applicable forms (and, if
necessary, its receipt of appropriate governmental authorization) at least fifteen (15) Business Days prior to the time the tax return is due for filing and/or that the Payments are due, whichever is earlier. If, in accordance with the
foregoing, I-MAB withholds any amount in connection with any Payment, it shall pay to Ferring the balance when due, make timely payment to the proper taxing authority of the withheld amount and send to Ferring
proof of such payment within fifteen (15) Business Days following such Payment. 

  
 30 

 7.5    Sub-License and Sub-Sub-License Income 
 In the event any right granted,
license, sub-license or sub-sublicense given to, or agreement entered into by I-MAB with any Third Party (not being an Affiliate
or Recognised Agent of I-MAB) in Sublicensed Intellectual Property or Licensed Ferring Intellectual Property or Know-How and where, but for such right granted, license, sub-license or sub-sublicense given or agreement entered into by I-MAB, Sublicensed Intellectual Property or Licensed Ferring
Intellectual Property or Know-How as granted by Ferring to I-MAB pursuant to this Agreement would be infringed or used by the commercialisation of a Licensed Product by
such Third Party, I-MAB shall be deemed to have sub-licensed and/or sub-sublicensed its rights in the Licensed Product for the
purposes of this Section 7.5 under a Third Party Agreement (“Third Party Agreements”). 
 Third Party Agreements shall also
include any related agreements with a Sub-licensee and/or a Sub-sub licensee such as for example any agreement on an exchange product for the Licensed Product or other
non-financial consideration but shall expressly exclude sales to wholesalers under distribution agreements and sales under any other agreements which are covered by Section 7.3 above and where sales of
Licensed Product to an end customer are not booked by I-MAB, its Affiliates, Sublicensees, Sub-sublicensees or Recognized Agents. For the sake of clarity, this exclusion
shall not apply to agreements covering or related to the supply and manufacture of Licensed Compound or Licensed Product where commercialisation of the Licensed Product accruing therefrom is covered under Sublicensed Intellectual Property and/or
Licensed Ferring Intellectual Property and/or Know-How as granted by Ferring to I-MAB pursuant to this Agreement. 

  
 31 

 I-MAB shall pay to Ferring a sum equivalent to 10%
(ten percent) of the annual total consideration received by I-MAB under all Third Party Agreements for as long as I-MAB is obliged to make payments to Ferring pursuant
to section 7.3 above. 
 For the avoidance of doubt, annual total consideration received by I-MAB
under Third Party Agreements shall also include the sales booked by I-MAB in respect of any product in-licensed and commercialized by I-MAB and acquired by I-MAB in consideration of any sub-license and/or sub-sublicense by I-MAB of the Licensed
Product, whereupon the Net Sales of any such product in-licensed and commercialised by I-MAB shall be deemed annual total consideration received by I-MAB under a Third Party Agreement. 
 I-MAB will disclose
to Ferring the terms of all Third Party Agreements within thirty (30) days of their conclusion in so far as the terms are directly applicable to the financial and/or non-financial consideration that I-MAB will receive under such Third Party Agreements. 
 Not later than thirty (30) days from the end
of each calendar year, I-MAB will: (i) confirm to Ferring by itemised accounts the annual total consideration received in the previous calendar year by I-MAB under
such Third Party Agreements; and (ii) make a payment to Ferring of 10% (ten percent) of such consideration as specified above. 
 Upon
receipt by Ferring of such valuation, Ferring will have thirty (30) days either to accept in writing the accounts submitted by I-MAB or to inform I-MAB in writing
that Ferring requires an independent accountant acceptable to both Ferring and I-MAB to review all Third Party Agreements and all books and accounts of I-MAB relevant
for the purposes of determining the annual total consideration received by I-MAB during the same calendar year under such Third Party Agreements. Following such review, the accountant shall inform both Parties
of the amount of such consideration and the amount shall then be binding on both Parties. Ferring may exercise the right during the term of this Agreement and until the end of three (3) years after the expiration or termination of this
Agreement once per calendar year. 

  
 32 

 In the event of the independent accountant confirming an amount of annual total
consideration received in the previous calendar year received by I-MAB under such Third Party Agreements equal to or within a margin of 5% (five percent) either above or below the valuation submitted by I-MAB, the costs of the independent accountant for such valuation shall be borne by Ferring. 
 In the
event of the independent accountant confirming an amount of annual total consideration received by I-MAB in the previous calendar year under such Third Party Agreements exceeding a margin of 5% (five percent)
either above or below the valuation submitted by I-MAB, the costs of the independent accountant for such valuation shall be borne by I-MAB. 

I-MAB shall promptly pay to Ferring the full amount of any underpayment owing to Ferring pursuant to
this Section 7.5 under such Third Party Agreements together with interest thereon at the rate of EURIBOR plus 2% (two percent) per year compounded monthly from the date payment was due. 

 

	7.6	 Audit Rights 

I-MAB shall keep and shall cause its Affiliates, Sublicensees,
Sub-sublicensees and Recognized Agents to keep records of the sale of the Licensed Product in sufficient detail to permit Ferring to confirm the accuracy of Net Sales and royalties payable reported. Ferring
shall have the right at its own expense (unless the result of such audit results in a variation or error exceeding 5% (five percent) of the payment made in the previous calendar year, in which case at the expense of
I-MAB), to have a certified public accounting firm examine the relevant books and records of I-MAB, its Affiliates, Sublicensees,
Sub-sublicensees and Recognized Agents. Ferring may exercise this right during the term of this Agreement and until the end of three (3) years after the end of the Royalty Term once per calendar year. I-MAB shall promptly pay to Ferring the full amount of any underpayment, together with interest thereon, at the rate of EURIBOR plus 2% (two percent) per year compounded monthly from the date payment was due. 

 

	7.7	 Confidentiality. Both Parties shall treat all information subject to review under this Section 7 in
accordance with the confidentiality provisions of Section 5. 

  
 33 

	8.	 INTELLECTUAL PROPERTY 

 

	8.1	 Ownership of Intellectual Property. 

8.1.1 Except as expressly set out herein, this Agreement does not affect the ownership of any
I-MAB IP, Ferring Intellectual Property, Ferring Know-How, Ferring Improvements or the Sublicensed Intellectual Property. The Parties acknowledge and agree that, as
between the Parties: (a) subject to the terms and conditions of this Agreement, including Section 10.3, I-MAB shall own and retain all right, title and interest in and to any and all I-MAB IP including I-MAB Improvements; and (b) Ferring shall own and retain all right, title and interest in and to any and all Ferring
Know-How, Ferring Intellectual Property and Ferring Improvements; (c) Conaris Research Institute AG shall own and retain all right, title and interest in and to any and all Sublicensed Intellectual
Property and (d) each Party shall own and retain all right, title and interest in and to any and all other Know-How and other intellectual property rights that are owned or otherwise Controlled (other
than pursuant to the license grants set forth in Section 2.1 and 2.2) by such Party, its Affiliates or any Sublicensees, Sub-sublicensees or its or their respective Affiliates. 

8.1.2 If an Improvement is made by or on behalf of both I-MAB and Ferring, then such Improvement
shall be deemed jointly-owned Intellectual Property and such Intellectual Property shall be licensed by Ferring to I-MAB under the terms of this Agreement. 

8.1.3 I-MAB hereby grants to Ferring a non-exclusive,
fully paid, royalty free, world-wide license to any I-MAB IP. 
 8.1.4 No other right of license.
Except as expressly set out herein, no provision in this Agreement shall operate to transfer, assign or otherwise grant any Party any right or interest in any Intellectual Property or other intellectual property rights of the other Party. 

 

	8.2	 Patent Filing, Prosecution and Maintenance 

8.2.1 Licensed Patents. Ferring shall prepare, file, prosecute and maintain (including with respect to related interference, re-issuance, re-examination, opposition and invalidation proceedings) the patents and patent applications of the Ferring Intellectual Property and Sublicensed Intellectual
Property in the Territory and the Optional Territory (as applicable) at its sole cost and expense, and shall not abandon any such patent or patent application in the Territory or the Optional Territory during the Option Right (as applicable) without
the prior written consent of I-MAB which shall not be unreasonably withheld. 

  
 34 

 8.2.2 Improvements. The Party owning an Improvement shall have responsibility for the
filing, prosecution and maintenance at its sole expense, in the applicable patent offices in the Territory and/or Optional Territory (as applicable), and that Party shall control all filings and actions in relation to procuring and maintaining such
New Intellectual Property. I-MAB shall have responsibility for jointly-owned Improvements. The Parties agree to keep each other regularly informed of the course of patent prosecution or other proceedings with
respect to Improvements and shall provide each other with copies of all official documents sent to or received by the respective patent offices in the Territory and/or Optional Territory (as applicable). 

Notwithstanding the foregoing, the Party having such responsibility for the filing, prosecution and maintenance of Improvements shall not be
required to file, prosecute or maintain any patent application or patent where that Party does not believe that such activities are commercially justified provided, however, that such Party shall not cease to file, prosecute and maintain any such
patent application or patent without giving the other Party the opportunity to take over the responsibility for filing, prosecution and maintenance at its own expense in which case that Party shall grant the other Party an irrevocable, non-exclusive, fully paid, royalty free, world-wide license, with the right to sublicense to such Improvements. The Parties agree and acknowledge that Conaris has the opportunity to take over responsibility for any
Improvements should both Parties decline to maintain patents or patent applications on Improvements. 
  

	8.3	 Cooperation and Assistance 

Each Party shall make available its authorized attorneys, agents or representatives, its employees, agents or consultants reasonably necessary
or appropriate to enable the other Party to file, prosecute and maintain patent applications and resulting patents with respect to the Improvements, and shall provide access to such documents and other information as may be reasonably required for
such purposes. The Party shall sign or cause to have signed all documents relating to said patent applications or patents at no cost or charge to the other Party. 

  
 35 

	8.4	 Patent Term Extensions and Supplementary Protection Certificates. 

Each Party shall notify the other Party of the issuance of each patent within the Ferring Intellectual Property or I-MAB IP in any country in the Territory and the Optional Territory (as applicable) giving the date of issue and patent number for each such patent. Ferring shall have the exclusive responsibility and shall use
commercially reasonable efforts to apply for and maintain any such extension, and shall not abandon any such extension in the Territory or the Optional Territory (as applicable) without the prior written consent of
I-MAB which shall not be unreasonably withheld. 
 The Parties shall cooperate with each other in
gaining such extensions and each Party shall execute such authorizations and other documents and take such other actions as may be reasonably requested by the other Party to obtain such extensions. If more than one patent is eligible for such
extension, Ferring shall have the right to make the election of which patent for which such extension will be sought. 
  

	8.5	 Patent Enforcement and Infringement 

8.5.1 Notice. If Ferring or I-MAB has knowledge of any suspected infringement of any
Intellectual Property by Third Parties or of any misappropriation or misuse of the Intellectual Property in the Territory and/or Optional Territory (as applicable), the Party having such knowledge shall promptly inform the other Party of such
infringement, misuse or misappropriation. 
 8.5.2 Course of Action. I-MAB shall have the
right, but not the obligation, at its cost to bring any legal action in the Territory and/or Optional Territory (as applicable) related to infringement by Third Parties, that impacts adversely on the enjoyment by
I-MAB of the rights licensed to it hereunder. Ferring shall join in any infringement proceeding as a party at I-MAB’s request and at
I-MAB’s expense in the event that an adverse party asserts, or I-MAB determines in good faith, that a court or other legal body lacks jurisdiction based on
Ferring’s absence as a party in such proceeding, or with respect to patents where such joinder is necessary or desirable to proceed with such claim. Ferring and Conaris shall each have the right, but not the obligation, to bring any legal
action related to infringement if I-MAB declines to do so. 

  
 36 

 8.5.3 Infringement of Third Party Rights. In the event that a Third Party alleges
that I-MAB’s or its Affiliate’s, Sublicensee’s and/or Sub-sublicensee’s, manufacture of the Licensed Product or use of Improvements infringes its
intellectual property in the Territory and/or Optional Territory (as applicable), I-MAB shall have the sole right to defend such action at its own expense and Ferring agrees to assist and cooperate where
reasonably necessary with I-MAB, at I-MAB’s own expense, in the defense of any such action. 

I-MAB has carried out its own analysis of Third Party patent rights in the Territory and/or Optional
Territory (as applicable) which could possibly be infringed or be alleged to be infringed by its exercise of the rights under this Agreement. I-MAB acknowledges that the grant of the license and/or sublicense
under this Agreement shall not imply any warranty against infringement of any Third Parties’ patent rights or any other rights of Third Parties. Ferring and I-MABe are in agreement that Ferring shall not
be liable for any patent infringement claims brought by a Third Party against I-MAB with regard to the manufacture or marketing of the Licensed Product in the Territory and/or Optional Territory (as
applicable) and shall be under no duty to indemnify I-MAB from claims and damages arising therefrom. 

8.5.4 Settlement of Third Party Claims. I-MAB, with respect to a particular claim pursuant to
Section 8.5.3, also shall have the right to control settlement of such claim; provided that: (a) no settlement shall be entered into without the prior consent of Ferring if such settlement would adversely affect or diminish the rights and
benefits of Ferring under this Agreement, or impose any new obligations or adversely affect any obligations of Ferring under this Agreement; and (b) I-MAB shall not be entitled to settle any such claim by
granting a license or covenant not to sue under or with respect to the Sublicensed Intellectual Property or Ferring Intellectual Property without the prior written consent of Ferring, such consent not to be unreasonably conditioned, withheld or
delayed. 

  
 37 

 8.5.5 Costs. Each Party shall unless otherwise stated in this Section 8.5 assume
and pay all of its own out-of-pocket costs incurred in connection with any litigation or proceedings described in this Section 8.5, including, without limitation,
the fees and expenses of such Party’s counsel. 
 8.5.6 Recoveries. Any recovery obtained by either Party as a result of any
proceeding described in this Section 8.5 or from any counterclaim or similar claim asserted in a proceeding described in this Section 8.5, by settlement or otherwise, shall be applied as follows: first, to reimburse each Party for all out-of-pocket litigation costs incurred in connection with such proceeding paid by that Party (on a pro rata basis based on each Party’s respective litigation costs, to the extent the recovery was less than all
such litigation costs); and second, the remainder of the recovery shall be paid one hundred percent (100%) to the Party which funded the infringement action. Any remainder of the recovery by I-MAB shall be
treated as sub-license income pursuant to Section 7.5. 
 8.5.7 Cooperation. In the event
that any Party takes action pursuant to this Section 8.5, the other Party shall cooperate fully with the Party so acting to the extent reasonably possible, including the joining of suit as required by this Agreement or as otherwise desirable
and, to the extent possible, make available relevant records, papers, information, samples, specimens, and the like. Each Party shall keep the other informed of developments in any action or proceeding, including the status of any settlement
negotiations and the terms of any offer related thereto. 
  

	8.6	 Validity and Enforceability Challenge by Third Party 

In the event that a Third Party attacks the validity or enforceability of any of the Ferring Intellectual Property in the Territory and/or the
Optional Territory (as applicable), then Ferring shall promptly notify I-MAB and Ferring, at its own discretion, subject to good business judgement, shall promptly take such legal action as is required and
appropriate to defend the validity thereof. 
 If Ferring does not take such legal action as is required to defend the validity of the
Ferring Intellectual Property in the Territory and/or Optional Territory (as applicable), Ferring shall provide at least sixty (60) days written notice to I-MAB prior to a corresponding deadline, if
applicable, and the Parties shall reasonably determine an appropriate alternative in the best interests of both Parties. 

  
 38 

 The Parties agree and acknowledge that should a Third Party attack the validity or
enforceability of any of the Sublicensed Intellectual Property in the Territory and/or the Optional Territory (as applicable) and Ferring does not take such legal action as is required to defend the validity of such Sublicensed Intellectual
Property, then Conaris at its option shall control defense. 
  

	8.7	 Product Trademarks 

8.7.1 Maintenance and Ownership of Product Trademarks. I-MAB, at its expense, shall be
responsible for the selection, registration and maintenance of all Trademarks that I-MAB employs in connection with the Licensed Product (“Product Trademarks”).
I-MAB shall own all right, title and interest to such Trademarks, trade dress and copyrights in the Territory and Optional Territory (as applicable) related to the Licensed Product. 

8.7.2 Enforcement of Product Trademarks. I-MAB may, at its sole discretion, take such action as I-MAB deems necessary against a Third Party based on any alleged, threatened, or actual infringement, dilution, misappropriation, or other violation of, or unfair trade practices or any other like offense relating
to, the Product Trademarks by a Third Party in the Territory or the Optional Territory (as applicable). I-MAB shall bear the costs and expenses relating to any enforcement action commenced pursuant to this
Section 8.7.2 and any settlements and judgments with respect thereto, and shall retain any damages or other amounts collected in connection therewith. 

8.7.3 Third Party Claims. I-MAB may, at its sole discretion, defend against any alleged,
threatened, or actual claim by a Third Party that the use or registration of the Product Trademarks in the Territory or the Optional Territory (as applicable) infringes, dilutes, or otherwise violates any trademark or other right of such Third Party
or constitutes unfair trade practices or any other like offense, or any other claims as may be brought by a Third Party against a Party in connection with the use of the Product Trademarks with respect to a Licensed Product in the Territory or the
Optional Territory (as applicable). I-MAB shall bear the costs and expenses relating to any defense commenced pursuant to this Section 8.7.3 and any settlements and judgments with respect thereto, and
shall retain any damages or other amounts collected in connection therewith. 

  
 39 

 8.7.4 Notice and Cooperation. Each Party shall provide to the other Party prompt
written notice of any actual or threatened infringement of the Product Trademarks in the Territory and the Optional Territory (as applicable) and of any actual or threatened claim that the use of the Product Trademarks in the Territory or the
Optional Territory (as applicable) violates the rights of any Third Party. Each Party shall cooperate fully with the other Party with respect to any enforcement action or defense commenced pursuant to this Section 8.7. 

 

	9.	 TERM AND TERMINATION 

 

	9.1	 Term. This Agreement shall commence on the Effective Date and shall, unless earlier terminated in
accordance with this Section 9, continue: (a) with respect to the Licensed Product in each country in the Territory and the Optional Territory (as applicable, cf. Clause 2.2), until the expiration of the Royalty Term for the Licensed
Product in such country; and (b) with respect to this Agreement in its entirety, until the later of: (i) the expiration of the Royalty Term for the Licensed Product for which there has been a First Commercial Sale in the Territory or the
Optional Territory (as applicable); or (ii) the first date on which I-MAB is not conducting any necessary and outstanding Clinical Study with respect to any Licensed Product or seeking to obtain any
necessary and pending Regulatory Approval for the Licensed Product in the Territory or the Optional Territory (if applicable) (such period, the “Term”). 

 

	9.2	 Termination of this Agreement for Material Breach. In the event that either Party materially breaches
this Agreement (such Party, the “Breaching Party”), in addition to any other right and remedy the other Party (the “Complaining Party”) may have, the Complaining Party may terminate this Agreement, in its entirety
upon thirty (30) days’ prior written notice (the “Termination Notice Period”) to the Breaching Party, specifying the material breach and its claim of right to terminate, provided that the termination shall not become
effective at the end of the Termination Notice Period if the Breaching Party cures the material breach complained of during the Termination Notice Period. 

  
 40 

	9.3	 Termination Upon Insolvency. Either Party may terminate this Agreement if, at any time, the other Party:
(a) files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for reorganization (other than for the purposes of merger or amalgamation) or for an
arrangement or for the appointment of a receiver or trustee of such other Party or of its assets; (b) proposes a written agreement of composition or extension of its debts; (c) is served with an involuntary petition against it, filed in
any insolvency proceeding that is not dismissed within thirty (30) days after the filing thereof; (d) proposes or is a party to any dissolution or liquidation; or (e) makes an assignment for the benefit of its creditors.

  

	9.4	 Termination of Sublicensed Intellectual Property. Ferring may terminate this Agreement with respect to
the license grant hereunder to Sublicensed Intellectual Property in the event the main license (Development and License Agreement dated November 11, 2008) governing the Sublicensed Intellectual Property is terminated by Conaris AG. The Parties
hereby agree to discuss in good faith how to resolve and mitigate to the satisfaction of both Parties any consequences negatively impacting I-MAB and its representatives, including potential participants in
clinical trials, in its continued efforts under the license grants under this Agreement due to such termination, (provided that such termination of Sublicensed Intellectual Property is not due to lack of diligence, negligence or breach of this
Agreement by I-MAB or its representatives). The agreed process should this happen shall be made in writing and shall be signed as an Amendment to this Agreement no later than forty five (45) days after
the Effective Date. 

  

	10.	 CONSEQUENCE OF TERMINATION 

 

	10.1	 In the event of Ferring’s termination of this Agreement pursuant to Sections 9.2 or 9.3, I-MAB shall within thirty (30) days of such termination pay to Ferring in full all unpaid amounts which otherwise became due and payable to Ferring prior to such termination in accordance with this Agreement.
The licenses, sublicenses, sub-sub licenses, if any, and other rights granted to I-MAB hereunder shall be terminated as of the effective date of the termination and
Ferring shall have an irrevocable, worldwide, royalty free, non-exclusive license with right to sublicense, to all I-MAB Intellectual Property. I-MAB shall transfer to Ferring without delay all applications to and approvals of Regulatory Authorities for clinical trials and/or sale of Licensed Product, all data and Information in its possession related to
the Licensed Compound and the Licensed Product including its database on the Licensed Compound and the Licensed Product, any master cell bank and the Manufacturing Process for the Licensed Compound and the Licensed Product, all quantities of
Licensed Compound, Licensed Product, clinical trial samples or Materials in its possession and as reasonably required by Ferring for progressing to the commercialization of a Licensed Product. 

  
 41 

	10.2	 In the event of Ferring’s termination pursuant to Section 9.2 or 9.3 after First Commercial
Sale, I-MAB shall transfer free of charge the ownership of its trademarks, trade dress and/or copyrights for the Licensed Product to Ferring and cooperate with Ferring in the transfer of any sales of Licensed
Product to Ferring or a Third Party designated by Ferring in addition to the consequences under Section 10.1. 

  

	11.	 ACCRUED RIGHTS; SURVIVING OBLIGATIONS 

 

	11.1	 Accrued Rights. Termination or expiration of this Agreement for any reason shall be without prejudice to
any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of
this Agreement. 

  

	11.2	 Survival. Without limiting the foregoing, Articles 10, 14, 17, 21 and 23 and Section 2.5.4, 5.2 -
5.7, 7.6, and 7.7 shall survive the termination or expiration of this Agreement for any reason. 

  

	12.	 GENERAL PERFORMANCE STANDARDS 

Each Party shall utilise qualified, skilled and experienced personnel in performing their obligations under this Agreement. Such personnel
shall be familiar with the GMP level relevant to their role in the process. 

  
 42 

 Each Party shall perform all its obligations under this Agreement with all due skill and
care, in a professional manner and in accordance with all Applicable Laws and regulations. 
 In relation to development, manufacturing and
other work necessary to obtain regulatory approvals of the Licensed Product, each Party shall perform its obligations in accordance with the present scientific state of the art as well as current demands from the relevant regulatory and other
authorities. 
 Should either Party become aware of any incident which will or is likely to cause delay to or impair the performance of its
obligations under this Agreement, such Party shall immediately notify the Joint Committee, and inform the other Party of actions, initiated and planned in order to remedy the delay. 

Each Party represents and warrants that it has, and will maintain during the term hereof, the authority and right to perform its obligations
under this Agreement and that it has, and will maintain during the term hereof, any permits, licences, facilities, knowledge, specialists and personnel necessary for performance of its obligations under this Agreement. 

 

	13.	 MANUFACTURE AND SUPPLY 

 

	13.1	 Supply by Ferring for Phase IB Clinical Trial 

13.1.2 Ferring will pay for the continued shelf life stability testing to the end of 2017 for the current Licensed Product. Ferring will
use reasonable efforts to assist I-MAB with additional testing at I-MAB’s cost in the event that further extensions are required beyond 2017. Stability testing and
payment of costs therefore have been detailed in attached Schedule C. 
  

	13.2	 I-MAB’s Manufacture Duty.
I-MAB shall, at its own cost, Manufacture or have Manufactured the Licensed Compound and/or the Licensed Product required for completing the relevant Clinical Studies.
I-MAB shall, at its own cost, complete all testing, shipping, labelling and other readiness work required for completing the Phase II Clinical Studies; provided that Ferring shall provide assistance as
reasonably requested by I-MAB. 

  
 43 

	14.	 WARRANTIES, REPRESENTATIONS, INDEMNIFICATION AND INSURANCE 

 

	14.1	 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party as
of the Effective Date as follows: 

 14.1.1 Corporate Authority. Such Party: (a) has the power and authority
and the legal right to enter into this Agreement and perform its obligations hereunder; and (b) has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations
hereunder. This Agreement has been duly executed and delivered by such Party and constitutes a legal, valid and binding obligation of such Party and is enforceable against it in accordance with its terms subject to the effects of bankruptcy,
insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered in a
proceeding at law or equity. 
 14.1.2 Consent and Approvals. To the best of its belief and knowledge, all necessary consents,
approvals and authorizations of all Regulatory Authorities and other Persons required to be obtained by such Party in connection with the execution and delivery of this Agreement and the performance of its obligations hereunder have been obtained.

 14.1.3 Conflicts. To the best of its belief and knowledge, the execution and delivery of this Agreement and the performance of such
Party’s obligations hereunder: (a) do not conflict with or violate any requirement of Applicable Law or any provision of the articles of incorporation or bylaws of such Party in any material way; and (b) do not conflict with, violate
or breach or constitute a default or require any consent under, any contractual obligation or court or administrative order by which such Party is bound. 
  

	14.2	 Representations and Warranties of I-MAB. I-MAB represents and warrants to Ferring as follows, as of the Effective Date: 

14.2.1 No Debarment. Neither I-MAB nor any of its Affiliates has been debarred or is subject to
debarment and neither I-MAB nor any of its Affiliates will use in any capacity, in connection with the activities to be performed under this Agreement, any Person who has been debarred under Applicable Law in
the relevant jurisdiction; and 

  
 44 

 14.2.2 Compliance. I-MAB shall, at all times,
comply in all material respects with all Applicable Laws, rules and regulations and standards applicable to the Development Plan. 
  

	14.3	 Representations and Warranties of Ferring. Ferring represents and warrants to I-MAB as follows, to the best of its belief and knowledge as of the Effective Date: 

14.3.1 Title; Encumbrances. It has sufficient legal and/or beneficial title, ownership or license, free and clear from any mortgages,
pledges, liens, security interests, conditional and installment sales agreements, encumbrances, charges or claims of any kind, of or to the Sublicensed Intellectual Property to grant the licenses and sublicenses to
I-MAB as purported to be granted pursuant to this Agreement; 
 14.3.2 Notice of Infringement or
Misappropriation. It has not received any written notice from any Third Party asserting or alleging that any use of the Licensed Compound or any development of the Licensed Product would infringe, misappropriate or otherwise violate the
intellectual property rights of such Third Party; 
 14.3.3 No Proceeding. There are to the best of its knowledge no pending, and no
threatened, adverse actions, suits or proceedings against Ferring involving the Sublicensed Intellectual Property. 
 14.3.4 No Debarment.
Neither Ferring nor any of its Affiliates has been debarred or is subject to debarment and neither Ferring nor any of its Affiliates will use in any capacity, in connection with the activities to be performed under this Agreement, any Person who
has been debarred under Applicable Law in the relevant jurisdiction; and 
 14.3.5 Compliance. Ferring shall, and shall procure its
Affiliates to, comply with all Applicable Laws when performing its and their respective obligations under this Agreement. 

  
 45 

	14.4	 No Benefit to Third Parties. The representations, warranties, covenants and agreements set forth in this
Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and they shall not be construed as conferring any rights on any Third Parties. 

 

	14.5	 Indemnification. 

14.5.1 Indemnification by the Parties. Each Party (the “Indemnifying Party”) shall indemnify and hold harmless the
other Party’s officers, directors, shareholders, employees, successors and assigns (“Indemnified Party”) from any loss, damage or liability, including reasonable attorney’s fees resulting from any claim, complaint, suit,
proceeding or course of action brought by or on behalf of an injured Third Party or a spouse, relative or companion of an injured Third Party, against any of them, alleging personal or related injury, including death, loss of service or consortium
or a similar such claim, due to such personal injury or death, and arising out of the performance of this Agreement (the “Loss”), save that the Indemnifying Party shall not be obliged to indemnify and hold harmless the Indemnified
Party in accordance with the terms of this Section 14.5.1 to the extent that such Loss is attributable to the material breach of this Agreement, failure to adhere to Applicable Laws or regulations, or the negligence or willful misconduct of the
Indemnified Party. 
 14.5.2 With respect to any claim for indemnification asserted by the Indemnified Party pursuant to
Section 14.5.1: 
  

	 	(a)	 The Indemnifying Party shall have no obligation to indemnify the Indemnified Party requesting indemnification
unless: 

  

	 	(i)	 the Indemnified Party gives the Indemnifying Party prompt written notice of any claim or lawsuit or other
action for which it seeks to be indemnified under this Agreement; 

  

	 	(ii)	 the Indemnifying Party is granted full authority and control over the defense including settlement against such
lawsuit or other action; provided, however, that: (i) such settlement involves only the payment of monetary damages and no injunctive relief binding on the Indemnified Party, and such monetary damages are paid by the Indemnifying Party;
(ii) the Indemnified Party is not required under such settlement to admit any liability; and (iii) the Indemnified Party is released from all further liability with respect to such claim; and 

  
 46 

	 	(iii)	 the Indemnified Party co-operates fully with the Indemnifying Party and
its agents in defense of the claims or lawsuit or other action. 

  

	 	(b)	 The Indemnified Party shall have the right to participate, at its sole cost and expense, in the defense
of any such claim, complaint, suit proceeding or course of action referred to in this paragraph utilizing legal counsel of its choice, provided however that the Indemnifying Party shall have full authority and control to handle any such claim,
complaint, suit, proceeding or course of action, including any settlement or other disposition thereof, for which indemnification has been sought under this Section. 

14.5.3 No Consequential Damages: In no event shall either Party be liable or responsible to the other Party under this Agreement for any
special, indirect, incidental or consequential loss or damage of any nature whatsoever, including without limitation, any actual or anticipated profits, loss of time, inconvenience, commercial loss, out of pocket expenses reasonably incurred by a
Party hereto or any other similar losses. 
  

	14.6	 Insurance. I-MAB shall secure and keep in force during the term
of this Agreement, at its sole cost and expense, a commercial product insurance and clinical trial insurance policy and any other insurance policies as customarily used in the pharmaceutical industry in the Territory and/or Optional Territory, as
applicable. 

  

	15.	 ASSIGNMENT 

  

	15.1	 This Agreement and the licenses and sublicenses herein granted shall be binding upon and inure to the
benefit of the successors in interest of the respective Parties. 

  

	15.2	 Without the prior written consent of the other Party, neither Party shall sell, transfer, assign,
delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided that I-MAB may, with such
consent, but not to be unreasonably withheld, assign this Agreement and its rights and obligations hereunder to an Affiliate, to the purchaser of substantially all of its assets required for the further Development and Commercialization of the
Licensed Products in the Territory and the Optional Territory (as applicable), or to its successor entity or acquirer in the event of a merger, consolidation or change in control of I-MAB. Any attempted
assignment or delegation in violation of the preceding sentence shall be void and of no effect. All validly assigned and delegated rights and obligations of the Parties hereunder shall be binding upon and inure to the benefit of and be enforceable
by and against the successors and permitted assigns of Ferring or I-MAB, as the case may be. In the event either Party seeks and obtains the other Party’s consent to assign or delegate its rights or
obligations to another Party, the assignee or transferee shall assume all obligations of its assignor or transferor under this Agreement. Notwithstanding anything herein to the contrary, in no event may Ferring assign or grant a license under any
portion of the Sublicensed Intellectual Property in the Territory or Optional Territory (as applicable), or sell, transfer, assign, delegate, pledge or otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this
Agreement or any of its rights or duties hereunder, to a then existing or prospective direct competitor of I-MAB for the Licensed Product in the Territory or Optional Territory (as applicable). Any attempted
assignment, license or delegation in violation of the preceding sentence shall be void and of no effect. 

  
 47 

	16.	 INDEPENDENT CONTRACTORS 

 

	16.1	 It is expressly agreed that Ferring, on the one hand, and I-MAB,
on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither Ferring, on the one hand, nor I-MAB,
on the other hand, shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party to do so, such consent
not to be unreasonably conditioned, withheld or delayed. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and
expense of such Party. 

  
 48 

	17.	 NOTICES 

  

	17.1	 Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication
permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally
recognized overnight delivery service that maintains records of delivery, addressed to the Parties at their respective addresses specified in Section 17.2 or to such other address as the Party to whom notice is to be given may have provided to
the other Party in accordance with this Section 17. Such notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on the third Business Day (at the place of
delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable thereafter. This Section 17 is not intended to govern
the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 

 

	17.2	 Address for Notice. 

If to I-MAB, to: 

*** 
 If to FERRING, to: 

*** 
  

	18.	 ENTIRE AGREEMENT; WAIVER 

 

	18.1	 Entire Agreement; Amendments. This Agreement, together with the Schedules attached hereto, sets forth
and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and representations, whether written or oral, with respect thereto are superseded
hereby, including that certain confidential disclosure agreement between Ferring and I-MAB dated September 25, 2016. Each Party confirms that it is not relying on any representations or warranties
of the other Party except as specifically set forth herein. No amendment, modification, release or discharge shall be binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. 

  
 49 

	18.2	 Waiver and Non-Exclusion of Remedies. Any term or condition of
this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.
The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by the other Party whether of a similar
nature or otherwise. 

  

	18.3	 English Language. This Agreement shall be written and executed in, and all other communications under or
in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the English version and such
translation, the English version shall control. 

  

	18.4	 References. Unless otherwise specified; (a) references in this Agreement to any Article, Section or
Schedule means references to such Article, Section or Schedule of this Agreement; (b) references in any section to any clause are references to such clause of such section; and (c) references to any agreement, instrument or other document
in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently varied, replaced or supplemented from time to time, as so varied, replaced or supplemented and in effect at the relevant time of
reference thereto. 

  

	18.5	 Construction. Except where the context otherwise requires, wherever used, the singular shall include the
plural, the plural shall include the singular, the use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in
no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein means including, without limiting the generality of any
description preceding such term. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party. 

  
 50 

	19.	 SEVERABILITY 

  

	19.1	 To the fullest extent permitted by Applicable Law, the Parties waive any provision of law that would
render any provision in this Agreement invalid, illegal, or unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal, or unenforceable, in any respect, then such provision will be given no effect by the Parties
and shall not form part of this Agreement. To the fullest extent permitted by Applicable Law and if the rights or obligations of either Party will not be materially and adversely affected, all other provisions of this Agreement shall remain in full
force and effect, and the Parties shall use their best efforts to negotiate a provision in replacement of the provision held invalid, illegal, or unenforceable that is consistent with Applicable Law and achieves, as nearly as possible, the original
intention of the Parties. 

  

	20.	 FURTHER ASSURANCE AND REGISTRATION 

 

	20.1	 Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed and
delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 

  
 51 

	20.2	 Registration. Either Party shall have the right at any time to record, register or otherwise notify
(collectively, “Register”) this Agreement with or to appropriate governmental or regulatory offices after having first given thirty (30) days’ written notice to the other Party of its intention so to do; provided however, that if
feasible, such Registration shall be made pursuant to confidentiality protections, if available, and otherwise, except as may be required under law, all financial and other material and sensitive business terms of this Agreement shall be redacted
from any copy of this Agreement that is to Registered. The other Party shall provide reasonable assistance in effecting such Registration. 

  

	21.    GOVERNING	 LAW; RELIEF 

  

	21.1	 Governing Law. This Agreement shall be governed by, and construed in accordance with Swiss law,
excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of
the United Nations Convention on Contracts for the International Sale of Goods. 

  

	21.2	 Injunctive Relief. Notwithstanding anything to the contrary in this Agreement, either Party shall be
entitled to seek interim relief from, and bring suit before, any court of competent jurisdiction based on the cause of action of intellectual property infringement. 

 

	21.3	 Equitable Relief. The Parties acknowledge and agree that the restrictions set forth in Section 5
are reasonable and necessary to protect the legitimate interests of the Parties and that neither Party would not have entered into this Agreement in the absence of such restrictions imposed on the other Party by these provisions, and that any breach
or threatened breach of any provision of Section 5 may result in irreparable injury to the non-breaching Party for which there will be no adequate remedy at law. Notwithstanding anything to the
contrary in this Agreement, in the event of a breach or threatened breach of any provision of Section 5, the non-breaching Party shall be authorized and entitled to obtain from any court of competent
jurisdiction injunctive relief, whether preliminary or permanent, specific performance and an equitable accounting of all earnings, profits and other benefits arising from such breach, which rights shall be cumulative and in addition to any other
rights or remedies to which such non-breaching Party may be entitled in law or equity. To the maximum extent permitted under Applicable Law, both Parties agree to waive any requirement that the other Party:
(a) post a bond or other security as a condition for obtaining any such relief; and (b) show irreparable harm, balancing of harms, consideration of the public interest or inadequacy of monetary damages as a remedy. Nothing in this
Section 21.3 is intended, or should be construed, to limit either Party’s right to equitable relief or any other remedy for a breach of any other provision of this Agreement. 

  
 52 

	22.	 FORCE MAJEURE 

 

	22.1	 If either Party is prevented from complying, either totally or in part, with any of the terms or
provisions of this Agreement, by reason of a Force Majeure, then, upon written notice by the Party liable to perform to the other Party, the requirements of this Agreement or such of its provisions as may be affected (excluding, however, any
obligation to pay money) and to the extent so affected, shall be suspended during the period of such Force Majeure; provided, that the Party asserting a Force Majeure shall bear the burden of establishing the existence of the Force Majeure, shall
use its best efforts to remove the Force Majeure, shall continue performance with dispatch whenever such causes are removed, and shall notify the other Party of the Force Majeure not more than ten (10) calendar days from the time of the event;
provided, however, that the Party not asserting the Force Majeure shall have the right, upon payment of all sums due and owing under this Agreement, to terminate the Agreement upon written notice to the Party asserting the Force Majeure if the Force
Majeure continues for more than three (3) months. 

  

	23.	 DISPUTE RESOLUTION 

 

	23.1	 Dispute Resolution. If a dispute arises between the Parties in connection with the interpretation,
validity or performance of this Agreement or any document or instrument delivered in connection herewith (a “Dispute”), then either Party shall have the right to refer such dispute to the Parties’ executive officers for
attempted resolution by good faith negotiations during a period of thirty (30) days. Any final decision mutually agreed to by the executive officers shall be conclusive and binding on the Parties. If such executive officers are unable to
resolve such Dispute within such thirty-day period, the Dispute will be settled by the Courts of the city of Lausanne. Either Party may enter such award in a court having competent jurisdiction and any Party
to the Dispute may apply to a court of competent jurisdiction for enforcement of such award. 

  
 53 

	23.2	 Continuing Performance. The Parties agree to continue performing their respective obligations under this
Agreement to the extent practicable while any Dispute is being resolved hereunder unless and until such obligations are terminated or expire in accordance with the provisions hereof 

 

	24.	 EXECUTION IN COUNTERPARTS 

 

	24.1	 This Agreement may be executed in any number of counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile or other electronic signatures and such signatures shall be deemed to bind each Party as if they were original signatures.

 [SIGNATURE PAGE FOLLOWS] 

  
 54 

 This Agreement is executed by the authorized representatives of the Parties as of the
Effective Date. 
  

					
	FERRING INTERNATIONAL CENTER SA
			
	 /s/ Ferring International Center SA
	 	        	 	 /s/ Ferring International Center SA

	Print name:***	 		 	Print name: ***
	Title:***	 		 	Title: ***
	Date: 04/11/2016	 		 	Date: 04/11/2016

  

			
	I-MAB
	
	 /s/ I-Mab

	 Print name: ***

	 Title: ***

	 Date: 04/11/2016

  
 55 

 Schedule A 

Licensed Know-How 

[***] 

  
 56 

 Schedule B 

[***] 

  
 57 

 Schedule C 

Materials as of the Effective Date + additional shelf line testing 

[***] 

  
 58EX-10.17

 Exhibit 10.17 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i)
NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED 
 COLLABORATION AGREEMENT

 This Collaboration Agreement (“Agreement”), effective as of July 9, 2019 (the “Effective Date”), is entered into by
and between MacroGenics, Inc., a Delaware corporation with a place of business at 9704 Medical Center Drive, Rockville, MD 20850, USA (“MacroGenics”), and I-MAB Biopharma, US Limited, a
Maryland corporation with a place of business at 9801 Washingtonian Blvd., Suite 710, Gaithersburg, MD 20878, USA (“I-MAB”). MacroGenics and I-MAB may
be referred to herein individually as a “Party” or collectively as the “Parties.” 
 Recitals: 

A.    MacroGenics has expertise in, and platforms for, the discovery and development of products for the treatment of
patients with cancer, inflammatory and infectious diseases. 
 B.    I-MAB
conducts research and development with respect to pharmaceutical products. 

C.    I-MAB and MacroGenics desire to enter into collaboration for the development
of MacroGenics’ Fc-optimized Antibody that targets B7-H3 known as enoblituzumab, including in combination with other agents such as the anti-PD-1 Antibody known as MGA012, and if approved for commercialization, the commercialization of the Product (defined below) in the Territory, all upon the terms and
conditions set forth in this Agreement. 
 D.    MacroGenics desires to grant to
I-MAB, and I-MAB desires to receive, an exclusive license for all Indications in the Field for all pharmaceutical forms of the Product in the Field for the Territory,
upon the terms and conditions set forth in this Agreement. 
 In consideration of the foregoing premises and the mutual covenants herein
contained, the Parties hereby agree as follows: 
 Agreement: 

 

	1.	 DEFINITIONS. 

Unless specifically set forth to the contrary herein, the following capitalized terms, whether used in the singular or plural, shall have the
respective meanings set forth below: 
 1.1    “Acting Improperly” has the meaning set forth in
Section 4.4(a). 
 1.2    “Affiliate” means with respect to any Party, any person or entity
controlling, controlled by or under common control with such Party. For purposes of this Section 1.2, “control” means (a) in the case of a corporate entity, direct or indirect ownership of at least fifty percent (50%) or more of
the stock or shares having the right to vote for the election of directors of such corporate entity and (b) in the case of an entity that is not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the
direction of, the management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise. 

 1.3    “Antibody” means a [***] molecule [***] and
comprises or contains: (a) [***]; (b) fragments, variants, modifications or derivatives of such immunoglobulin variable domains; and(c) the nucleic acid consisting of a sequence of nucleotides encoding (or complementary to a nucleic acid encoding)
the foregoing molecules in (a) or (b). 
 1.4    “Anti-Corruption Laws” means the U.S. Foreign
Corrupt Practices Act, as amended, the UK Bribery Act 2010, as amended, and any other applicable anti- corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism, including those within the Territory. 

1.5    “Audit” has the meaning set forth in Section 4.4(f). 

1.6    “Applicable Laws and Regulations” means all international, national, federal, state, regional,
provincial, municipal and local government laws, rules, and regulations that apply to either Party or to the conduct of the Collaboration under this Agreement including cGMP, GCP, GBPS, and the laws, rules and regulations of the ICH, the United
States and the Territory, each as may be then in effect, as applicable and amended from time to time. 

1.7    “Biosimilar Product” means, with respect to a Product (but specifically excluding any MGA012
component thereof) sold in a Country or Region, a product that: (a) is marketed by a Third Party that has not obtained the rights to such product as a Sublicensee or distributor of, or through any other contractual relationship with, I-MAB or any of its Affiliates or Sublicensees; contains the same or substantially similar amino acid sequence as the applicable Product; and with respect to a Region or Country of the Territory, has been granted
Regulatory Approval as a biosimilar or interchangeable biological product by the applicable Regulatory Authority in such Region or Country according to a biosimilar regulatory pathway that is materially equivalent to that of Section 351(k) of
the US Public Health Service Act (42 U.S.C. § 262(k)), as may be amended, or any subsequent or superseding law, statute or regulation. 

1.8    “BLA” means (a) a Biologics License Application or New Drug Application
(“NDA”) filed with the FDA for marketing approval of a Product or any successor applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, or similar filings outside the Territory
with applicable Regulatory Authorities, for approval to commercially market, import and sell a Product, or (b) similar filings in the Territory with applicable Regulatory Authorities, including the CFDA, for approval to commercially market,
import and sell a Product. The term BLA shall exclude pricing and reimbursement approvals. 
 1.9    “Business
Day” means a day on which banking institutions in Washington, DC, USA and Beijing, PRC are open for business, excluding any Saturday or Sunday. 

1.10    “Calendar Quarter” means the respective periods of three (3) consecutive calendar months
ending on March 31, June 30, September 30 and December 31. 

  
 2 

 1.11    “Calendar Year” means the respective periods of
twelve (12) months commencing on January 1 and ending on December 31. 
 1.12    “CFDA” means
China Food and Drug Administration, or any successor agency thereto. 
 1.13    “cGMP” or
“current Good Manufacturing Practices” means current Good Manufacturing Practices as set forth in the FDCA and the Public Health Service Act (the “PHS Act”), and in regulations at 21 C.F.R. Parts 210, 211 and 600,
as in effect at the time when any clinical trial regarding a Product is being conducted, provided, and to the extent applicable to such clinical trial, as such regulations are interpreted and enforced by the FDA, including as set forth in applicable
guidance documents issued by the FDA, and in accordance with applicable, generally accepted industry standards, and the equivalent legal requirements in other applicable jurisdictions, including within the Territory, all as the same may be amended
from time to time. 
 1.14    “Clinical Data” means all data generated or arising from the conduct of a
Clinical Trial or other Development efforts under this Agreement. 
 1.15    “Clinical Trial” means a
Phase I Clinical Trial, Phase II Clinical Trial, Phase III Clinical Trial, Phase IV Clinical Trial or Registration Trial, as applicable. 

1.16    “CMC” means chemistry, manufacturing and controls. 

1.17    “CMO” means a contract manufacturing organization. 

1.18    “Collaboration” means the program established under this Agreement, which includes collaborative
Development of the Product. 
 1.19    “Combination Product” means (a) any single product
comprising both (i) Enoblituzumab and (ii) one or more other therapies or pharmaceutically active compounds or substances not included in the MacroGenics Licensed Technology; (b) any sale of the Product with another therapy(ies) or
product(s) for a single invoice price; or (c) any sale of the Product as part of a bundle with other therapy(ies), product(s) or service(s) (i.e., where the Product and such other therapy(ies), product(s) or service(s) are sold for a
single invoice price or where a discount, rebate or other amount that reduces the price of the Product is provided in exchange for (or otherwise conditioned upon) the purchase of such other therapy(ies), product(s) or services), to the extent not
described in clause (a) or (b). The Enoblituzumab portion of any Combination Product shall be deemed the “Licensed Component” and the other portion of such Combination Product [***] shall be deemed the “Other
Component”, and each Combination Product shall be deemed a Product hereunder. For the avoidance of doubt, [***]. 

1.20    “Combination Regimen” means a therapeutic combination comprising MGA012 and Enoblituzumab in
concurrent or sequential administration. 
 1.21    “Combination Regimen Study” means, a Clinical Trial
of a Combination Regimen conducted under the Global Development Plan or Territory Specific Development Plan in the Field in the Territory. 

  
 3 

 1.22    “Commercial Supply Agreement” has the meaning
set forth in Section 5.1(b). 
 1.23    “Commercialization” or “Commercialize”
means activities taken before and after obtaining Regulatory Approval relating specifically to the pre-launch, launch, promotion, marketing, sales force recruitment, sale and distribution of a pharmaceutical
product and post- launch medical activities, including: (a) distribution for commercial sale; (b) strategic marketing, sales force detailing, advertising, and market and product support; (c) medical education and liaison and any Phase
IV Clinical Trials, to the extent permitted by this Agreement; (d) all customer support and product distribution, invoicing and sales activities; and (e) all post-approval regulatory activities, including those necessary to maintain
Regulatory Approvals. 
 1.24    “Commercialization Plan” means a Commercialization plan, to be updated
from time to time and which shall include: (a) periodic sales forecasts by revenue and volume of material; (b) pricing, rebating, and discounting assumptions; (c) sales force deployment estimates; (d) a marketing plan; and
(e) other elements as reasonably requested by MacroGenics. 
 1.25    “Commercially Reasonable
Efforts” means with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar
objective of such Party under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of the Product, such efforts shall be similar to those efforts and resources commonly used by
pharmaceutical or biopharmaceutical companies, as applicable, of comparable size and resources to such Party for a similar biological or pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its
development or product life and is of similar market potential taking into account efficacy, safety, approved labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, and the
likelihood of Regulatory Approval given the regulatory structure involved. 
 1.26    “Completion” or
“Completed” for a clinical trial means the database lock for such clinical trial. 

1.27    “Confidential Information” means any and all non-public
scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information and data, in any tangible or intangible form, including all
Know-How subject to Section 10. 
 1.28    “Control,”
“Controls” or “Controlled by” means (except as used in Section 1.2), with respect to any item of or right under Patents or Know-How, the extent of the ability of a Party
(whether through ownership or license, other than pursuant to this Agreement) to grant access to, or a license or sublicense of, such item or right as provided for herein without violating the terms of any agreement or other arrangement with any
Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense. 

  
 4 

 1.29    “Co-Owned
Clinical Data” has the meaning set forth in Section 3.7. 
 1.30    “Cost Reimbursement
Amounts” has the meaning set forth in Section 13.5(b)(iv). 
 1.31    “Country” means for
the purposes of this Agreement each of PRC and Taiwan. 
 1.32    “Cover” means, with respect to a
product, technology, process or method, that, in the absence of possession of the right (by ownership, license or otherwise) under a Valid Claim, the practice or exploitation of such product, technology, process or method would infringe such Valid
Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue). 

1.33    “CRO” means a clinical research organization. 

1.34    “CTA” means a Clinical Trial Application or its equivalent used to obtain approval to conduct
human clinical investigations filed with or submitted to a Regulatory Authority in order to establish the clinical safety or efficacy of one or more investigational products in conformance with the requirements of such Regulatory Authority. 

1.35    “Data Exclusivity Period” means the period during which the CFDA (or, in regions or countries
other than the PRC, an equivalent Regulatory Authority) prohibits reference, without the consent of the owner of a BLA, to the clinical and other data that is contained in such BLA, and that is not published or publicly available outside of such
BLA. 
 1.36    “Deadlock” has the meaning set forth in Section 2.1(d). 

1.37    “Depot Subcontractor” means any subcontractor [***] to supply a Clinical Trial. 

1.38    “Develop” or “Development” or “Developing” means research,
discovery, and preclinical and clinical drug or biological development activities, including toxicology, formulation, statistical analysis, preclinical and clinical studies and regulatory affairs, approval and registration, in each case, of products
in the Field. “Development” shall specifically exclude Manufacturing. 
 1.39    “Development
Costs” means all costs incurred in connection with any Development activities, including (i) [***], (ii) [***], (iii) [***], (iv) [***], (v) [***], (vi) [***], (vii) [***], (viii) [***], and [***] related to any [***], and (ix) [***]. 

1.40    “Dispute” means any dispute, claim, or controversy (other than matters that are within the
decision-making authority of the JSC or a Party pursuant to Section 2.1(d), or are expressly stated herein to require the consent of both Parties) arising from or related to this Agreement or to the interpretation, application, breach,
termination, or validity of this Agreement, including any claim of inducement of this Agreement by fraud or otherwise. 

1.41    “Enoblituzumab” means the therapeutic Antibody which binds to the
B7-H3 receptor described in [***]. 

  
 5 

 1.42    “Executive Officer” means, with respect to
either Party, the Chief Executive Officer of such Party (or his or her designee). 
 1.43    “Existing
CDA” has the meaning set forth in Section 16.7. 
 1.44    “FDA” means the United States
Food and Drug Administration, or any successor agency thereto. 
 1.45    “FDCA” means the Federal
Food, Drug and Cosmetic Act, as amended. 
 1.46    “Field” means all fields of use (including
treatment and diagnosis), provided, however, that in the case of a Product covered by a Patent or other intellectual property right licensed in one or more MacroGenics Third Party Agreement(s), “Field” shall be limited to the minimum
extent necessary to comply with the terms of such MacroGenics Third Party Agreement for so long as such limitation is necessary to avoid a breach of the MacroGenics Third Party Agreement. 

1.47    “Finance Officers” has the meaning set forth in Section 3.5(c). 

1.48    “First Commercial Sale” means, with respect to the Product, the first sale to a Third Party for
end use or consumption of such Product in the Territory after Regulatory Approval has been granted by the Regulatory Agency for the Product in the Territory other than any sale of the Product for use in a Clinical Trial. 

1.49    “FTE” means [***] devoted to or in direct support of Manufacturing, conducted by one or more
qualified employees of MacroGenics or its Affiliate. For clarity, any individual contributing less than [***] (or equivalent pro-rata portion thereof for the period beginning on the Effective Date and ending
on the last day of the first Calendar Year) shall be deemed a fraction of an FTE on a pro-rata basis. 

1.50    “FTE Cost” means, with respect to any, the FTE Rate multiplied by the number of FTEs expended by
MacroGenics or its Affiliate during such period; provided that I-MAB shall not be charged twice for any FTE Cost if such FTE Cost is already included as a component of Manufacturing expenses payable under this
Agreement. 
 1.51    “FTE Rate” means a rate of [***] per FTE per Calendar Year (pro-rated for the period beginning on the Effective Date and ending on the last day of the first Calendar Year); provided, however, that such rate shall be increased or decreased annually beginning on [***] by the
applicable CPI Adjustment. The FTE Rate includes all direct and indirect costs, i.e., is fully burdened and covers costs including, but not limited to, employee salaries, benefits, travel and other such costs, in each case treated in a manner
consistent with MacroGenics’ accounting policies consistently applied and in accordance with generally accepted accounting practices in the United States (with respect to MacroGenics) and international financial reporting standards (with
respect to I-MAB). 
 1.52    “Force Majeure” has the meaning
set forth in Section 16.1. 

  
 6 

 1.53    “Fully Burdened Manufacturing Cost” or
“FBMC” means, with respect to the Product and [***] of MacroGenics or its Affiliates hereunder, [***]%) of (1) MacroGenics’ cost to Manufacture, if Manufactured by MacroGenics or its Affiliates or (2) the actual Third
Party costs of such Manufacturing incurred by MacroGenics or its Affiliates, if Manufactured by a Third Party, in each case ((1) and (2)) as determined for each stage of the manufacturing process, including [***] (except, in the case of (1), to the
extent attributable to MacroGenics’ or any of its Affiliates’ negligence or willful misconduct, or in the case of (2), to the extent MacroGenics or any of its Affiliates receive a refund, credit or other recovery from such Third Party),
all in accordance with GAAP. Such Fully Burdened Manufacturing Cost shall include the following incurred by or on behalf of MacroGenics or its Affiliates and reasonably allocated to the Product and [***]: 

(a)    FTE Costs and costs of consultants, contractors or other personnel performing Manufacturing or supply activities;

 (b)    direct materials costs (including costs of vials, labeling and packaging); 

(c)    raw materials and reagents costs specifically for actual manufacturing of goods and raw material warehouse costs;

 (d)    operating costs of facilities and equipment (including start up and cleaning costs of production), excluding
any surplus or idle capacity costs; 
 (e)    a charge for depreciation, repairs and maintenance costs of facilities and
equipment, excluding any surplus or idle capacity costs; 
 (f)    quality and
in-process control costs; 
 (g)    a charge for overhead costs proportional to
the total daily rate for the plant for manufacturing plant administration and plant management, materials management, storage and handling, manufacturing and employee training, and all administrative costs associated with the manufacturing operation
of the site (including human resources, information technology and finance costs; raw material and raw material warehouse costs shall be charged directly to the process order); 

(h)    charges for spoilage, scrap or rework costs; and 

(i)    charges for shipping (including all duties and import fees). 

1.54    “GAAP” means U.S. Generally Accepted Accounting Principles as the same may be in effect from time
to time. 
 1.55    “GBPS” means the General Biological Products Standards as set forth in 21 C.F.R.
Part 610, to the extent applicable to the Collaboration. 

  
 7 

 1.56    “GCP” or “Good Clinical
Practices” means current Good Clinical Practices as set forth in the Applicable Laws and Regulations, such as FDCA and the PHS Act and regulations set forth at 21 C.F.R. Part 312, as well as (but not limited to) the requirements set forth
in Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 and Commission Directive 2005/28/EC of 8 April 2005, to the extent applicable to a clinical trial regarding any Product, as such obligations are
interpreted and enforced by the applicable Regulatory Authority (e.g., FDA and Member States of the European Union), and as interpreted under prevailing industry standards, including standards of medical ethics, applicable guidance documents
issued by the FDA and any other Regulatory Authority, including ICH GCP, the informed consent requirements set forth in 21 C.F.R. Part 50 and the equivalent legal requirements in other applicable jurisdictions, the requirements relating to
Institutional Review Boards set forth in 21 C.F.R. Part 56 and the equivalent legal requirements in other applicable jurisdictions, including within the Territory, all as the same may be amended from time to time. 

1.57    “Global Branding Strategy” has the meaning set forth in Section 4.2. 

1.58    “Global Development Plan” means the written Development plan attached to this Agreement as
Exhibit C intended to support Development and Regulatory Approval of the Product in the Field both within the Territory and outside of the Territory, as may be updated and amended periodically in form and substance approved by the JSC in accordance
with Section 3.2 and otherwise at times requested by the JDC or JSC. 
 1.59    “GLP” or
“Good Laboratory Practices” means the recognized rules governing the conduct of non-clinical safety studies and ensuring the quality, integrity and reliability of study data as set forth in
Applicable Laws and Regulations, such as 21 C.F.R. Part 58, and the equivalent legal requirements in other applicable jurisdictions, including within the Territory, all as the same may be amended from time to time. 

1.60    “Government Official” means any Person employed by or acting on behalf of a government,
government-owned or -controlled entity or public international organization; any political party, party official or candidate; any Person who holds or performs the duties of an appointment, office or position created by custom or convention; and any
Person who holds himself out to be the authorized intermediary of any of the foregoing. 
 1.61    “Health
Insurance Portability and Accountability Act” or “HIPAA” means the act enacted by the U.S. Congress in 1996 and took effect in 2003 that strictly dictates the parameters that identifiable private health information (PHI)
can be shared outside of the research environment, as amended. 
 1.62    “ICH” means the International
Conference on Harmonisation. 
 1.63    “I-MAB Indemnitees” has
the meaning set forth in Section 12.2. 
 1.64    “I-MAB Licensed Know-How” means all Know-How (excluding any Patent) Controlled by I-MAB as of the Effective Date or at any time during the
Term that is: (a) related to the Product (including MGA012 as a component of a Combination Regimen); and (b) incorporated or used by I-MAB in connection with the Development or Commercialization of
the Product and MGA012 as a component of a Combination Regimen in the Territory; and (c) necessary or reasonably useful for MacroGenics to exercise the rights licensed to or retained by it under this Agreement or perform its obligations under this
Agreement. The term I-MAB Licensed Know- How shall also be deemed to include I-MAB’s interest in any Know-How jointly owned
pursuant to Section 13.1(c). 

  
 8 

 1.65    “I-MAB Licensed
Patents” means any and all Patents Controlled by I-MAB as of the Effective Date or at any time during the Term that: (a) are related to any data, result or invention conceived, created or reduced
to practice in the course of conducting the Collaboration solely by or on behalf of I-MAB specifically in relation to the Product or Combination Regimen (including in relation to MGA012 as a component of a
Combination Regimen) and (b) I-MAB’s interest in any Patent jointly owned pursuant to Section 13.1(c). 

1.66    “I-MAB Outside Cost Share” means, subject to the
information sharing requirement set forth in Section 2.1(b)(vii), twenty percent (20%) of all Outside Development Costs incurred after the Effective Date and related to (i) activities supporting a MacroGenics Global Clinical Trial in which
I-MAB participates, (ii) process characterization (PC) and process validation (PV) for material that is intended to be incorporated into Clinical Trials conducted in the Territory, or (iii) companion
diagnostic development and validation for Indications that are being studied in the Territory. 
 1.67    “I-MAB Product-Specific Patents” has the meaning set forth in Section 13.2(b)(i). 

1.68    “Improvement Plan” has the meaning set forth in Section 4.4(c)(i). 

1.69    “Incyte Agreement” means that certain Global Collaboration and License Agreement between
MacroGenics and Incyte Corporation effective as of October 24, 2017 as may be amended or restated from time to time. 

1.70    “IND” means an Investigational New Drug application, or similar application or submission for
approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 

1.71    “Indemnifying Party” means the Party that is obligated to indemnify the Indemnitee under
Section 12. 
 1.72    “Indemnitee” means either the I-MAB
Indemnitee or the MacroGenics Indemnitee, as applicable. 
 1.73    “Independent Ethics Committee” or
“IEC” means an independent body (a review board or a committee, institutional, regional, national, or supranational), constituted of medical professionals and non-medical members, whose
responsibility it is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial and to provide public assurance of that protection, by, among other things, reviewing and approving / providing favorable
opinion on, the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to be used in obtaining and documenting informed consent of the trial subjects. The legal status, composition, function, operations and
regulatory requirements pertaining to IEC may differ among countries, but should allow the Independent Ethics Committee to act in agreement with GCP as described in this guideline. 

  
 9 

 1.74    “Indication” means a discrete clinically
recognized form of a disease, [***]. For the sake of clarity, treatment of different subpopulations within a population of patients having a disease shall not be treated as a separate Indication based on different lines of treatment (e.g.,
front-line treatment vs. second-line treatment). 
 1.75    “Investigational Review Board” or
“IRB” means in accordance with 45 C.F.R. 46, Protection of Human Subjects (Revised November 13, 2001) and 21 C.F.R. 45, Subpart C, IRB Functions and Operations, (as amended June 18, 1991 and other applicable regulations), an
independent body comprising medical, scientific, and nonscientific members, whose responsibility is to ensure the protection of the rights, safety, and well-being of the subjects involved in a clinical trial. It may also be referred to as an IEC in
accordance with ICH E6, Section 1.27. 
 1.76    “Involved Party” has the meaning set forth in
Section 16.2. 
 1.77    “Joint Commercialization Committee” or “JCC” has the
meaning set forth in Section 2.1(h)(ii)(1). 
 1.78    “Joint Development Committee” or
“JDC” has the meaning set forth in Section 2.1(h)(i)(1). 
 1.79    “Joint Steering
Committee” or “JSC” has the meaning set forth in Section 2.1(a). 

1.80    “Jointly Owned IP” has the meaning set forth in Section 13.1(c). 

1.81    “Jointly Owned Patents” has the meaning set forth in Section 13.2(b)(i). 

1.82    “Know-How” means (a) any proprietary scientific or
technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, formulations, formulae, knowledge,
know-how, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability
and safety data, assays, studies and procedures, and manufacturing process and development information, results and data, and investigator brochures, all reports, statistical analyses, expert opinions and any other data and information, and
(b) any proprietary biological, chemical or physical materials. 
 1.83    “Licensed Component”
has the meaning set forth in Section 1.19. 
 1.84    “Licensing Transaction” has the meaning set
forth in Section 10.3(d)(ii)(C). 
 1.85    [***] means that certain License Agreement by and between [***] and
MacroGenics, Inc. effective as of [***] as may be amended or restated from time to time. 

  
 10 

 1.86    “Losses” has the meaning set forth in
Section 12.1. 
 1.87    “MacroGenics Global Clinical Trial” means a global Phase III Clinical
Trial for the Product undertaken, by MacroGenics or its Affiliates or permitted assigns or licensees which includes one or more investigator sites within and outside the Territory. 

1.88    “MacroGenics Indemnitee” has the meaning set forth in Section 12.1. 

1.89    “MacroGenics Licensed Know-How” means the Know-How (excluding any Patents) that is Controlled by MacroGenics as of the Effective Date or at any time during the Term, that is: (a) related to the Product, including in the Combination Regimen that
includes MGA012 (but not MGA012 itself) and (b) necessary or reasonably useful for I-MAB to exercise the rights licensed to it pursuant to this Agreement or to perform its obligations under this Agreement
with respect to the Territory. “MacroGenics Licensed Know-How” shall specifically exclude any Know-How licensed by MacroGenics under the [***]. 

1.90    “MacroGenics Licensed Patents” means the Patents in the Territory Controlled by MacroGenics as of
the Effective Date or at any time during the Term that: (a) claim the composition of matter of the Product, including in the Combination Regimen that includes [***] (b) would be infringed by Developing or Commercializing Enoblituzumab or any
Product, including as a component of the Combination Regimen (but not the Development or Commercialization [***]) but for the license granted hereunder, (c) would be infringed by use of [***] in a Combination Regimen but for the license granted
hereunder, or (d) are otherwise necessary or reasonably useful for I-MAB to Develop and Commercialize the Product in accordance with this Agreement, including as a component of the Combination Regimen
(but not the Development or Commercialization [***]). The MacroGenics Licensed Patents existing as of the Effective Date are listed in Exhibit A attached hereto. “MacroGenics Licensed Patents” shall include MacroGenics’ interest in
any Patents deemed jointly owned pursuant to Section 13.1(c), but shall specifically exclude any Patents licensed by MacroGenics under the [***]. 

1.91    “MacroGenics Licensed Technology” means the MacroGenics Licensed Patents and the MacroGenics
Licensed Know-How. 
 1.92    “MacroGenics Licensed Trademarks”
means any and all Trademarks Controlled by MacroGenics as of the Effective Date or at any time during the Term, (i) that are registered for or apply to a Product; and (ii) as otherwise listed on Exhibit B. 

1.93    “MacroGenics Outside Cost Share” has the meaning set forth in Section 3.5(b). 

1.94    “MacroGenics Third Party Agreement” means each of (i) the [***], (ii) the Incyte Agreement,
and (iii) such other license agreements between MacroGenics and its Third Party licensor pursuant to which MacroGenics in-licenses intellectual property from such Third Party that is included within the
MacroGenics Licensed Technology and identified as such in writing by MacroGenics to I-MAB (collectively referred to as the “MacroGenics Third Party Agreements”). 

  
 11 

 1.95    “MacroGenics Product-Specific Patent” means
each MacroGenics Licensed Patent that solely and exclusively Covers (i.e., that does not also Cover the composition of matter of, or the method of using, any other product): (a) the [***], or (b) the [***], in each case ((a) and (b)) in
the Territory, but excluding all MacroGenics Licensed Patents that Cover MGA012 (including its use), in whole or in part, (including as a component of a Combination Regimen). 

1.96    “Major Safety Issue” means, with respect to a Product, any of the following: (a) an [***] of
a Product, or receipt or generation by a Party of any [***] or other data, indicating or signaling, as measured by [***] and methodology customarily used by a majority of clinicians conducting studies on similar products in the applicable region
(including Region) or country (including Country), that such Product has or would have serious enough risks for medical applications in humans to require a [***]; or (b) any notice, information or correspondence received by a Party from a
Regulatory Authority, or any action taken by a Regulatory Authority, in each case, indicates that [***] or, if [***], the [***] therefor would [***], or causes the [***] or, if [***], to be [***]. 

1.97    “Manufacture” or “Manufacturing” means all operations involved in the
manufacturing (including process development, process characterization (PC) and process validation (PV)), quality assurance and quality control testing (including test method development and in-process,
release and stability testing, if applicable), storage, releasing, packaging and importation of the Product or MGA012 to supply the Product or MGA012 for Development of the Product under the Global Development Plan and the Territory Specific
Development Plan and Commercialization under the Commercialization Plan. For purposes of clarification “Manufacturing” is not included in Development or Commercialization. 

1.98    “MGA012” means the
anti-PD-1 Antibody coded as “MGA012”, as further described in [***]. 

1.99    “MGA012 Commercial Forecasts” has the meaning set forth in Section 5.1(a). 

1.100    “Milestone Payment” has the meaning set forth in Section 7.2(a). 

1.101    “Net Sales” means the gross amount invoiced for the Product sold by I-MAB or its Related Parties, in the Territory initially and directly to Third Parties which are not Related Parties after deducting, if not previously deducted, from the amount invoiced, the following, in each case
to the extent included in the gross invoice price: 
 (a)    reasonable trade, quantity and cash discounts and rebates
(including wholesaler inventory management fees), chargebacks, and retroactive price reductions or allowances actually allowed or granted from the billed amount; 

(b)    credits or allowances actually granted upon claims, rejections or returns of such sales of the Product, including
recalls and amounts credited or repaid because of retroactive price reductions specifically identifiable to the Product; 

(c)    taxes imposed on the production, sale, import, delivery or use of the Product (including sales, use, excise or
value added taxes but excluding income taxes), duties or other governmental charges (including charges for product testing required for importation) levied on or measured by the billing amount when included in billing, as adjusted for rebates and
refunds; and 

  
 12 

 (d)    costs incurred for importing (including transportation, freight
and insurance, and warehousing in the Territory); 
 (e)    rebates or discounts on sales of Products given to health
insurance and other types of payers in any given country of the Territory due to specific agreement (“claw-back” type of agreements) with respect to the Products; and 

(f)    the actual amount of any write-offs for bad debt in accordance with standard practices for writing off
uncollectible amounts consistently applied; provided with respect to such write-off that (i) any deduction taken pursuant to this Section 1.101(f) may not exceed [***] ([***]%) of Net Sales in any
given Calendar Quarter and (ii) an amount subsequently recovered or reversed with respect to such write-off will be treated as Net Sales in the quarter in which it is recovered or reversed. 

For the avoidance of doubt, if a single item falls into more than one of the categories set forth in clauses (a)-(f) above, such item may not be deducted more
than once. 
 Such amounts shall be determined from the books and records of I-MAB or its Related
Party, maintained in accordance with International Financial Reporting Standards (IFRS) or such similar accounting principles, consistently applied. I-MAB further agrees, in determining such amounts, it shall
use I-MAB’s then-current standard procedures and methodology. Notwithstanding the foregoing, any conversion of foreign currency sales into U.S. Dollars will be made at the conversion rate existing in the
United States [***]. Without limiting the generality of the foregoing, non-invoiced transfers or dispositions of Product for charitable, compassionate use, promotional (including samples, in amounts reasonably
customary in the industry), non-clinical, clinical, or regulatory purposes shall be excluded from Net Sales, as will sales or transfers of Product among a Party and its Related Parties unless such Party or
Related Party is the end user of such Product, but rather the Net Sales shall be deemed to have arisen upon the subsequent sale or transfer of Product to Third Parties. 

If I-MAB or any of its Related Parties sells a Product as a Licensed Component of a Combination
Product in the Territory in any Calendar Quarter, then Net Sales shall be calculated by multiplying the Net Sales of the Combination Product during such Calendar Quarter by the fraction A/(A+B), where A is the average Net Sales per unit sold of the
Licensed Component when sold separately in the Territory during such Calendar Year (calculated by determining the Net Sales of the Licensed Component during such Calendar Quarter in accordance with the definition of Net Sales set forth herein and
dividing such Net Sales by the number of units of the Licensed Component during such Calendar Quarter) and B is the average Net Sales per unit sold of the Other Component(s) included in the Combination Product when sold separately during such
Calendar Quarter (calculated by determining the Net Sales of such Other Component(s) sold during such Calendar Quarter by applying the definition of Net Sales set forth herein as if it applied to sales of such Other Component(s) and dividing such
Net Sales by the number of units of such Other Component(s) sold during such Calendar Quarter). 

  
 13 

 For purposes of calculating the average Net Sales per unit sold of a Licensed Component and
Other Component(s) of a Combination Product, any of the deductions described herein that apply to such Combination Product shall be allocated among sales of the Licensed Component and sales of the Other Component(s) included in such Combination
Product as follows: (i) deductions that are attributable solely to the Licensed Component or one of the Other Component(s) shall be allocated solely to Net Sales of the Licensed Component or such Other Component, as applicable, and
(ii) all other deductions shall be allocated among sales of the Licensed Component and sales of the Other Component(s) in proportion to I-MAB ’s and MacroGenics’ mutual agreement of the fair
market value of the Licensed Component and the Other Component(s). 
 In the event that no separate sales of the Licensed Component or any
Other Component(s) included in a Combination Product are made by I-MAB or its Related Parties, during a Calendar Quarter in which such Combination Product is sold, the average Net Sales per unit sold in the
above described equation shall be replaced with I-MAB ’s and MacroGenics’ mutual agreement of the fair market value of the Licensed Component and each of the Other Component(s) included in such
Combination Product. 
 1.102    “NDA” has the meaning set forth in Section 1.8. 

1.103    “Noninvolved Party” has the meaning set forth in Section 16.2. 

1.104    “Other Component” has the meaning set forth in Section 1.19. 

1.105    “Outside Development Costs” means all [***] and [***] and Development Costs incurred after the
Effective Date by or on behalf of I-MAB, MacroGenics or a Related Party outside the Territory in connection with the conduct of the Development Plan for activities that support the Development of the Product
for the Territory including companion [***]. 
 1.106    “Party Representatives” has the meaning set
forth in Section 4.4. 
 1.107    “Patent Prosecution” means the responsibility for
(a) preparing, filing, prosecuting, and pursuing registration of, applications (of all types) for any Patent (b) for maintaining any Patent, and (c) for managing any interference or opposition proceeding relating to the foregoing.

 1.108    “Patent(s)” means (a) all patents and patent applications in any country (including
Country), region (including Region) or supranational jurisdiction and (b) any provisionals, substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions,
supplementary protection certificates and the like, of any such patents or patent applications. 

1.109    “Permitted Subcontractors” has the meaning set forth in Section 3.6. 

1.110    “Person” means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department
or agency of a government. 

  
 14 

 1.111    “Phase I Clinical Trial” means a human
clinical trial, or the relevant portion of such trial, of a product in patients in any country (including Country or Region) in accordance with GCP that generally provides for the first introduction into humans of a product and is intended to
determine safety, metabolism and pharmacokinetic properties and clinical pharmacology of a product in health patients, or that would otherwise satisfy the requirements of Applicable Laws and Regulations for such country in which such human clinical
trial is conducted, such as 21 C.F.R. § 312.21(a), relating to human clinical trials conducted in the United States, or any successor regulation thereto or foreign equivalents. 

1.112    “Phase II Clinical Trial” means a human clinical trial, or the relevant portion of such trial,
conducted in patients with a product, in accordance with GCP and intended to demonstrate efficacy and a level of safety in the particular Indication tested, as well as to obtain a preliminary Indication of the unit or daily dosage regimen required,
or that would otherwise satisfy the requirements of Applicable Laws and Regulations of the country (including Country or Region) in which such human clinical trial is conducted, such as 21 C.F.R. § 312.21(b), relating to human clinical trials
conducted in the United States, or any successor regulation thereto or foreign equivalents. 
 1.113    “Phase
III Clinical Trial” means a human clinical trial, or the relevant portion of such trial, in any country that is conducted in accordance with GCP and the results of which are intended to be used as a pivotal study to establish both safety
and efficacy of a product as a basis for a BLA submitted to the FDA, CFDA or the appropriate Regulatory Authority of such other country (including Country or Region), or that would otherwise satisfy the requirements of 21 

C.F.R. § 312.21(c), or any successor regulation thereto or foreign equivalents. 

1.114    “Phase IV Clinical Trial” means a human clinical trial conducted after the Regulatory Approval
of a Product in a country (including Country or Region), which trial is conducted (a) voluntarily to enhance scientific knowledge of such Product (e.g., for expansion of product labeling or dose optimization); or (b) conducted due
to a request by or a requirement of a Regulatory Authority of a country (including Country or Region). 

1.115    “PHS Act” has the meaning set forth in Section 1.13. 

1.116    “PRC” means the People’s Republic of China, which for purposes of this Agreement, excludes
the Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan. 

1.117    “Product” means a product that incorporates a biopharmaceutical form of Enoblituzumab as an
active ingredient, including as part of a Combination Regimen. 
 1.118    “Product Brand” has the
meaning set forth in Section 4.2. 
 1.119    “Region” means individually and collectively Hong
Kong Special Administrative Region, and Macau Special Administrative Region. 

  
 15 

 1.120    “Registration Trial” means the first Clinical
Trial which is designed to secure Regulatory Approval for the Product in a Country or Region in the Territory. 

1.121    “Regulatory Approval” means a BLA approval from the relevant Regulatory Authority in a region
(including Region) or country (including Country) to market and sell a product in such region or country. 

1.122    “Regulatory Authority” means any applicable government regulatory authority involved in granting
approvals for the conduct of Clinical Trials or the manufacturing, marketing, reimbursement or pricing, as applicable, of a Product, including in the United States, the FDA and in the PRC, the CFDA, and any successor governmental authority having
substantially the same function. 
 1.123    “Regulatory Submissions” means any filing, application, or
submission with any Regulatory Authority, including authorizations, approvals or clearances arising from the foregoing, including CTAs, INDs, BLAs, NDAs, and Regulatory Approvals, and all correspondence or communication with or from the relevant
Regulatory Authority, as well as minutes of any material meetings, telephone conferences or discussions with the relevant Regulatory Authority, in each case, with respect to a Product. 

1.124    “Related Party” means, with respect to a Party, its Affiliates and Sublicensees. 

1.125    “Requesting Party” has the meaning set forth in Section 8.2(a). 

1.126    “Required Clinical Trials” has the meaning set forth in Section 3.1(a). 

1.127    “Required License” has the meaning set forth in Section 7.4. 

1.128    “Royalty Term” means, with respect to sales of a Product in the Territory, on a Country-by-Country and Region-by-Region basis, the time period beginning on the First
Commercial Sale of such Product in the Territory and expiring on the latest of the following dates: 
 (a)    the [***]
anniversary of the date of First Commercial Sale of the Product in such Country or Region; 
 (b)    the expiration in
the Territory of the last-to-expire MacroGenics Licensed Patent having a Valid Claim covering the composition, Manufacture, use, method of treatment, sale or import of
the Product in such Country or Region; or 
 (c)    the expiration of the latest Data Exclusivity Period for the Product
in such Country or Region. 
 1.129    “Safety Management Plan” or “SMP” has the
meaning set forth in Section 6.5. 
 1.130    “SAIC” has the meaning set forth in
Section 14.3. 

  
 16 

 1.131    “SAIC Rules” has the meaning set forth in
Section 14.3. 
 1.132    “Site Regulatory Package” or “SRP” means a set of
investigational site-specific regulatory documents requiring review and approval by the JSC. The SRP typically consists of the following documents: Form FDA 1572 (or an equivalent document used in a region (including Region) or country (including
Country) in the Territory that identifies any relationships that pose a potential conflict of interest for an investigator or other person whose responsibilities are critical to conduct of a clinical trial), principal investigator curriculum vitae,
signed protocol signature page, site-specific informed consent or informed assent forms (back-translated into English if the local language is other than English), investigator brochure, clinical trial agreement, clinical trial approval, IRB/IEC
approval, study site qualification documents, privacy requirements (e.g., HIPAA), IRB/IEC membership, and other country (including Country)-specific or region (including Region)-specific requirements. 

1.133    “Study Material(s)” means the Product and MGA012 Manufactured in accordance with the
specifications as adopted by MacroGenics and laws, rules and regulations of the United States and in the Territory (a) for preclinical activities, and (b) for administration to subjects in Clinical Trials. 

1.134    “Sublicensee” means a Third Party that is granted a sublicense under the licenses granted to a
Party under this Agreement, as permitted under this Agreement. 
 1.135    “Term” has the meaning set
forth in Section 15.1. 
 1.136    “Territory” means the PRC, Hong Kong Special Administrative
Region, Macau Special Administrative Region, and Taiwan. 
 1.137    “Territory Development Costs” has
the meaning set forth in Section 3.5(a). 
 1.138    “Territory Specific Development Plan” means
the written plan for Development of the Product in the Field in the Territory attached to this Agreement as Exhibit D that is primarily intended to support Regulatory Approval of the Product in the Territory (and, for clarity, not outside the
Territory) and not otherwise included within the Global Development Plan. 
 1.139    “Territory Specific
Regulatory Submissions” has the meaning set forth in Section 6.3. 
 1.140    “Territory Subjects
Enrolled” means that portion of the Total Subjects Enrolled recruited directly by I-MAB (as a direct result of I-MAB’s Development efforts) in the
Territory for the applicable Clinical Trial. 
 1.141    “Third Party” means an entity other than (a) I-MAB and its Affiliates, and (b) MacroGenics and its Affiliates. 

1.142    “Total Subjects Enrolled” means, with respect to a given Clinical Trial, the total number of
study subjects enrolled in such Clinical Trial worldwide. 

  
 17 

 1.143    “Trademark Prosecution” means the
responsibility for (a) preparing, filing, and seeking registration of, trademark applications (of all types) for any Trademark, (b) for maintaining any Trademark, and (c) for managing any interference or opposition proceeding relating
to the foregoing. 
 1.144    “Trademark(s)” means all trade names, logos, common law trademarks and
service marks, trademark and service mark registrations and applications throughout the world. 

1.145    “Triggered Third Party Payment” means [***] payable by MacroGenics in each case pursuant to:
(x) the MacroGenics Third Party Agreements in effect as of the Effective Date and (y) any additional MacroGenics Third Party Agreements identified by MacroGenics after the Effective Date that includes intellectual property that would
otherwise prevent MacroGenics from fulfilling its obligations under this Agreement or from supplying the Product in the Territory, in each case ((x) and (y)) as a result of the Collaboration or the Parties’ activities under this Agreement with
respect to the Development or Commercialization of the Product for the Territory, including the Development, Manufacture and supply (by or on behalf of MacroGenics or its designee), or Commercialization thereof. 

1.146    “United States” or “U.S.” means the United States of America and its
territories and possessions, including the Commonwealth of Puerto Rico and the U.S. Virgin Islands. 

1.147    “U.S. Dollars” means United States Dollars, the lawful currency of the United States. 

1.148    “Valid Claim” means a claim of: (a) an issued and unexpired Patent included within the
MacroGenics Licensed Patents in a country (including Country or Region) which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and has not been abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (b) a pending patent application that has been filed in good faith and that has not been
cancelled, withdrawn, abandoned, finally rejected or expired without the possibility of appeal or refiling, provided that Valid Claim will exclude any such pending claim in an application that has not been granted within [***] following the earliest
priority filing date for such application. For purposes of the definition of Valid Claim, “determination” means a determination with respect to a Patent that would prevent a Party from enforcing or continuing to enforce such Patent. To the
extent that any Patent is issued, restored or otherwise deemed valid and enforceable, then it once again shall be considered a Valid Claim as from the date of such issuance, restoration or determination. 

  
 18 

	2.	 GOVERNANCE 

 

	 	2.1	 Joint Steering Committee 

(a)    Membership. The Parties hereby establish a joint steering committee (the “Joint
Steering Committee” or “JSC”), to coordinate and oversee activities on which the Parties collaborate under this Agreement. The JSC shall consist of [***] representatives from each Party. [***] shall
designate one (1) of its representatives as the initial chairperson of the JSC. Thereafter, the role of chairperson shall alternate between MacroGenics and I-MAB representatives on a yearly basis. Each
Party may replace its appointed JSC representatives at any time upon reasonable written notice to the other Party. The initial representatives and chair of the JSC shall be established within [***] after the Effective Date. The chair shall have the
responsibility to call meetings, circulate meeting agendas at least [***] prior to each regular JSC meeting, draft minutes for each JSC meeting and circulate such minutes for both Parties’ written approval. The chair shall have no other
authority or special voting power. 
 (b)    Responsibilities. The responsibilities of the JSC shall be: 

(i)    to provide a vehicle by which the Parties may share information regarding the overall strategy for the
Collaboration; 
 (ii)    to review, discuss and approve each of the Global Development Plan (with respect to the
regulatory activities, non-clinical and clinical Development activities under the Global Development Plan that are to be conducted in the Territory), the Territory Specific Development Plan, the
Commercialization Plan and any updates or amendments thereto and to share the progress of activities under each applicable plan on a [***]; 

(iii)    to facilitate the exchange of information between the Parties with respect to the activities hereunder and to
establish procedures for the efficient sharing of information necessary for the Parties to fulfill their respective responsibilities with respect to the Collaboration; 

(iv)    to share and discuss the data generated by or on behalf of the Parties in the course of performance towards the
goals set forth in the Global Development Plan, the Territory Specific Development Plan and the Commercialization Plan, respectively; 

(v)    to coordinate Development and Commercialization strategies, allocate resources and set timelines, in each case to
facilitate the activities under the Global Development Plan, the Territory Specific Development Plan and the Commercialization Plan, respectively; 

(vi)    to review proposed Clinical Trial sites in the Territory; 

(vii)    to provide information on Outside Development Cost projections or Global Clinical Trial cost projections, when
such projections have been reasonably requested by a Party and when such projections are reasonably available; 

(viii)    to review and approve [***]; 

(ix)    to review and approve proposed protocols for any Clinical Trial related to the Territory Specific Development
Plan prior to the submission to any Regulatory Authority; 

  
 19 

 (x)    to establish an overall regulatory strategy for the Product in
the Territory that is consistent with and complements the worldwide regulatory strategy being implemented by MacroGenics for the Product; 

(xi)    to establish such subcommittees (including the JDC and JCC), as are agreed upon in writing by the Parties, to
oversee the activities of subcommittees (including the JDC and JCC) created under this Agreement, and to seek to resolve any issues that such subcommittees cannot resolve; 

(xii)    to approve any CRO or Depot Subcontractor proposed to be engaged by
I-MAB to support or facilitate any Clinical Trial activities within the Territory; 

(xiii)    to establish an overall strategy for the filing, prosecution and maintenance of MacroGenics Licensed Patents,
MacroGenics Licensed Trademarks and I-MAB Licensed Patents in the Territory and Patent and Trademark term extensions; and 

(xiv)    to perform such other functions as expressly set forth in this Agreement or as appropriate to further the
purposes of this Agreement, as determined by the Parties. 
 (c)    Decision-Making. The JSC shall make decisions
[***], with each Party’s representatives collectively having [***] and at least [***] representative from each Party present. 

(d)    Deadlocks; Final Decision-Making Authority. In the event the JSC cannot reach an agreement regarding any
matter within the JSC’s authority for a period of [***] (a “Deadlock”), then either Party may elect to submit such issue to the Parties’ Executive Officers, and if a Party makes an election to refer a matter to the
Executive Officers, the Executive Officers shall use good faith efforts to resolve promptly such matter, which good faith efforts shall include [***] Executive Officers within [***] after the submission of such matter to them. If the Executive
Officers are unable to reach consensus on any such matter within [***] after its submission to them, the Deadlock shall be resolved in accordance with the provisions of this Section 2.1(d): 

(i)    Except for [***] set forth in [***] shall have the [***], including regarding: 

(1)    Manufacturing of Product and MGA012 (including with respect to aspects of Development, Regulatory Approval and
Commercialization of the Product and MGA012 related to the Manufacture thereof); 
 (2)    global Development of the
Product or MGA012, including the conduct of all MacroGenics Global Clinical Trials; 
 (3)    global Commercialization
of the Product or MGA012; and 
 (4)    protocols for any MacroGenics Global Clinical Trial of a Product to be
conducted by I-MAB and protocols for any Clinical Trial conducted by I-MAB that includes MGA012. 

  
 20 

 (ii)    [***] shall have the [***] on all [***] pertaining solely and
specifically to (A) the [***] specifically and exclusively for the Territory, provided that this [***] to (1) [***] or (2) [***] or (B) execution of [***] (consistent with the [***] for such Product in accordance with
Section 4.1) of the Product in the Field for the Territory conducted by I-MAB and its Related Parties hereunder, including [***] (other than the matters described in
sub-clause (i) above), except where MacroGenics considers in [***] that the conduct of the [***] the clinical or regulatory program or Commercialization of the Product or MGA012 outside the Territory.

 All disputes that are not subject to the decision-making authority of the Parties under Section 2.1(d)(i) and 2.1(d)(ii), shall be subject to
binding arbitration in accordance with Section 14. No exercise of a Party’s decision-making authority on any such matters may, without the other Party’s prior written consent, unilaterally (a) make a determination as to whether a
particular milestone or other criteria has been achieved or that any if its obligations under this Agreement has been fulfilled, (b) override, amend or add to such Party’s consent or approval rights or otherwise expand or reduce such
Party’s obligations set forth under this Agreement, (c) impose any requirements that the other Party take or decline to take any action that would result in a violation of Applicable Laws and Regulations or any agreement with any Third
Party (including any MacroGenics Third Party Agreements) or the infringement of intellectual property rights of any Third Party, (d) make a decision that is expressly stated in this Agreement to require the consent or approval of the other
Party, or (e) otherwise conflict with this Agreement. 
 (e)    JSC Meetings. JSC meetings shall be held
[***], or on any other schedule mutually agreed by the Parties. With the consent of the representatives of each Party serving on the JSC, other representatives of each Party may attend meetings as non-voting
observers (provided such non-voting observers have confidentiality obligations to such Party that are at least as stringent as those set forth in this Agreement). A JSC meeting may be held either in person or
by audio, video or internet teleconference with the consent of each Party. Meetings of the JSC shall be effective only if at least [***] representative of each Party is present or participating. Each Party shall be responsible for all of its own
expenses of participating in the JSC meetings. The Parties shall alternate hosting the in-person meeting, and the Party hosting is responsible for preparing and circulating the minutes of the JSC meetings.

 (f)    Duration of JSC. The JSC shall continue to exist until the first to occur of 

(a)    the Parties mutually agreeing in writing to disband the JSC or (b) termination of this Agreement in accordance
with the terms hereof. 
 (g)    Limitations. The JSC shall have no authority other than that expressly set forth
in this Section 2.1 and, specifically, shall have no authority (a) to amend or interpret this Agreement, or (b) to determine whether or not a breach of this Agreement has occurred. 

  
 21 

 (h)    Subcommittees. Each Subcommittee (including the JDC and
JCC) shall be composed of [***]. Each Party may replace its subcommittee representatives upon written notice to the other Party. All decisions of a Subcommittee shall be made by unanimous vote, with each Party’s representatives having one vote.
In the event the Parties are unable to reach a unanimous vote with respect to a matter, such matter shall be referred to the JSC for resolution. 

(i)    Joint Development Committee. 

(1)    General. Within [***] of the Effective Date, the Parties shall establish a joint development committee (the
“Joint Development Committee” or the “JDC”) (1) to oversee the day-to-day Development of the Product and Combination Regimen and the
execution of the Global Development Plan and the Territory Specific Development Plan, (2) to oversee the progress of Regulatory Approvals and Regulatory Submissions for the Product and Combination Regimen, (3) to share information
regarding Clinical Trials in the Territory (including Clinical Data), and (4) such other Development related activities delegated to it by the JSC. Each Party shall appoint [***] to the JDC, each of whom shall be an officer or employee of the
applicable Party having sufficient knowledge regarding Development of the Product. 
 (2)    Meetings. For so
long as a Party is planning or conducting a Clinical Trial for a Product in the Territory, the JDC shall meet at least [***]. The Parties shall endeavor to schedule meetings of the JDC at least [***] in advance. 

(ii)    Joint Commercialization Committee. 

(1)    General. Within [***] after initiating the Registration Trial, the Parties shall establish a joint
commercialization committee (the “Joint Commercialization Committee” or the “JCC”) to oversee and coordinate (1) the day- to-day Commercialization of the Product in the Territory and the execution of the Commercialization Plan, including review of branding, marketing strategy, Product positioning, pricing and reimbursement strategy (to
the extent legally permissible), (2) the progress of Commercialization activities for the Product, and (3) such other Commercialization related activities delegated to it by the JSC. Each Party shall appoint [***] to the JCC, each of whom shall
be an officer or employee of the applicable Party having sufficient knowledge regarding Commercialization of the Product. 

(2)    Meetings. While the Parties are Commercializing the Product in the Territory, the JCC shall meet at least
[***]. The Parties shall endeavor to schedule meetings of the JCC at least [***]. 

  
 22 

	3.	 DEVELOPMENT 

3.1    I-MAB Responsibilities. I-MAB
shall use Commercially Reasonable Efforts to Develop the Product in the Territory in accordance with this Agreement. Without limiting the foregoing, I-MAB shall Develop the Product in the Territory in
accordance with the Global Development Plan and Territory Specific Development Plan, as set forth below, with the goal of achieving Regulatory Approval for the marketing of the Product in the Territory. I-MAB
shall use [***] those set forth in the Global Development Plan, or that are otherwise acceptable to MacroGenics. I-MAB shall conduct all activities assigned to I-MAB by
the JSC in the Global Development Plan, and will lead the activities in the Territory Specific Development Plan. I-MAB [***] (in accordance herewith) unless (i) such other [***], (ii) the Regulatory
Authorities [***] as anticipated in the Territory Specific Development Plan without (A) resulting in a [***] that is reasonably anticipated to be [***], relative to the [***] or (B) requiring a [***] that is reasonably likely to require a
[***] above the [***], and (iii) such other [***] is either [***] that is mutually acceptable to both Parties. 
 (a)    I-MAB ’s responsibilities shall include (i) conducting all Clinical Studies (other than MacroGenics Global Clinical Trials) required for Regulatory Approval of the Product in the
Territory under the Territory Specific Development Plan and the Global Development Plan (subject to MacroGenics’ right under Section 3.6 to select Permitted Subcontractors to conduct activities under the Global Development Plan); (ii)
participating in either the Phase 3 portion of the proposed Clinical Trial [***] or another mutually acceptable MacroGenics Global Clinical Trial of a Combination Regimen; (iii) completing [***] Phase II Clinical Trials or Phase III Clinical
Trials of the Product in the Territory focused on other [***] (e.g., [***] and [***]) (such trials, the “Required Clinical Trials”); (iv) the submission of all CTAs in the Territory;
(v) interaction with the Regulatory Authorities in the Territory; (vi) translation of necessary documents required for Regulatory Approval in the Territory; (vii) recruiting, qualifying and establishing Clinical Trial sites for the
Territory, including the preparation, collection, review, approval and translation of all Site Regulatory Packages required to authorize shipment of Study 

Materials to all participating clinical trial sites in the Territory, monitoring of all Clinical Trial sites in the Territory; and
(viii) providing reasonable assistance to MacroGenics (at MacroGenics’ cost) with submissions to and interactions with the FDA and other Regulatory Authorities outside of the Territory; provided, however, that with respect to the provision
of data, information and materials, such obligation to assist shall not require I-MAB to generate any data not within its possession or control; 

(b)    I-MAB shall use Commercially Reasonable Efforts to initiate (where [***] of
[***]) (i) the [***] (e.g., for the treatment of [***] using the Product [***]) within [***] after the Effective Date and (ii) the [***] (e.g., for the [***]) within [***] after the Effective Date, provided, however that, with the
prior consent of MacroGenics (such consent shall not be unreasonably withheld, conditioned or delayed), such timeframes shall be extended for so long as reasonably necessary for I-MAB to (i) address
information or other requests from Regulatory Authorities in the Territory or (ii) ensure the availability of enough Product to conduct such Clinical Trial. 

(c)    I-MAB shall support other additional Development activities responsive to
unique regulatory or commercial requirements in the Territory. 

  
 23 

 3.2    Development Plans. The Development of the Product in the
Territory under this Agreement shall be governed by the Global Development Plan and Territory Specific Development Plan, which may be revised from time to time in accordance with this Section 3.2. During the Term, the Global Development Plan and
Territory Specific Development Plan shall contain in reasonable detail the major Development and regulatory activities conducted by or on behalf of I-MAB (or its Affiliates or Sublicensees), including those
necessary to (i) gain Regulatory Approval [***] and (ii) the timelines for achieving such activities until such Regulatory Approval in each Country or Region in the Territory has been obtained. In accordance with Section 2.1(b)(ii),
the JDC shall review and submit to the JSC for approval, and the JSC shall review and approve the Global Development Plan and the Territory Specific Development Plan and any updates or amendments to the Global Development Plan and Territory Specific
Development Plan. The initial Global Development Plan is attached hereto as Exhibit C and initial Territory Specific Development Plan is attached hereto as Exhibit D. 

(a)    Review of Development. The JDC shall review the progress of the conduct of the Global Development Plan and
Territory Specific Development Plan at each meeting of the JDC. 
 (b)    Review of the Global Development Plan and
the Territory Specific Development Plan. On [***], the JDC shall review the Global Development Plan with respect to its conduct in the Territory and the Territory Specific Development Plan, each with respect to its respective progress, as
appropriate, and shall recommend any amendment, and any changes (which for the Global Development Plan shall be limited to its conduct in the Territory) to such plans, which shall be submitted to and subject to the approval by the JSC. Once approved
by the JSC, the Parties agree that any such updated Global Development Plan or Territory Specific Development Plan shall supersede and replace, as applicable, the then-current Global Development Plan and Territory Specific Development Plan with
respect to the Territory. 
 3.3    MacroGenics Responsibilities. As between the Parties, MacroGenics shall be
responsible for (itself or through its Affiliates or licensees) Developing the Product outside of the Territory. Without limiting the foregoing, MacroGenics’ responsibilities shall include, either by itself or through its Affiliates or
licensees, using Commercially Reasonable Efforts to conduct those Development activities assigned to MacroGenics under the MacroGenics Global Development Plan or the Territory Specific Development Plan. 

(a)    MacroGenics agrees to use Commercially Reasonable Efforts to (i) cooperate in all material respects and be
actively involved with I-MAB in such efforts and to provide reasonable assistance to I-MAB with submissions (including an [***]) to and interactions with the CFDA and
other Regulatory Authorities and (ii) conduct ancillary Development or Manufacturing activities and provide reasonable access to related information necessary to obtain Regulatory Approval for the Product in the Territory including those listed
in Exhibit E, at I-MAB’s reasonable request and at I-MAB’s cost and expense (including FTE Costs and out of pocket costs). Notwithstanding the reimbursement
provisions under Section 3.3(b) and Section 3.5, I-MAB shall reimburse MacroGenics for [***] ([***]%) of MacroGenics’ FTE Costs and out-of-pocket expenses for conducting such activities [***] MacroGenics for such costs and expenses. 

  
 24 

 (b)    MacroGenics agrees to use Commercially Reasonable Efforts to
[***] on a design and timeline mutually agreed upon by the Parties. I-MAB shall reimburse MacroGenics for [***] ([***]%) of MacroGenics’
out-of-pocket expenses for conducting such study [***] MacroGenics for such out-of-pocket
expenses and shall be entitled to a one-time credit of [***] ([***]%) of the total amount of such reimbursement against the next Milestone Payment due to MacroGenics pursuant to Section 7.2(a). 

(c)    MacroGenics shall use Commercially Reasonable Efforts to complete the [***] and to generate sufficient material to
support the Territory Specific Development Plan on a timeline mutually agreed upon by the Parties. 
 3.4    Conduct
of Development. I-MAB shall conduct the Development activities under the Territory Specific Development Plan and those Development activities allocated to I-MAB
under the Global Development Plan and achieve the corresponding Development goals as described in the Global Development Plan and Territory Specific Development Plan, in compliance with: (a) the terms and conditions of this Agreement;
(b) the Global Development Plan and Territory Specific Development Plan, as updated from time to time; (c) all applicable GLP, GCP and applicable cGMP requirements, including those specified by the ICH; and (d) all Applicable Laws and
Regulations. MacroGenics shall conduct its activities under this Agreement in compliance with: (w) the terms and conditions of this Agreement; (x) the Global Development Plan, as updated from time to time; (y) all applicable GLP, GCP
and applicable cGMP requirements, including those specified by the ICH; and (z) all Applicable Laws and Regulations. 

3.5    Development Costs. 

(a)    Territory Specific. I-MAB shall be responsible for all Development
Costs incurred by I-MAB and all Development Costs incurred in the Territory by MacroGenics or a Related Party in connection with the conduct of the Global Development Plan, subject to Section 2.1(b)(vii),
or Territory Specific Development Plan, including the applicable cost of the supply of Study Materials (the “Territory Development Costs”). Costs for the supply of Study Materials by or on behalf of MacroGenics to I-MAB are addressed in Section 5.1(b). 
 (b)    Outside Territory. I-MAB shall be responsible for the I-MAB Outside Cost Share, and, as between the Parties, MacroGenics shall be responsible for all Outside Development Costs other than the I-MAB Outside Cost Share (the “MacroGenics Outside Cost Share”). 

  
 25 

 (c)    Reconciliation/Reimbursement. Within [***] after [***]
during which MacroGenics incurs any Outside Development Costs or Territory Development Costs, MacroGenics shall submit to a finance officer designated by MacroGenics and a finance officer designated by I-MAB
(the “Finance Officers”) a report setting forth a good faith estimate of the Outside Development Costs and Territory Development Costs it incurred in [***]. Within [***] following the [***], MacroGenics shall update
such report to reflect the final amount of Outside Development Costs and Territory Development Costs incurred by it in [***]. Such report shall specify in reasonable detail all such costs and shall include reasonably detailed supporting
documentation, and, any additional documentation reasonably requested by I-MAB shall be promptly provided. [***] after receipt of such updated report, the Finance Officers shall confer and agree in writing on
the amount of the reimbursement payment owed to MacroGenics by I-MAB, such that all Territory Development Costs and the I-MAB Outside Cost Share for [***] are borne
[***] ([***]%) by I-MAB and the MacroGenics Outside Cost Share for [***] is borne [***] ([***]%) by MacroGenics. With respect to each such reimbursement payment owed to MacroGenics, I- MAB shall (or any of its Affiliates shall) submit such payment to MacroGenics (or any of its designated Affiliates) [***] after the end of [***] conferral period. In the event of any disagreement with respect to
the calculation of any such payment under this Section 3.5(c), any undisputed portion of such payment shall be paid in accordance with the foregoing timetable specified in this Section 3.5(c), and the remaining, disputed portion shall be
paid [***] on which the Parties, using good faith efforts, resolve the dispute. In addition, following the Effective Date, each Party shall consider in good faith other reasonable procedures proposed by the other Party for sharing financial
information in order to permit each Party to close its books in a periodic timely manner. For the avoidance of doubt, no cost or expense shall be counted more than once in calculating Territory Development Costs and Outside Development Costs, even
if such costs or expense falls into more than one of the cost categories that comprise Territory Development Costs and Outside Development Costs. 

3.6    Subcontractors. Each Party shall have the right to engage Third Party contractors to perform any portion of
its obligations under this Agreement (each such subcontractor, a “Permitted Subcontractor”), provided, however, that (i) for any [***] shall solely have the right to select [***]; and (ii) each [***] to support or
facilitate any Clinical Trial activities within the Territory must first be approved in writing by the JSC in order to be deemed a Permitted Subcontractor. MacroGenics’ JSC representatives shall not unreasonably withhold, condition or delay
their approval in connection with the JSC’s consideration of any such CRO and Depot Subcontractor. Any such Permitted Subcontractor engaged by I-MAB hereunder shall be required to agree in writing to be
bound by terms regarding maintaining the confidentiality of proprietary information that are no less stringent than those contained in this Agreement and regarding ownership of intellectual property that are consistent with those contained in this
Agreement. Either Party’s use of Permitted Subcontractors shall not relieve it of any of its obligations pursuant to this Agreement. 

3.7    Ownership of Clinical Data. To the extent permitted by Applicable Laws and Regulations, all Clinical Data
generated or arising from any Territory-specific Clinical Trial conducted exclusively by or on behalf of I-MAB in the Territory (“Co-Owned Clinical
Data”) shall be jointly owned by the Parties. Subject to any restrictions imposed by Applicable Laws and Regulations, each Party hereby assigns, transfers and conveys (and to the extent a present assignment is prohibited by Applicable Laws
and Regulations, shall assign) to the other Party one- half (1/2) of its (and its Affiliates’ and Sublicensees’) right, title and interest in and to such Co-
Owned Clinical Data so that I-MAB and MacroGenics will be equal joint owners of such Clinical Data. I-MAB shall provide a copy of all such Clinical Data to MacroGenics
promptly following generation thereof, but in any event, on a schedule reasonably requested by MacroGenics. All Clinical Data generated or arising from any MacroGenics Global Clinical Trial shall be owned solely and exclusively by MacroGenics. In
addition, if the Parties are not legally permitted, according to Applicable Laws and Regulations, to jointly own any Clinical Data that would otherwise constitute Co-Owned Clinical Data under this
Section 3.7, then MacroGenics shall be sole and exclusive owner of such Clinical Data. I-MAB hereby assigns, transfers and conveys (and to the extent a present assignment is prohibited by Applicable Laws
and Regulations, shall assign) to MacroGenics all of I-MAB’s (and its Affiliates’ and Sublicensees’) right, title and interest in and to all Clinical Data for which MacroGenics shall be the sole
owner pursuant to this Section 3.7. 

  
 26 

 3.8    Information and Cooperation. In addition to the
obligations under Section 3.7, each Party shall use Commercially Reasonable Efforts to reasonably cooperate with the other Party in relation to the work under this Agreement and keep the other Party informed of its Development and
Commercialization (including promotional) activities reasonably related to the work under this Agreement, and shall provide to the other Party, as appropriate, regular summary updates. If reasonably necessary for a Party to perform its work under
this Agreement or to exercise its rights under this Agreement, or in the case of MacroGenics, to further the Development, including clinical or regulatory programs, or Commercialization of the Product outside the Territory (or inside the Territory
in connection with a MacroGenics Global Clinical Trial) or MGA012 inside or outside the Territory, that Party may request that the other Party provide more detailed information and data regarding the updates it earlier provided, and the other Party
shall promptly provide the requesting Party with information and data as is reasonably available and reasonably related to the work under this Agreement. Neither Party is required to generate additional data or prepare additional reports (except to
the extent required to comply with safety reporting requirements under Applicable Laws and Regulations) to comply with the foregoing obligation. All such reports, information and data provided shall be subject to Section 10.1. 

3.9    MacroGenics’ Development in Territory and MacroGenics Global Clinical Trials.
Notwithstanding the foregoing, MacroGenics shall have the right to conduct non-clinical Development and clinical Development (solely in connection with MacroGenics Global Clinical Trials in the Field in the
Territory) and with respect to such clinical Development, with I-MAB’s prior written consent (which shall not be unreasonably withheld, conditioned or delayed). MacroGenics shall solely control and be
responsible for conducting such Development and, [***], all associated Development Costs incurred by MacroGenics in the conduct of such Development shall [***]. 
  

	4.	 COMMERCIALIZATION 

4.1    Overview. I-MAB shall have full responsibility and authority (subject
to Sections 2.1(c) and (d)) for all aspects of the Commercialization of the Product in the Territory at its sole expense, including developing and executing a plan for commercial launch, obtaining all required approvals from Regulatory Authorities
for Commercialization (including reimbursement activities), marketing and promotion, booking sales and distribution and performance of related services, providing customer support, including handling medical queries, and performing other related
functions. I-MAB shall use Commercially Reasonable Efforts to Commercialize the Product. I-MAB shall update MacroGenics regarding its Commercialization activities at
regular meetings of the JSC as contemplated by Section 2.1(e). As between I-MAB and MacroGenics, I- MAB shall book all sales of the Product in the Territory, and
shall have the sole right to determine all pricing of the Product in the Territory. I-MAB shall bear all of the costs and expenses incurred in connection with all such Commercialization activities in the
Territory. I-MAB shall provide written notification to MacroGenics as to the occurrence of the First Commercial Sale in the Territory [***] after such occurrence. MacroGenics shall have full responsibility and
authority for all aspects of the Commercialization of the Product outside the Territory at its sole expense, including obtaining all required approvals from Regulatory Authorities for Commercialization (including reimbursement activities), marketing
and promotion, booking sales and distribution and performance of related services, providing customer support, including handling medical queries, and performing other related functions. 

  
 27 

 4.2    Product Labeling; Promotional Materials. I-MAB shall reasonably cooperate with MacroGenics and its designees to establish a global branding strategy for the Product worldwide. I-MAB shall Commercialize the Product in
the Territory under the worldwide brand and consistent with the global branding strategy, in each case, specified by MacroGenics (the “Product Brand” and “Global Branding Strategy”, respectively), except to the
extent such branding is not permitted by any applicable Regulatory Authority in the Territory, in which case MacroGenics shall specify an alternate Product Brand or adjustment to the Global Branding Strategy, as MacroGenics deems appropriate. Except
for the depiction of trademarks, logos and other symbols that are intended to identify MacroGenics’ as a company or the manufacturer or owner of the Product or MGA012 and Incyte Corporation as the developer and/or seller of MGA012, I-MAB shall be responsible for designing and supplying the printable artworks of Product labeling in electronic version and promotional materials for the Product for the Territory.
I-MAB shall be responsible for how and the manner in which the Product shall be presented and described in the Territory to the medical community in any promotional materials for the Product intended to be
disseminated in the Territory, and the placement of the name and logos of I-MAB therein, in each case as permitted by Applicable Law and consistent with the Product Brand and labeling for the Product approved
by the applicable Regulatory Authority, and consistent with the Global Branding Strategy. 
 4.3    Sales and
Distribution 
 (a)    Orders and Sales. I-MAB shall be solely
responsible for handling all returns, order processing, invoicing and collection, distribution, and inventory and receivables for the Product throughout the Territory. I-MAB shall have the right and sole
responsibility for establishing and modifying the terms and conditions with respect to the sale of the Product in the Territory, including any terms and conditions relating to or affecting the price at which the Product shall be sold, discounts
available to any Third Party payers (including managed care providers, indemnity plans, unions, self-insured entities, and government payer, insurance or contracting programs), any discount attributable to payments on receivables, distribution of
the Product, and credits, price adjustments, or other discounts and allowances to be granted or refused; provided, however, that I-MAB shall act in good faith when doing the foregoing. 

(b)    Pricing. I-MAB shall determine all pricing of the Product in the
Territory, with the understanding that I-MAB shall also be solely responsible for preparing and implementing the reimbursement strategy for the Product in the Territory. MacroGenics shall, subject to any
restrictions imposed under Applicable Laws and Regulations, use reasonable efforts to provide all the data deemed necessary by MacroGenics and within its possession or control so as to support any application by
I-MAB for desired medical reimbursement rates in the Territory. 

4.4    Compliance. Each Party shall comply with the terms of this Agreement and all Applicable Laws and Regulations
relating to activities performed or to be performed by such Party(or its Affiliates, contractor(s) or Sublicensee(s)) under or in relation to the Commercialization of the Product pursuant to this Agreement. Notwithstanding the foregoing, each Party
agrees, on behalf of itself, its officers, directors and employees and on behalf of its Affiliates, agents, representatives, consultants, and Permitted Subcontractors (together with each Party, the “Party Representatives”) that for
the performance of its obligations hereunder: 

  
 28 

 (a)    The Party Representatives shall not directly or indirectly pay,
offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to: (i) any Government Official in order to influence official action; (ii) any Person
(whether or not a Government Official) (a) to influence such Person to act in breach of a duty of good faith, impartiality or trust (“Acting Improperly”), (b) to reward such Person for Acting Improperly, or
(c) where such Person would be Acting Improperly by receiving the money or other thing of value; (iii) any other Person while knowing or having reason to know that all or any portion of the money or other thing of value shall be paid,
offered, promised or given to, or shall otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement; or (iv) any Person to
reward that Person for Acting Improperly or to induce that Person to Act Improperly. 
 (b)    The Party Representatives
shall not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of the Anti-Corruption Laws. 

(c)    The Party Representatives shall comply with the Anti-Corruption Laws and shall not take any action that shall, or
would reasonably be expected to, cause either Party (or its Affiliates) to be in violation of any such laws. In furtherance of the foregoing, each Party acknowledges and confirms the following: 

(i)    Each Party has reviewed its internal programs in relation to the Anti- Corruption Laws and the ability of its Party
Representatives to adhere to such laws in performance of its obligations hereunder in advance of the signing of this Agreement and warrants that it and its Party Representatives can and shall continue to comply with such Anti-Corruption Laws in
performance of its obligations hereunder and further represents and warrants that should the other Party identify in writing to such Party any measures that should be reasonably taken to improve such Party’s and its Party Representatives’
compliance with such Anti-Corruption Laws for the performance of its obligations hereunder (the “Improvement Plan”), such Party shall use Commercially Reasonable Efforts to implement such Improvement Plan within an agreed reasonable
timeframe (which shall in any event [***]) from the date the Improvement Plan is delivered to the receiving Party. In the absence of the full implementation by a Party of such Improvement Plan within [***], the other Party shall be entitled to
terminate this Agreement, upon written notice to the non-implementing Party with immediate effect, to be relieved of any obligations, and to seek compensation from the
non-implementing Party; 
 (ii)    To the best of each Party’s and its
Affiliates’ knowledge after reasonable diligence, none of its Party Representatives that shall participate or support such Party’s performance of its obligations hereunder has, directly or indirectly, (x) paid, offered or promised to
pay, or authorized the payment of any money; (y) given, offered or promised to give, or authorized the giving of anything else of value; or (z) solicited, received or agreed to accept any payment of money or anything else of value, in each
case ((x), (y) and (z)), in violation of the Anti- Corruption Laws during [***]. 

  
 29 

 (iii)    To the best of each Party’s and its Affiliates’
knowledge, none of its intellectual property rights, technology, contracts, materials, or licenses or other assets that are the subject of this Agreement were procured in violation of any Anti-Corruption Laws. 

(d)    Each Party, on behalf of itself and its Party Representatives, represents and warrants to the other Party that all
information provided by such Party and its Party Representatives to the other Party in any anti-bribery and corruption due diligence checklist, similar due diligence process performed by the other Party or its Affiliates or inquiry by the other
Party related to such Party’s or its Party Representatives’ compliance with Anti-Corruption Laws is true, complete and correct in all material respects at the date it was provided and that any material changes in circumstances relevant to
the answers provided in such exercise shall be promptly disclosed to the other Party. 
 (e)    Each Party shall, to the
extent permitted by the relevant government authority, promptly provide the other Party with written notice of the following events: (i) upon becoming aware of any actual, alleged or potential breach or violation by a Party or any of its Party
Representative of any representation, warranty or undertaking set forth in this Section 4.4; or (ii) upon receiving a formal notification that it is the target of a formal investigation by a government authority for any violation of any
Anti-Corruption Law or upon receipt of information from any of the Party Representatives that any of them is the target of a formal investigation by a government authority for a violation of any Anti-Corruption Law, in each case ((i) and (ii)),
where such formal investigation is related to this Agreement. 
 (f)    For the Term and [***] following the expiration
or earlier termination of the Agreement, each Party shall for the purpose of auditing and monitoring the performance of its compliance with this Agreement and particularly this Section 4.4 permit the other Party, its Affiliates, any auditors of
any of them and any government authority to have reasonable access to any premises of the Party or other Party Representatives used in connection with this Agreement, together with a right to reasonably access personnel and records that relate to
this Agreement (“Audit”). Each Party shall ensure that its Party Representatives shall provide all cooperation as reasonably requested by the other Party for the purposes of the Audit, with the understanding that the other Party
shall be responsible for all costs and fees of any Audit and the other Party shall ensure that any auditor enters into a confidentiality agreement consistent with the confidentiality provisions in this Agreement in all material respects.
Notwithstanding the foregoing, each Party’s obligations under this Section 4.4(f) with respect to its agents, representatives, consultants, and Permitted Subcontractors existing as of the Effective Date shall be subject to the contractual
rights and obligations that such Party has in place with such Party Representatives, and with respect to agents, representatives, consultants, and Permitted Subcontractors engaged after the Effective Date, shall be subject to contractual rights and
obligations that such Party negotiates with such future Party Representatives, provided that the applicable Party shall use Commercially Reasonable Efforts to negotiate contractual rights and obligations with such future Party Representative to
allow compliance with this Section 4.4(f). 
 (g)    On the occurrence of any of the following events: 

  
 30 

 (i)    Either Party becomes aware, whether or not through an Audit,
that the other Party (or any other Party Representative) is in breach or violation of any representation, warranty or undertaking in Section 4.4 or of the Anti-Corruption Laws; or 

(ii)    Notification is received by a Party that a suspected or actual violation of an Anti-Corruption Law has occurred
by the other Party or any Party Representative of the other Party; 
 the notified Party shall have the right, in addition to any other rights or remedies
under this Agreement or to which the notified Party may be entitled in law or equity, to take such steps as are reasonably necessary in order to avoid a potential violation or continuing violation by the notified Party or any of its Affiliates of
the Anti-Corruption Laws, including by requiring that the other Party agrees to and uses Commercially Reasonable Efforts to implement any curative actions requested by the notified Party. In the event that the other Party refuses to agree to all of
the curative actions requested by the notified Party (and provided that the notified Party has (x) provided the other Party with an explanation in reasonable detail as to why the notified Party considers such actions necessary, (y) given
the other Party a reasonable opportunity to review and comment upon the proposed actions and to provide its view as to the necessity or usefulness of these to address the event concerned, and (z) considered such comments in good faith), the
notified Party shall be entitled to terminate this Agreement with immediate effect. Any termination of this Agreement pursuant to this Section 4.4 shall be treated as a termination for breach by the other Party of this Agreement and the
consequences of termination shall apply and additionally, subject to the accrued rights of the Parties prior to termination, the notified Party shall have no liability to the other Party for any fees, reimbursements or other compensation or for any
loss, cost, claim or damage resulting, directly or indirectly, from such termination. 
 (h)    Each Party shall be
responsible for any breach of any representation, warranty or undertaking in this Section 4.4 or of the Anti-Corruption Laws by any of its Party Representatives. 

(i)    Each Party may disclose the terms of this Agreement or any action taken under this Section 4.4 to prevent a
potential violation or continuing violation of applicable Anti- Corruption Laws, including the identity of the other Party and the payment terms, to any government authority if the Party determines, upon advice of counsel, that such disclosure is
appropriate. 
 4.5    Commercialization Diligence 

(a)    Prior to Submission of First BLA. [***] before the expected Completion of the Registration Trial, I-MAB shall submit the first Commercialization Plan to the JCC for review and submission to the JSC for review and approval. From time to time during the Term, I-MAB may
submit amendments to the Commercialization Plan to the JCC for review and submission to the JSC for review and approval. I-MAB shall regularly report on its Commercialization activities at each meeting of the
JSC. Such reports shall cover subject matter at a level of detail similar to that which I-MAB affords to its senior executives with respect to similar I-MAB products.
All such plans and information shall be presented for discussion purposes, and I-MAB agrees to consider in good faith any comments or suggestions MacroGenics may make with respect to Commercialization of the
Product. 

  
 31 

 (b)    Following Regulatory Approval. I-MAB shall use Commercially Reasonable Efforts to Commercialize the Product throughout the Territory after Regulatory Approval for the Product is obtained. 

 

	5.	 MANUFACTURE AND SUPPLY 

5.1    Supply of the Product 

(a)    MacroGenics shall (i) be responsible for the Manufacture, either by itself or through one or more Third
Parties selected by MacroGenics at its sole discretion, of (A) the Product and MGA012 required for the Clinical Trials described in the Global Development Plan and the Territory Specific Development Plan and (B) all commercial supplies of
the Product required by I-MAB for the Commercialization of the Product in the Territory, [***], such Manufacture of the Product will be pursuant [***], in each case ((A) and (B)) using Commercially Reasonably
Efforts and in accordance with this Section 5.1, except as the Parties may otherwise agree in writing and (ii) either (A) [***], in accordance with the terms and conditions of the [***] sufficient quantity based on demand, or
(B) solely in the event that MacroGenics has control over the Manufacture and supply of MGA012 for the Territory, make supply of MGA012 available in a reasonably sufficient quantity based on demand, in each case ((A) and (B)) in the Territory
for the Commercialization of the Combination Regimen in the Territory after the Regulatory Approval of such Combination Regimen in the Territory. Any Product or MGA012 supplied to I-MAB by MacroGenics shall be
delivered to I-MAB in unlabeled vials for subsequent packaging and labeling by I-MAB, unless the Parties otherwise agree to a different delivery format. MacroGenics
shall use Commercially Reasonable Efforts to fulfill under the Incyte Agreement the forecasts for MGA012 provided by I- MAB for use in clinical development and/or pursuant to the Commercial Supply Agreement
(“MGA012 Commercial Forecasts”). In the event of a shortfall of MGA012, MacroGenics shall use the same efforts to fulfill a MGA012 Commercial Forecast under the Incyte Agreement as if MacroGenics was procuring MGA012 under the
Incyte Agreement for use by itself or its other licensees or partners. 
 (b)    Supply Agreements. [***] after
the Effective Date, the Parties shall negotiate and enter into a supply agreement governing (i) the clinical supply of the Product to I-MAB for its requirements of the Product for Development in the
Territory and (ii) the clinical supply of MGA012 to I-MAB for its requirements to Develop MGA012 solely as a component of the Combination Regimen in the Territory (which supply agreement will be subject
to the Incyte Agreement). [***] projected commercial launch date of a Product in any Country or Region in the Territory, the Parties shall negotiate and enter into a supply agreement (the “Commercial Supply Agreement”)
governing (i) the commercial supply of the Product to I-MAB for its requirements of the Product for Commercialization in the Territory and (ii) the commercial supply of MGA012 to I-MAB for its requirements of MGA012 for Commercialization of a Combination Regimen in the Territory (which supply shall be subject to the Incyte Agreement), which Commercial Supply Agreement shall include pricing,
payment, and delivery terms consistent with the provisions set forth in Sections 5.1(b) and 5.1(d). The Commercial Supply Agreement shall provide other customary terms and conditions, such as acceptance and rejection procedures, forecast and order
procedures, release documentations and audit rights by I-MAB. In addition, the Commercial Supply Agreement shall include further provisions for the commercial supply of the Product in the Territory, including
procedures for the MGA012 Commercial Forecasts. 

  
 32 

 (c)    Price; Payment. 

(i)    The price of clinical quantities of the Product ordered by I-MAB under
Section 5.1(a) and commercial quantities of the Product ordered by I-MAB under Section 5.1(a) shall [***] for the Product. MacroGenics’ supply of clinical quantities of MGA012 pursuant to
Section 5.1(a) shall be [***]. 
 (ii)    All payments due hereunder to MacroGenics shall be paid to MacroGenics
in U.S. Dollars [***] following the receipt of the applicable invoice. 
 (d)    Delivery. Unless otherwise
agreed by the parties in writing, all shipments shall be [***]. 
 5.2    Manufacturing Specifications. All Study
Materials and commercial supplies of Product shall be manufactured in accordance with the specifications determined by MacroGenics and all Applicable Laws and Regulations as set forth in the clinical supply agreement and Commercial Supply Agreement
to be negotiated by MacroGenics and I-MAB under Section 5.1(b). 

5.3    Change of Manufacturing Process. MacroGenics shall reasonably inform
I-MAB of developments in matters of process development and Manufacturing of the Product and MGA012, and shall consult with I-MAB with respect to the development and
manufacturing processes of the Product and MGA012 adopted by MacroGenics to the extent necessary to obtain Regulatory Approval(s) of the same in the Territory. I-MAB shall promptly notify MacroGenics of any
information that may impact approvability of the Product in the Territory. In addition, MacroGenics shall implement changes required by any Regulatory Authority in the Territory to the extent commercially practicable, provided that I-MAB shall bear any and all incremental costs resulting from any changes to the manufacturing specifications required by the applicable Regulatory Authority in the Territory but not by any of the Regulatory
Authorities outside the Territory. 
 5.4    Third Party Obligations; MacroGenics Third Party Agreements. All
licenses and other rights granted to I-MAB under this Agreement are subject to the rights and obligations of MacroGenics under the MacroGenics Third Party Agreements.
I-MAB will comply with all applicable provisions of the MacroGenics Third Party Agreements and I-MAB agrees to (and shall cause its Related Parties to) timely perform
and take such actions as may be required to allow MacroGenics to comply with its obligations thereunder, including to provide to MacroGenics such information and reports as it reasonably requires, comply with reasonable requests for access to I- MAB’s (and its Related Parties’) records or facilities or otherwise cooperate with MacroGenics, including with respect to any Product-related financial and regulatory reporting, audit and payment
obligations under each MacroGenics Third Party Agreement, insofar as they specifically relate to Enoblituzumab, MGA012 or any Product, including with respect to any Product that I-MAB sublicenses pursuant to
this Agreement. I-MAB shall pay all the Triggered Third Party Payments in accordance with Section 7.5. 

  
 33 

 5.5    Production of Product in the Territory. In the event that
MacroGenics elects to engage a Third Party to produce commercial supply of the Product in the Territory, MacroGenics shall promptly notify I-MAB of such intent. [***] of receiving such notice, I-MAB will confirm or decline its interest to secure such right. If I-MAB provides written confirmation of its interest within such period, and at such time I-MAB has [***], both Parties will enter good faith negotiations for the terms of a technology transfer and supply agreement to enable I-MAB for such Manufacture. Under the
terms of such agreement, I-MAB shall not be required [***]. In addition, the Parties agree that such supply agreement will [***]. If I-MAB declines its interest, fails
to notify MacroGenics [***], or the Parties fail to execute a binding agreement [***] after commencing such good faith negotiations, MacroGenics may enter into an agreement with a Third Party for such commercial supply in the Territory. 

 

	6.	 REGULATORY 

6.1    Overview. I-MAB shall develop an overall regulatory strategy and plan
for obtaining Regulatory Approval of the Product in the Territory to be included in the Global Development Plan and Territory Specific Development Plan and approved by the JSC. 

6.2    Product Information. MacroGenics shall use Commercially Reasonable Efforts to provide to I-MAB the information for the Product, Combination Regimen and relevant Data, Regulatory Materials, and other Know-How related to the Product and Combination Regimen set forth
in Exhibit E in accordance with a timeline and format to be determined by the JSC. On an ongoing basis, MacroGenics shall use Commercially Reasonable Efforts to promptly provide to I- MAB other Data,
Regulatory Materials, and other Know-How reasonably requested by I-MAB and specifically pertaining to the Product and Combination Regimen to accommodate requests from
Regulatory Authorities and to facilitate and support the conduct of the Territory Specific Development Plan and I-MAB’s efforts under the Global Development Plan. 

6.3    Regulatory Submissions. 

(a)    In each case ((i) and (ii)) other than Regulatory Submissions related to Regulatory Approvals (the ownership of
which is addressed in Section 9.1(e)), (i) MacroGenics or its designee shall hold and own all Regulatory Submissions that are submitted to the Regulatory Authorities under the Global Development Plan or related to or resulting from any
MacroGenics Global Clinical Trial(s); and (ii) subject to Applicable Laws and Regulations, I-MAB and MacroGenics or their respective designees shall jointly hold and own all other Regulatory Submissions
that are submitted to Regulatory Authorities in the Territory under the Territory Specific Development Plan (“Territory Specific Regulatory Submissions”). For any Territory Specific Regulatory Submission which the Parties are
not legally permitted to jointly own according to Applicable Laws and Regulations (i) MacroGenics shall be the sole and exclusive owner of any Territory Specific Regulatory Submission that MacroGenics is required by Applicable Laws and
Regulations to hold and own in order for MacroGenics to be the sole and exclusive owner of the Regulatory Approvals that cover Indications addressed under the Global Development Plan and (ii) I-MAB shall
be the sole and exclusive owner of all other Territory Specific Regulatory Submissions. I-MAB shall promptly provide all copies of Regulatory Submissions (including all updates thereof) to MacroGenics. 

  
 34 

 (b)    I-MAB shall be
responsible for, in I-MAB’s or its designees’ names ([***]) and/or MacroGenics’ or its designees’ names ([***]), at I-MAB’s sole cost and
expense, (x) the filing and obtaining all Regulatory Submissions, (y) responding to inquiries and correspondence from the Regulatory Authorities responsible for regulatory matters, and (z) the monitoring of all clinical experiences
(to the extent [***], in which case, such Permitted Contractor shall be responsible for such monitoring and [***]) and submission of all required reports throughout clinical Development and Commercialization, in each case ((x) through (z)) in or for
the Territory, in compliance with all Applicable Laws And Regulations. I-MAB shall notify MacroGenics of any material written or electronic communication received by
I-MAB from a Regulatory Authority in the Territory regarding a Product or MGA012 [***] of receipt of such communication and upon MacroGenics’ request, provide a copy of such communication that has been
translated into English [***] of receipt of such request unless otherwise specified by MacroGenics, provided, however, in the event I-MAB receives a material communication from a Regulatory
Authority that [***] to be submitted [***], I-MAB shall provide a copy of such communication to MacroGenics [***]. MacroGenics shall be responsible for providing to
I-MAB any revisions to the investigator’s brochure and CMC information required for Regulatory Submissions. MacroGenics (or its designee) shall have a right to participate (and I- MAB may otherwise request MacroGenics to participate) in meetings with the Regulatory Authorities regarding (i) any Product or (ii) MGA012. Each Party shall provide information to the other Party as
necessary, and reasonably consult with the other Party regarding any filings, and regarding significant or material notices, actions or requests from or by Regulatory Authorities. Each Party shall, at the other Party’s request, review and
comment on filings, submissions, and responses to Regulatory Authorities related to any Product. As between the Parties, MacroGenics shall be responsible for, and shall bear all costs related to (x) the filing and obtaining all Regulatory
Submissions, (y) responding to inquiries and correspondence from the Regulatory Authorities responsible for regulatory matters, and (z) the monitoring of all clinical experiences and submission of all required reports throughout clinical
Development and Commercialization, in each case ((x) through (y)) outside of the Territory, in MacroGenics’ sole discretion. To the extent a Regulatory Authority requests from I-MAB, an Affiliate or a
Sublicensee information regarding the Product or Combination Regimen that I-MAB, such Affiliate or such Sublicensee reasonably believes is required to be submitted to a Regulatory Authority in order to obtain
Regulatory Approval for any Product, then MacroGenics, upon request, shall provide reasonably requested assistance, materials, Data or Know-How in its possession that would be required to satisfy such
Regulatory Authority request. To the extent that MacroGenics is aware that the applicable information described in this Section 6.2(b) is with a MacroGenics Sublicensee, then MacroGenics will use reasonable efforts to obtain such information
from such MacroGenics Sublicensee. 
 6.4    Records of Correspondence with Regulatory Authorities. Following
each communication (whether by phone or in person) with a Regulatory Authority regarding matters arising under this Agreement, I-MAB will prepare a record of such meeting in accordance with its standard
business practices (e.g., written minutes) or other format reasonably requested by MacroGenics and provide to MacroGenics a copy of such record. 

6.5    Safety Management Plan. The Parties shall conduct in good faith and agree upon a safety management plan
(“Safety Management Plan” or “SMP”), which will detail the Clinical Trial specific responsibilities, processes and other matters to ensure that adverse event notification and reporting
requirements meet current health agency regulations and guidelines worldwide, as further detailed in Exhibit F. I-MAB shall cause its Related Parties and Permitted Subcontractors to submit all such
information, data and reports required under the SMP directly to MacroGenics (or its designee) as applicable. 

  
 35 

	7.	 PAYMENTS 

7.1    Upfront Payment [***] after the Effective Date, I-MAB shall pay to
MacroGenics Fifteen Million United States Dollars (US$15,000,000), which shall be [***] due under this Agreement. 

7.2    Development Milestone Payments. 

(a)    On [***], I-MAB shall pay to MacroGenics the milestone payments listed
below for the [***] (each, a “Milestone Payment”), which in each case shall be [***] (but shall be subject [***]). Except for the Milestone Payment described in subsection (i), each Milestone Payment shall be payable for the [***]
milestone event [***]. 
  

					
	Milestone Event	  	Milestone Payment
	(i) [***]	  	[***]
		
	(ii) [***]	  	[***]
		
	(iii) [***]	  	[***]
			
	(iv) [***]	  	(A) [***]	  	[***]
			
		  	(B) [***]	  	[***]
			
		  	(C) [***]	  	[***]
			
		  	(D) [***]	  	[***]
		
	(v) [***]	  	[***]
		
	(vi) [***]	  	[***]

  
 36 

 (b)    I-MAB shall provide
written notification to MacroGenics of the achievement of each of the milestones described in Sections 7.2(a)(i) and 7.2(a)(ii), and if they occur in the Territory 7.2(a)(iii) and 7.2(a)(iv) [***] after each such achievement under 7.2(a)(i),
7.2(a)(ii) 7.2(a)(iii) and 7.2(a)(iv). MacroGenics shall provide written notification to I-MAB of the achievement of each of the milestones described in Sections 7.2(a)(iii) and 7.2(a)(iv) if they occur
outside of the Territory. In addition, MacroGenics shall provide I-MAB with a complete list of milestone payments subject to payment under Section 7.5 for Triggered Third Party Payments under any
MacroGenics Third Party Agreements entered into by MacroGenics after the Effective Date, and I-MAB shall provide written notification to MacroGenics of the achievement of each such milestone event by or on
behalf of I-MAB or its Related Party. 
 7.3    Product Royalties. I-MAB shall pay to MacroGenics a royalty at the rate determined in accordance with the royalty chart included in Exhibit G attached hereto on Net Sales of the Product for the Royalty Term. 

7.4    Royalty Adjustments. If it is reasonably necessary for I-MAB or
MacroGenics to license one or more Patents from one or more Third Parties (a) with respect to MacroGenics, in order to Develop, Manufacture, Commercialize or use the Product [***], or (b) with respect to
I-MAB, solely in order to Commercialize or use the Product [***], in each case ((a) and (b)) without infringing the Patents of such Third Parties, then such Party may, in its sole discretion, negotiate and
obtain a license under such Patent(s) (each such Third Party license referred to herein as a “Required License”), provided that with respect to I- MAB, the foregoing shall [***]. The royalties
otherwise payable to MacroGenics under Section 7.3 with respect to Net Sales of Product by I-MAB, its Affiliates or Sublicensees for a Calendar Quarter [***] to Third Parties with respect to such Third
Party Patents pursuant to such Required Licenses for such Calendar Quarter, provided that in no event shall the total royalty payable to MacroGenics for Net Sales of Product in a given Calendar Quarter [***] of the royalty amounts under
Section 7.3 otherwise payable for Net Sales of Product, with any remainder creditable against royalties under Section 7.3 payable in subsequent Calendar Quarters. 

(a)    Biosimilar Product Market Effect. If there is no longer a Valid Claim within the MacroGenics Licensed
Patents covering a given Product in a Country or Region in the Territory, then I-MAB may reduce the royalty payments for Net Sales for such Product in such Country or Region by [***] ([***]%) in any Calendar
Quarter in which one or more Biosimilar Products for such Product are on the market in such Country or Region and sales of such Biosimilar Products in such Country or Region [***] of such Biosimilar Products and Product in such Country or Region.

 7.5    Triggered Third Party Payments. In addition to the other payments set forth in this Agreement, I-MAB shall reimburse MacroGenics for all Triggered Third Party Payments. I- MAB’s obligations under this Section 7.5 with respect to the payment of Triggered Third
Party Payments under a given MacroGenics Third Party Agreement shall terminate upon termination of MacroGenics’ obligation to pay such Triggered Third Party Payments under the terms of such MacroGenics Third Party Agreement. 

  
 37 

 7.6    Payment of Milestones. All milestone payments shall be due
and payable [***] after delivery by MacroGenics of an invoice therefor. 
 7.7    Reports; Payments. 

(a)    Net Sales Quarterly Reports. During the Term, following the First Commercial Sale of a Product in the
Territory, I-MAB shall furnish to MacroGenics: 
 (i)    a quarterly written
report for the Calendar Quarter showing the Net Sales of all Product subject to royalty payments sold by I-MAB and its Related Parties in the Territory during the reporting period and the royalties payable
under this Agreement; and 
 (ii)    a quarterly report for the Calendar Quarter showing the Triggered Third Party
Payments, I-MAB’s royalties payable to Third Parties on Net Sales made during such Calendar Quarter and any royalty adjustments taken by I-MAB pursuant to
Section 7.4, with such detail as shall reasonably allow MacroGenics to determine the basis for such quarterly costs. 

(b)    Submission and Payment Schedule 

(i)    Reports under this Section 7.7 shall be due on the [***] following the close of each Calendar Quarter. 

(ii)    Royalties (including those within the Triggered Third Party Payments) shown to have accrued by each report shall,
unless otherwise specified under this Agreement, [***]. 
 7.8    Payment Exchange Rate. All payments to be made
by I-MAB to MacroGenics under this Agreement shall be made in U.S. Dollars by bank wire transfer in immediately available funds to a bank account in the United States designated in writing by MacroGenics. For
invoices that I-MAB shall forward to MacroGenics, I-MAB shall use an exchange rate [***], or such other source as the Parties may agree in writing. I-MAB shall take all possible steps to ensure all payments are made to MacroGenics under this Agreement, including by paying from non-Territory sources. 

7.9    Taxes. All taxes applicable to the Development, Manufacture, Commercialization, use, import, distribution or
sale of the Product in the Territory or assessable on any payments made by I-MAB to MacroGenics under this Agreement shall be paid by I-MAB, with the exception of income
taxes owed by MacroGenics. If I-MAB is required under Applicable Laws and Regulations to deduct or withhold any taxes on any payments from I-MAB to MacroGenics pursuant
to this Agreement, [***]. I-MAB shall process such payment using an amount necessary [***]. I-MAB shall [***] taxes or other amount required by Applicable Laws and
Regulations [***] under this Agreement to MacroGenics. 

  
 38 

	8.	 RECORD KEEPING, INSPECTIONS AND
AUDITS 

 8.1    Records 

(a)    Collaboration Activities. Each Party shall maintain appropriate records of: 

(i) all research, Development, Manufacturing and Commercialization events and activities conducted by it or on its behalf related to the Product hereunder, and
all costs incurred in connection therewith, as applicable; and (ii) all significant information generated by it or on its behalf in connection with Development of the Product under this Agreement, in each case in accordance with such
Party’s usual documentation and record retention practices, provided, that, without limiting the foregoing, I-MAB shall maintain appropriate records of all information generated by it or on its behalf in
connection with the use of MGA012 and research and Development of the Product related thereto under this Agreement. All records referenced by this Section 8.1(a) shall be in sufficient detail to properly reflect, in good scientific manner, all
significant work done and results of studies and trials undertaken, and further shall be at a level of detail appropriate for patent and regulatory purposes. Upon the reasonable request of a Party, the other Party shall make such records available
to the requesting Party. I-MAB shall cause its Related Parties and Permitted Subcontractors to comply with this Section 8.1(a). 

(b)    Records for I-MAB Payments. Without limiting Section 8.1(a), I-MAB shall keep complete and accurate records in sufficient detail to (i) ensure that MacroGenics receives the full amount of royalties payable to it under Section 7.3 and Triggered Third Party Payments
payable under Section 7.5 and (ii) reasonably allow MacroGenics to determine the basis for the MacroGenics Outside Cost Share. At the reasonable request of MacroGenics, I-MAB shall make such records
available to MacroGenics. 
 (c)    MacroGenics’ FBMC and Development Costs. MacroGenics shall keep complete
and accurate records with such detail as shall reasonably allow I-MAB to determine the basis for such FBMC, the Territory Development Costs and the I-MAB Outside Cost
Share. At the reasonable request of I-MAB, MacroGenics shall make such records available to I-MAB. 

8.2    Audit Rights. 

(a)    Upon the written request of a Party (“Requesting Party”) with reasonable advance notice and [***],
the other Party shall permit an independent certified public accounting firm of internationally recognized standing selected by the Requesting Party and reasonably acceptable to the other Party, at its own expense, to have access during normal
business hours to such of the records as may be reasonably necessary to verify the that the correct amounts have been paid to such Party under this Agreement during any Calendar Year ending [***] prior to the date of such request. The accounting
firm shall disclose to the Requesting Party only whether the reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Requesting Party in connection with this audit right. This
right to audit shall remain in effect throughout the life of this Agreement and [***] the termination of this Agreement (and thereafter until [***] under the terms of the [***]). 

  
 39 

 (b)    Discrepancies. If such accounting firm identifies a
discrepancy, the other Party shall pay Requesting Party the amount of the discrepancy [***] of the date Requesting Party delivers to the other Party such accounting firm’s written report so concluding, or as otherwise agreed upon by the
Parties. The fees charged by such accounting firm shall be paid by Requesting Party unless the underpayment by the other Party [***] ([***]%) of the amount owed for such Calendar Year, in which case the other Party shall pay to Requesting Party the
reasonable fees charged by such accounting firm. 
 (c)    Confidentiality. Each Party shall treat all
information of the other Party subject to review under this Section 8 in accordance with the confidentiality and non-use provisions of this Agreement, and shall cause its accounting firm to enter into an
acceptable confidentiality agreement with the audited Party and any applicable Related Parties, obligating it or them to retain all such information in confidence pursuant to such confidentiality agreement. 

 

	9.	 LICENSES 

9.1    License to I-MAB. 

(a)    Product. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to I-MAB an exclusive, royalty-bearing license (or sublicense, as applicable), with the right to grant sublicenses (subject to Section 9.1(d)), under the MacroGenics Licensed Technology and the MacroGenics
Licensed Trademarks to conduct the Development activities allocated to I-MAB under the Global Development Plan and the Territory Specific Development Plan (subject to MacroGenics’ reserved rights to
conduct Development under Section 9.1(g)), and to Commercialize and otherwise distribute, sell, offer for sale and import the Product in the Field in the Territory during the Term. For clarity, I-MAB
shall not have the right to Manufacture the Product except to the extent approved by the JSC. 
 (b)    Subject to the
terms and conditions of this Agreement, MacroGenics hereby grants to I-MAB an exclusive, royalty-bearing license (or sublicense, as applicable), with the right to grant sublicenses (subject to
Section 9.1(d)), under the MacroGenics Licensed Technology to utilize MGA012 solely as a component of the Combination Regimen in the conduct of the Development activities allocated to I-MAB under the
Global Development Plan and the Territory Specific Development Plan (subject to MacroGenics’ reserved rights to conduct Development under Section 9.1(g)), which for clarity shall include the conduct of one or more Combination Regimen
Study(ies), and, following Regulatory Approval of such Combination Regimen in the Territory, to market and promote such Combination Regimen in accordance with the approved label in the Field in the Territory during the Term. For clarity, I-MAB shall not have the right to (i) Manufacture MGA012 or (ii) to Develop or Commercialize MGA012 as an independent product or as part of any combination product or combination regimen with any product or
compound other than Enoblituzumab. 
 (c)    Notwithstanding anything to the contrary hereunder, with respect to any
MacroGenics Licensed Technology which MacroGenics Controls pursuant to the license granted to MacroGenics from Incyte under the Incyte Agreement, the foregoing sublicenses granted to I- MAB under Sections
9.1(a) and (b) shall be non-exclusive. 

  
 40 

 (d)    Sublicensees. 

(i)    [***], I-MAB shall have the right to grant a sublicense to a Third Party
to Develop or Commercialize a Product in the Territory, provided that [***]. 
 (ii)    [***], I-MAB shall have the right to grant a sublicense to a Third Party [***]. 

(iii)    Each sublicense granted by I-MAB shall be in writing and subordinate to
this Agreement, and I-MAB shall remain responsible to MacroGenics for the compliance of each Sublicensee with the terms and conditions of this Agreement, including with respect to the financial and other
obligations due under this Agreement. I-MAB shall provide a copy of each such sublicense (and all amendments or restatements thereof) to MacroGenics so that MacroGenics can confirm I-MBA’s compliance with the foregoing (which copy may be redacted as necessary to protect confidential or commercially sensitive information, provided, however, that such redaction shall not impede
MacroGenics’ ability to confirm compliance with this Agreement). Each sublicense granted by I-MAB under this Agreement shall permit the conversion of such sublicense to a direct license with MacroGenics
at MacroGenics’ sole option (and discretion) in the event this Agreement is terminated and, upon such conversion, MacroGenics shall be responsible for all former obligations of I-MAB under such
sublicense. I-MAB shall include in each such sublicense a requirement obligating such Sublicensee to cooperate with MacroGenics. 

(e)    Regulatory Approvals. 

(i)    MacroGenics or its designee shall solely hold and exclusively own all Regulatory Approvals in the Territory under
the Global Development Plan (and Regulatory Submissions related to such Regulatory Approvals). I-MAB hereby assigns, transfers and conveys to MacroGenics all of
I-MAB’s (and its Affiliates’ and Sublicensees’) right, title and interest in and to such Regulatory Approvals and Regulatory Submissions related to such Regulatory Approvals such that
MacroGenics shall be the sole owner thereof as specified in this Section 9.1(e)(i); 
 (ii)    To the extent
required or permitted by Applicable Laws and Regulations, I-MAB and MacroGenics or their respective designees shall jointly own and hold all Regulatory Approvals in the Territory under the Territory Specific
Development Plan (and Territory Specific Regulatory Submissions related to such Regulatory Approvals). Subject to the restrictions imposed by the Applicable Laws and Regulations, each Party hereby assigns, transfers and conveys to the other Party one-half (1/2) of its (and its Affiliates’ and Sublicensees’) right, title and interest in and to such Regulatory Approvals and Regulatory Submissions related to such Regulatory Approvals such that I-MAB and MacroGenics shall be equal joint owners thereof as specified in this Section 9.1(e)(ii). 

  
 41 

 (iii)    For any Regulatory Approvals in the Territory under the
Territory Specific Development Plan (and Territory Specific Regulatory Submissions related to such Regulatory Approvals) which the Parties [***] Regulatory Approvals and Territory Specific Regulatory Submissions that MacroGenics is [***] in order
for MacroGenics to be the [***] under the Global Development Plan and (B) [***] of all other such Regulatory Approvals and Territory Specific Regulatory Submissions. Subject to any restrictions imposed by Applicable Laws and Regulations, [***]
Regulatory Approvals and Regulatory Submissions related to such Regulatory Approvals such that I-MAB shall [***]. 

(f)    Limitations. During the Term, I-MAB shall not (either by itself, or
with or through a Related Party or Third Party) (i) Develop or Commercialize the Product or MGA012 or (ii) utilize any Clinical Data or (iii) practice the MacroGenics Licensed Technology outside of the scope of this Agreement. 

(g)    MacroGenics Retained Rights. MacroGenics shall retain the following: (i) the right to Manufacture or
have Manufactured the Product and MGA012 in the Territory, (ii) all rights to conduct non-clinical Development in the Territory and clinical Development in the Territory solely in connection with a
MacroGenics Global Clinical Trial in accordance with Section 3.9; (iii) the right to develop and/or Commercialize MGA012, except as a component of the Combination Regimen, in the Territory, (iii) all rights not otherwise granted to I-MAB and (iv) the right to use any Clinical Data in connection with the Development of a combination of the Product and any PD-1 directed molecule outside the Territory.
For clarity, notwithstanding the licenses granted to I-MAB pursuant to Section 9.1, no right or license is granted by MacroGenics to I-MAB under the MacroGenics
Licensed Technology or MacroGenics Licensed Trademarks with respect to any compound or product covered by such MacroGenics Licensed Technology or MacroGenics Licensed Trademarks, including without limitation, any Other Component of a Combination,
other than Enoblituzumab and solely in accordance with Section 9.1(a) and use of MGA012 solely in accordance with Section 9.1(b). 

9.2    License to MacroGenics. I-MAB hereby grants to MacroGenics a
royalty-free, license outside the Territory, with the right to grant sublicenses (through multiple tiers), under the I-MAB Licensed Patents and I-MAB Licensed Know-How that is incorporated into the Product, and all other intellectual property Controlled by I-MAB that is specifically related to the Product or MGA012 to the extent
useful or necessary for MacroGenics (its Affiliates or licensees) to research, identify, develop, make, have made, use, sell, offer for sale and import the Product, MGA012 or products containing or incorporating MGA012 (whether as a monotherapy,
multi- therapy, combination or otherwise). Such license shall be non-exclusive with respect to the Product and exclusive with respect to MGA012. MacroGenics shall provide a copy of each such sublicense (and
all amendments or restatements thereof) to I-MAB, which copy may be redacted as necessary to protect confidential or commercially sensitive information. 

9.3    Clinical Data Licenses. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to I-MAB a royalty-free license, with the right to grant sublicenses, during the Term to use (a) all Clinical Data and (b) other data Controlled by MacroGenics, as necessary or reasonably useful for I-MAB to exercise its rights and fulfill its obligations under this Agreement, in each case ((a) and (b)) solely with respect to the Development and Commercialization of the Product in the Field in the Territory
hereunder. The limited license granted to I-MAB pursuant to this Section 9.3 shall be co-exclusive (with MacroGenics, its Affiliates and its and their respective
licensees and sublicensees) with respect to the Clinical Data and non-exclusive with respect to any other data. At I-MAB’s request, MacroGenics shall provide a copy
of the foregoing Clinical Data (not already in I-MAB’s possession) on a commercially reasonable schedule to I-MAB. 

  
 42 

 9.4    Negative Covenant. Each Party covenants that, except to
the extent Third Parties generally are lawfully permitted to do so without a granted license from or other contractual right with the other Party, it shall not use or practice any of the other Party’s intellectual property rights licensed to it
under this Section 9 except for the purposes expressly permitted in the applicable license grant. 
 9.5    No
Implied Licenses. Except as explicitly set forth in this Agreement, neither Party grants any license, express or implied, under its intellectual property rights to the other Party. 

9.6    Diversion. 

(a)    I-MAB hereby covenants and agrees that it shall not, either directly or
indirectly, promote, market, distribute, import, sell or have sold the Product or MGA012, including via the Internet or mail order, to any Third Party, address or Internet Protocol address outside of the Territory. 

(b)    If any of I-MAB ’s Product is diverted for use outside the Territory,
the following shall apply: (i) if such Product was diverted by an identifiable customer, distributor, employee, consultant or agent of I-MAB then, upon the request of MacroGenics, I-MAB shall not sell such Product to, or allow the sale of such Product by, any such customer, distributor, employee, consultant or agent for the remaining Term and shall use Commercially Reasonable Efforts to buy
back all such Product from such customer, distributor, employee, consultant or agent [***] of such request from MacroGenics; or (ii) I-MAB shall use Commercially Reasonable Efforts to investigate the
location of such diverted Product and buy it back; but, if and to the extent that, I-MAB elects not to, or is unable to, buy back the applicable diverted Product, then MacroGenics may, in its sole discretion,
buy back the applicable diverted Product, and I- MAB shall reimburse MacroGenics for all reasonable costs incurred by MacroGenics in connection with the buy-back or lost
sales of any such diverted Product. 
  

	10.	 CONFIDENTIALITY; PUBLICATION 

10.1    Nondisclosure Obligation 

(a)    Definition and Restrictions. All Confidential Information disclosed by one Party
to the other Party at any time, including before the Effective Date or after the expiration or termination of this Agreement, shall be maintained in confidence by the receiving Party and shall not be disclosed by the receiving Party to any Third
Party or used by the receiving Party for any purpose except as set forth herein without the prior written consent of the disclosing Party, during the Term and for a period [***], provided that with respect to any Confidential Information of
MacroGenics that constitutes (i) [***], such confidentiality and non-use obligations shall continue beyond [***] for so long as such information [***], or (ii) confidential information of a Third Party to
which MacroGenics has an obligation of confidentiality or non- use, the confidentiality and non-use obligations in this Agreement shall (A) further include such
additional confidentiality and non-use obligations as MacroGenics is required to undertake with respect to such confidential information, and (B) continue beyond [***] for so long as MacroGenics is
required to maintain such confidential information as confidential, in each case ((A) and (B)) pursuant to its agreement with such Third Party (including any MacroGenics Third Party Agreements). The following shall not be deemed Confidential
Information for purposes of the restrictions set forth in this Section 10.1(a): 

  
 43 

 (i)    Information that is known by the receiving Party at the time of
its receipt, and not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records; 

(ii)    Information that is or becomes part of the public domain through no fault of the receiving Party; 

(iii)    Information that is subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is
not under an obligation of confidentiality to the disclosing Party; and 
 (iv)    Information that is developed by the
receiving Party independently of Confidential Information received from the disclosing Party, as documented by the receiving Party’s business records. 

(b)    Combinations. Any combination of features or disclosures shall not be deemed to fall within the exclusions
set forth in Section 10.1(a) merely because individual features are published or available to the general public or in the rightful possession of the receiving Party unless the combination itself and principle of operation are published or
available to the general public or in the rightful possession of the receiving Party. 
 (c)    Permitted
Disclosures. Notwithstanding the restrictions set forth in Section 10.1(a), the receiving Party may disclose Confidential Information of the other Party to: 

(i)    governmental or other regulatory agencies in order to obtain Patents or to gain or maintain approval to conduct
clinical trials or to market the Product, but such disclosure may be only to the extent reasonably necessary to obtain Patents or authorizations; or 

  
 44 

 (ii)    as the receiving Party deems necessary to be disclosed, to its
Affiliates, agents, consultants, or other Third Parties for the Development, Manufacture (with respect to MacroGenics permitted disclosures) or Commercialization of the Product, or in connection with a licensing transaction or contractual obligation
related to the Product or loan, financing or investment or acquisition, merger, consolidation or similar transaction (or for such entities to determine their interest in performing such activities or to determine their rights and obligations as a
result of completing such transactions) or in order to perform its obligations or exercise its rights under this Agreement, in each case on the condition that any Third Parties, other than Regulatory Authorities, to whom such disclosures are made
agree to be bound by confidentiality and non-use obligations substantially similar to those contained in this Agreement; provided that the term of confidentiality and
non-use applicable to such Third Parties shall be [***] (but of shorter duration if customary given the nature of such Person (i.e., investors, lenders and banking institutions; provided that with
respect to any Confidential Information of MacroGenics hereunder that MacroGenics informed I-MAB in writing at or prior to the time of disclosure to I-MAB that such
Confidential Information (either in itself or as a category of information) constitutes confidential information under the Incyte Agreement such shorter duration [***]) from the date of disclosure to I-MAB,
provided further, that with respect to Confidential Information of MacroGenics that constitutes (a) a trade secret, such confidentiality and non-use obligations shall apply for so long as such information
constitutes a trade secret under Applicable Laws and Regulations, or (b) confidential information of a Third Party under a MacroGenics Third Party Agreement, such confidentiality and non-use obligations
shall apply for so long as MacroGenics is required to keep such information confidential under such a MacroGenics Third Party Agreement. Without limiting the foregoing or remainder of this Section 10.1, with respect to Confidential Information
of MacroGenics disclosed to I-MAB hereunder that at the time of disclosure to I-MAB, MacroGenics identifies such confidential information as a trade secret under the
Incyte Agreement, prior to I-MAB disclosing such trade secret to a Third Party (to the extent permitted hereunder), I-MAB shall expressly contractually bind the Third
Party to obligations to keep the trade secret confidential to the extent protected as a trade secret under Applicable Laws and Regulations. 

(d)    Disclosure Required by Judicial or Administrative Process. If a Party is required by judicial or
administrative process to disclose Confidential Information of the other Party that is subject to the non-disclosure provisions of this Section 10.1, such Party shall promptly inform the other Party of
the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject
to the confidentiality and non-use provisions of this Section 10.1, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including
obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information. 

(e)    Obligations Upon Termination. Upon the termination or expiration of this
Agreement, or upon the earlier request of either Party, the receiving Party shall return to the disclosing Party, all of the disclosing Party’s Confidential Information, including all copies thereof, provided that the receiving Party may retain
one copy for archival purposes, and provided further, that a receiving Party shall not be required to destroy electronic files containing such Confidential Information of the disclosing Party that are made in the ordinary course of its business
information back-up procedures pursuant to its electronic record retention and destruction practices that apply to its own general electronic files and information, and any such retained copies shall continue
to be subject to the confidentiality and non-use obligations in accordance with this Agreement. 

  
 45 

 10.2    Publication 

(a)    Publication of Results. I-MAB and MacroGenics each acknowledge the
other Party’s interest in publishing the results of its activities under the Collaboration in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual
interest in obtaining valid patent protection and in protecting business interests and trade secret information. The JSC shall establish procedures for review of publications related to the Collaboration, ensuring that, except for disclosures
permitted pursuant to Section 10.1, either Party and its employees wishing to make a publication related to work performed under this Agreement shall deliver to the other Party a copy of the proposed publication for review. If such publication
will be written, delivery will occur at least [***] ([***] if an abstract) before publication submission. If such publication will be an oral disclosure, delivery of a written outline of the disclosure will occur at last [***] before publication
submission. Publications related to MacroGenics Global Clinical Trials conducted by MacroGenics or its Affiliates or permitted licensees in which the majority of patients reside outside the Territory which shall not be subject to this
Section 10.2. 
 (b)    Review of Publications and Presentations 

(i)    Prior to its publication submission, a Party that receives a publication copy under Section 10.2(a) to review
shall have the right (a) to propose modifications to the publication for patent reasons, trade secret reasons, or for purposes of removing the Confidential Information of the reviewing Party, or (b) to request a reasonable delay in
publication or submission for presentation in order to protect trade secret or patentable information. 
 (ii)    If
the reviewing Party requests the removal of the reviewing Party’s Confidential Information or a delay, the publishing Party shall remove such Confidential Information and if requested by the reviewing Party delay submission for publication or
submission for presentation for a period of [***] to enable patent applications protecting each Party’s rights in such Confidential Information to be filed in accordance with Section 13 below. 

(iii)    Upon expiration of such [***] and satisfaction of any other conditions imposed by the JSC, the publishing Party
shall be free to proceed with the publication or submission for presentation. 
 (iv)    Upon request of the Party
seeking publication, the reviewing Party shall consider expediting the time frames set forth in this Section 10.2. 

(v)    If the reviewing Party requests modifications to the publication or submission for presentation, the publishing
Party shall edit such publication to prevent disclosure of the Confidential Information of the reviewing Party. 

  
 46 

 10.3    Publicity; Use of Names 

(a)    Press Releases. The Parties shall issue a mutually acceptable press release announcing the execution of this
Agreement, substantially in the form of Exhibit H. A Party may issue any subsequent press release relating to this Agreement or activities conducted hereunder upon prior written approval of the other Party, such approval not to be unreasonably
withheld or delayed; provided, however, that no approval of the other Party shall be required if a subsequent press release or securities filing solely discloses the information that (1) a milestone under this Agreement has been achieved or any
payments associated therewith have been received; (2) the filing or approval of a BLA generally has occurred (provided, however, that specific dates of filing shall not be disclosed); (3) initiation of any clinical trial; and
(4) commercial launch of a Product or any information that has previously been approved and disclosed as permitted by this Section 10.3(a). In the case of items (1) to (4) of the preceding sentence, the disclosing Party shall provide
the other Party a copy of such proposed disclosures [***] prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in light of any reporting obligations of such disclosing Party under
Applicable Laws and Regulations, including the rules and regulations promulgated by the United States Securities and Exchange Commission or any other governmental agency. 

(b)    No Other Use of Company Names. Neither Party shall use the name, trademark, trade name or logo of the other
Party or its employees in any publicity or news release relating to this Agreement or its subject matter without the prior express written permission of the other Party. 

(c)    Approved Press Releases. In addition and notwithstanding anything to the contrary herein, (a) if the
relevant text of a proposed press release has already previously been reviewed and approved for disclosure by the other Party then such text may be disclosed or republished in such proposed press release provided that the Party issuing such press
release provides notice to the other Party of such press release [***] prior to the issuance of such press release, where practicable, and (b) if the relevant text of a proposed public announcement such as a corporate presentation or comments
to analysts or investors has already previously been reviewed and approved for disclosure by the other Party (whether in the form of an approved press release or prior approved presentation materials, Q&A script or the like) then such text may
be included in such proposed public announcement (but not a press release) without resubmission and review by the other Party. 

(d)    Existence of Agreement 

(i)    No Disclosure. Neither Party shall disclose the existence or terms of this Agreement pursuant to a press
release or otherwise except as provided in this Section 10.3(d). 
 (ii)    Permitted Disclosures 

(A)    Notwithstanding the terms of this Section 10, either Party shall be permitted to disclose the existence and
terms of this Agreement and the conduct of the Collaboration under this Agreement, to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with Applicable Laws and Regulations, including the rules and
regulations promulgated by the United States Securities and Exchange Commission or any other governmental agency or pursuant to the rules of any recognized stock exchange. The disclosing Party shall take reasonable and lawful actions to avoid or
minimize the degree of such disclosure. 

  
 47 

 (B)    Either Party may also disclose the existence and terms of this
Agreement to its attorneys, accountants and advisors, and to potential acquirors, in connection with a potential acquisition or other change of control transaction and to existing and potential investors or lenders of such Party, as a part of their
due diligence investigations, or to potential licensees or to potential and current permitted assignees in each case under an agreement to keep the terms of this Agreement confidential under terms of confidentiality and non-use substantially similar to the terms contained in this Agreement, provided that the term of confidentiality may be of shorter duration if customary owing to the nature of such Person (i.e., investors,
lenders and banking institutions) and to use such confidential information solely for the purpose of the contemplated transaction. 

(C)    MacroGenics may also disclose the existence and terms of this Agreement pursuant to transactions related to the
research, Development, Manufacture or Commercialization or exploitation of the Product or MGA012 (“Licensing Transactions”), in each case under an agreement to keep the terms of this Agreement confidential under terms of
confidentiality and non-use substantially similar to the terms contained in this Agreement and to use such confidential information solely for the purpose of the contemplated transaction. The transactions
described in Section 10.3(d)(ii)(B) shall not be deemed Licensing Transactions for purposes of this Section 10.3(d)(ii)(C). 
  

	11.	 REPRESENTATIONS AND WARRANTIES 

11.1    Representations and Warranties of MacroGenics. MacroGenics represents and warrants to I-MAB that, as of the Effective Date: 
 (a)    it has the full right, power and
authority to enter into this Agreement, to perform the Collaboration, and to grant the licenses contemplated under Section 9, and the fulfillment of its obligations and performance of its activities hereunder do not materially conflict with,
violate, or breach or constitute a default under any contractual obligation or court or administrative order by which MacroGenics is bound; 

(b)    all necessary consents, approvals and authorizations of all government authorities and other persons required to be
obtained by MacroGenics as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained; 

(c)    it Controls the right, title and interest in and to the MacroGenics Licensed Patents, and has the right to grant to
I-MAB the licenses under such MacroGenics Licensed Patents that it purports to grant hereunder and has not granted any Third Party rights under such MacroGenics Licensed Patents that would interfere or be
inconsistent with I-MAB ’s rights hereunder; 
 (d)    to its knowledge,
except for those licensed or sublicensed under the MacroGenics Third Party Agreements, the MacroGenics Licensed Patents are not subject to any existing royalty or other payment obligations to any Third Party; and 

  
 48 

 (e)    to its knowledge, the issued Patents in the MacroGenics Licensed
Patents are valid and enforceable and it is not aware of any action, suit, inquiry, investigation or other proceeding threatened, pending, or ongoing brought by any Third Party that challenges or threatens the validity or enforceability of any of
the MacroGenics Licensed Patents or that alleges the use of the MacroGenics Licensed Patents or the Development, Manufacture, Commercialization, and use of the Product would infringe intellectual property rights of any Third Party (and it has not
received any notice alleging such an infringement). In the event that MacroGenics receives written notice of any such action or proceeding, it shall notify I-MAB in writing. 

11.2    Representations and Warranties of I-MAB. I-MAB represents and warrants to MacroGenics that as of the Effective Date: 

(a)    it has the full right, power and authority to enter into this Agreement, to perform the Collaboration, to grant the
licenses granted hereunder and the fulfillment of its obligations and performance of its activities hereunder do not materially conflict with, violate, or breach or constitute a default under any contractual obligation or court or administrative
order by which I-MAB is bound; 
 (b)    all necessary consents, approvals and
authorizations of all government authorities and other persons required to be obtained by I-MAB as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been
obtained. 
 (c)    to its knowledge, no I-MAB Licensed Patents or I-MAB Licensed Know- How exists as of the Effective Date that are or would be necessary for the Development, Manufacture or Commercialization of the Product. 

(d)    it Controls the right, title and interest in and to the I-MAB Licensed
Patents and I-MAB Licensed Know-How, and has the right to grant to MacroGenics the licenses that it purports to grant hereunder and has not granted any Third Party
rights that would interfere or be inconsistent with MacroGenics’ rights hereunder; 
 (e)    to its knowledge, the I-MAB Licensed Patents and I-MAB Licensed Know-How are not subject to any existing royalty or other payment obligations to any Third Party; and 

(f)    to its knowledge, the issued Patents in the I-MAB Licensed Patents are
valid and enforceable and it is not aware of any action, suit, inquiry, investigation or other proceeding threatened, pending, or ongoing brought by any Third Party that challenges or threatens the validity or enforceability of any of the I-MAB Licensed Patents or that alleges the use of the I-MAB Licensed Patents or the development, manufacture commercialization and use of the Product would infringe
intellectual property rights of any Third Party (and it has not received any notice alleging such an infringement). In the event that I-MAB becomes aware of any such action or proceeding, it shall immediately
notify MacroGenics in writing. 
 11.3    No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN
THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY
EXPRESSLY EXCLUDED. 

  
 49 

	12.	 INDEMNIFICATION 

12.1    By I-MAB. I-MAB agrees to
indemnify and hold harmless MacroGenics, its Affiliates, and their directors, officers, employees and agents (individually and collectively, the “MacroGenics Indemnitee(s)”) from and against all losses, liabilities, damages and
expenses (including reasonable attorneys’ fees and costs) incurred in connection with any claims, demands, actions or other proceedings by any Third Party (individually and collectively, “Losses”) first arising after the
Effective Date to the extent arising from (a) activities by I-MAB or any of its Affiliates or Permitted Subcontractors with respect to the research, Development, use, Commercialization, import,
distribution, or sale of the Product or any other exercise of their rights or performance of their obligations hereunder, (b) the use by I-MAB or any of its Related Parties or Permitted Subcontractors of
the MacroGenics Licensed Patents or MacroGenics Licensed Know-How, (c) the negligence, illegal conduct or willful misconduct of I-MAB, or (d) I-MAB ’s breach of this Agreement, except to the extent such Losses arise out of any of MacroGenics Indemnitee’s negligence, illegal conduct or willful misconduct, or breach of this Agreement.

 12.2    By MacroGenics. MacroGenics agrees to indemnify and hold harmless I-MAB, its Affiliates, and their directors, officers, employees and agents (individually and collectively, the “I-MAB Indemnitee(s)”) from and against all
Losses to the extent arising from (a) activities by MacroGenics or any of its Affiliates or Permitted Subcontractors with respect to the research, Development, use, Commercialization or sale of the Product for the purpose of Commercialization
or sale of the Product or any other exercise of their rights or performance of their obligations hereunder, (b) the negligence, illegal conduct or willful misconduct of MacroGenics, (c) the use by MacroGenics or any of its Related Parties
or Permitted Subcontractors of the I-MAB Licensed Patents or I-MAB Licensed Know-How, or (d) MacroGenics’ breach of
this Agreement, except to the extent such Losses arise out of any of I-MAB Indemnitee’s negligence, illegal conduct or willful misconduct, or breach of this Agreement. 

12.3    Defense. If any such claims or actions are made, the Indemnitee shall be defended at the Indemnifying
Party’s sole expense by counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnitee, provided that the Indemnitee may, at its own expense, also be represented by counsel of its own choosing. The Indemnifying Party
shall have the sole right to control the defense of any such claim or action, subject to the terms of this Section 12. 

  
 50 

 12.4    Settlement. The Indemnifying Party may settle any such
claim, demand, action or other proceeding or otherwise consent to an adverse judgment (a) with prior written notice to the Indemnitee but without the consent of the Indemnitee where the only liability to the Indemnitee is the payment of money
and the Indemnifying Party makes such payment, provided such settlement would not subject the Indemnitee to an injunction or otherwise adversely impact any of the Indemnitee’s rights under this Agreement or constitute an admission of guilt or
wrongdoing by the Indemnitee, or (b) in all other cases, only with the prior written consent of the Indemnitee, such consent not to be unreasonably withheld. 

12.5    Notice. The Indemnitee shall notify the Indemnifying Party promptly of any claim, demand, action or other
proceeding under Section 12.1 or Section 12.2 and shall reasonably cooperate with all reasonable requests of the Indemnifying Party with respect thereto. 

12.6    Settlement by Indemnifying Party. The Indemnitee may not settle any such claim, demand, action or other
proceeding or otherwise consent to an adverse judgment in any such action or other proceeding or make any admission as to liability or fault without the express written permission of the Indemnifying Party. Provided, however, that such permission
shall not be required if such settlement does not involve (a) any admission of legal wrongdoing by the other Party’s Indemnitee(s), or (b) the imposition of any equitable relief against the other Party’s Indemnitee(s). 

12.7    Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL,
INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 12.7 IS
INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 12, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF CONFIDENTIALITY OBLIGATIONS IN SECTION 10. 

 

	13.	 INVENTIONS; PATENT PROVISIONS 

13.1    Ownership of Intellectual Property 

(a)    Ownership of MacroGenics IP. As between MacroGenics and I-MAB,
MacroGenics shall remain the sole and exclusive owner of all MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and MacroGenics Licensed Know-How that (i) exist as of the Effective Date; or
(ii) that comes into existence after the Effective Date that MacroGenics does not own under Section 13.1(c). 

(b)    Ownership of I-MAB IP. As between
I-MAB and MacroGenics, I-MAB shall remain the sole and exclusive owner of all I-MAB Licensed
Know-How that exists as of the Effective Date; or (ii) that comes into existence after the Effective Date that I-MAB does not own under Section 13.1(c). 

  
 51 

 (c)    Ownership of Collaboration
IP. MacroGenics shall own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting the Collaboration solely by MacroGenics, its Affiliates or its or its Affiliates’
respective consultants or subcontractors, together with all intellectual property rights therein. I-MAB shall own all data (other than Clinical Data, the ownership of which is addressed in Section 3.7),
results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting the Collaboration solely by I-MAB or its Affiliates or its or its Affiliates’ respective
consultants or subcontractors, together with all intellectual property rights therein. MacroGenics and I-MAB shall jointly own all data (other than Clinical Data, the ownership of which is addressed in
Section 3.7), results and inventions, whether patentable or not, conceived or reduced to practice jointly by MacroGenics (or its Affiliates or its or its Affiliates’ respective consultants or subcontractors) on one hand and I-MAB (or its Affiliates or its or its Affiliates’ respective consultants or subcontractors) on the other hand (“Jointly Owned IP”), together with all intellectual property rights therein, with
each Party owning an undivided half interest and the right to exploit without the duty of accounting or seeking consent from the other Party to the extent to be permitted under Applicable Laws and Regulations. 

13.2    Patent and Trademark Filing, Prosecution and Maintenance 

(a)    Overall Strategy. The JSC shall establish an overall strategy for the filing, prosecution and maintenance of
MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and I-MAB Licensed Patents in the Territory. 

(b)    Prosecution 

(i)    The responsibility for Patent Prosecution and Trademark Prosecution related to a Patent or Trademark that is
within the MacroGenics Licensed Patents and MacroGenics Licensed Trademarks or the I-MAB Licensed Patents that is owned solely by a Party shall be the responsibility of such Party, except that (A) I-MAB shall have the right (but not the obligation), at its election and cost and expense, to file, prosecute and maintain, in the name of MacroGenics, MacroGenics Product-Specific Patents and MacroGenics
Licensed Trademarks in the Territory, (B) MacroGenics shall have the right (but not the obligation), at its election and cost and expense, to file, prosecute and maintain, in the name of I-MAB, outside
the Territory, I-MAB Licensed Patents that are specific to the Product (i.e., do not Cover any product that is not a Product, such I-MAB Licensed Patents, the
“I-MAB Product-Specific Patents”) (within the scope of the license granted by I-MAB to MacroGenics pursuant to Section 9.2 outside the Territory).
In accordance with Section 13.2(b)(v) below, MacroGenics shall be responsible for undertaking the Patent Prosecution with respect to Patents jointly owned by the Parties (the “Jointly Owned Patents”) outside the Territory and I-MAB shall be responsible for undertaking the Patent Prosecution with respect to Jointly Owned Patents in the Territory, and each shall do as directed by the JSC. 

  
 52 

 (ii)    In the event that I-MAB
elects not to undertake the Patent Prosecution for the MacroGenics Product-Specific Patents in the Territory, I-MAB shall notify MacroGenics [***] before any such Patent would become abandoned or otherwise
forfeited, and MacroGenics shall have the right (but not the obligation), at its sole cost and expense, to undertake the Patent Prosecution of such MacroGenics Product-Specific Patents. Thereafter, any MacroGenics Product-Specific Patents that are
the subject of such opt-out notice by I-MAB shall cease to be MacroGenics Licensed Patents for all purposes under this Agreement, including for purposes of the license
granted by MacroGenics to I-MAB under Section 9.1. In the event that MacroGenics elects not to undertake the Patent Prosecution for the I-MAB Product- Specific
Patents outside the Territory, MacroGenics shall notify I-MAB [***] before any such Patent would become abandoned or otherwise forfeited, and I-MAB shall have the right
(but not the obligation), at its sole cost and expense, to undertake the Patent Prosecution of such I-MAB Product-Specific Patents outside the Territory. Thereafter, any
I-MAB Product- Specific Patents that are the subject of such opt-out notice by MacroGenics shall cease to be I-MAB Product-Specific Patents for all purposes under this
Agreement, including for purposes of the license granted by I-MAB to MacroGenics under Section 9.2. With respect to Jointly Owned Patents, in the event that the prosecuting Party elects not to undertake
the Patent Prosecution for the Jointly Owned Patents in the Territory (with respect to I-MAB) or outside the Territory (with respect to MacroGenics), the prosecuting Party shall notify the non-prosecuting Party [***] before any such patent rights would become abandoned or otherwise forfeited, and the previously non-prosecuting Party shall have the right (but not
the obligation), to undertake the Patent Prosecution of such Jointly Owned Patents in such territory and become the prosecuting Party therefor. The right to assume Patent Prosecution of a MacroGenics Product-Specific Patent, I-MAB Product-Specific Patent or Jointly Owned Patent shall not apply in the event such a patent application would become abandoned or otherwise forfeited as a result of the prosecuting Party discontinuing Patent
Prosecution of such patent application but also filing a continuation application claiming the same invention or (y) settling an opposition to obtain a license to a competing Patent. 

(iii)    The prosecuting Party shall keep the JSC and the other Party informed of the status of all matters affecting
Patent Prosecution and Trademark Prosecution of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and Jointly Owned Patents in the Territory, and the I-MAB Product-Specific Patents and Jointly
Owned Patents outside the Territory, including providing a copy of all Patent applications filed hereunder and any material correspondence from or with any governmental authorities (including the applicable patent office) to the JSC and the other
Party in sufficient time to allow for review and comment by the non- prosecuting Party, and timely consulting with the non-prosecuting Party and its patent counsel on
the strategy and content of submissions to such governmental authorities in advance of any submissions. Timely advice and suggestions of the non-prosecuting Party and its patent counsel shall be taken into
consideration in good faith by the prosecuting Party and its patent counsel in connection with such filing. With respect to the MacroGenics Product-Specific Patents, I-MAB (if the prosecuting Party) shall
pursue in good faith all reasonable claims requested by MacroGenics for the Territory. 
 (iv)    Any dispute regarding
Patent Prosecution and Trademark Prosecution of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks, I-MAB Product-Specific Patents (outside the Territory only) or Jointly Owned Patents that cannot
be resolved by intellectual property counsel of the Parties, shall be resolved by the JSC. 
 (v)    Without limiting
the generality of the foregoing, MacroGenics shall prosecute and maintain Jointly Owned Patents outside the Territory and I-MAB shall prosecute and maintain Jointly Owned Patents in the Territory, and each
prosecuting Party shall instruct its counsel to provide copies of correspondence and filings directly to the other Party and otherwise permit the other Party to participate with the prosecuting Party in any of the activities of such counsel with
respect to the Patent and Trademark Prosecution of such Jointly Owned Patents. Before taking any material step in the Patent Prosecution or Jointly Owned Patents, the prosecuting Party and its counsel shall allow the other Party a reasonable
opportunity to comment on the action proposed to be taken, and agrees to incorporate in such filings all reasonable comments of the other Party. All Patent Prosecution of Jointly Owned Patents shall be in the names of both MacroGenics and I-MAB. 

  
 53 

 (vi)    I-MAB rights and
obligations under this Section 13.2 with respect to the MacroGenics Licensed Patents are secondary to and shall be subject to any Third Party rights and obligations under the applicable MacroGenics Third Party Agreement. 

(c)    Patent Invalidations. The JSC shall decide whether and how to undertake activities intended to invalidate
pending or issued Third Party Patents in the Territory that cover the composition, use or manufacture of the Product. 
  

	 	13.3	 Costs of Patent and Trademark Prosecution 

(a)    Costs. All out-of-pocket
costs for Patent Prosecution and Trademark Prosecution of a Party’s solely owned Patent or Trademark and for maintaining a Party’s solely owned Patent or Trademark shall be solely incurred by and the sole responsibility of that Party. All out-of-pocket costs for Patent Prosecution of Jointly Owned Patents and for maintaining Jointly Owned Patents in the Territory shall be shared equally by the Parties. In the
event I-MAB assumes the responsibility to conduct the Patent Prosecution of MacroGenics Product-Specific Patents and MacroGenics Licensed Trademarks in the Territory under Section 13.2(b)(i)(A), the costs
of such activities conducted by or on behalf of I-MAB shall be borne solely by I-MAB. In the event MacroGenics assumes the responsibility to conduct the Patent
Prosecution of the I-MAB Product- Specific Patents outside the Territory under Section 13.2(b)(i)(B), the costs of such activities conducted by or on behalf of MacroGenics shall be borne solely by
MacroGenics. 
 13.4    Patent and Trademark Prosecution Cooperation. With respect to all Patent Prosecution and
Trademark Prosecution related to pending or issued Patents and Trademarks included in MacroGenics Licensed Patents in the Territory, MacroGenics Licensed Trademarks in the Territory or I-MAB Product-Specific
Patents, each Party shall: 
 (a)    execute all further instruments to document their respective ownership consistent
with this Agreement as reasonably requested by the other Party; 
 (b)    make its employees, agents and consultants
reasonably available to the other Party (or to the other Party’s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable the appropriate Party hereunder to undertake its Patent Prosecution and Trademark
Prosecution responsibilities; 
 (c)    cooperate, if necessary and appropriate, with the other Party in gaining Patent
and Trademark term extensions; and 
 (d)    endeavor in good faith to coordinate its efforts under this Agreement with
the other Party to minimize or avoid interference with the Patent Prosecution and Trademark Prosecution of the other Party’s Patents and Trademarks. 

  
 54 

	 	13.5	 Enforcement 

(a)    Notice. Promptly, but in no event no [***], a Party after becoming aware of actual or alleged infringement in
the Territory of any Patent or Trademark Controlled by the other Party and subject to a license under Sections 9.1 or 9.2, shall provide such other Party with written notice reasonably detailing such infringement. 

 

	 	(b)	 Enforcement of Intellectual Property Rights 

(i)    Subject to Sections 13.5(b)(ii) and 13.5(b)(iii) below, the sole owner of a Patent, Trademark, Know-How or Confidential Information shall have the exclusive right to institute and direct legal proceedings against any Third Party believed to be infringing such Patent or Trademark or misappropriating or
otherwise violating such Know-How or Confidential Information, provided that any such enforcement of Patents, Trademarks, Know-How or Confidential Information owned by I-MAB that claims, covers or relates to (A) a Product (including a Combination Regimen) outside the Territory or (B) a Combination Regimen in the Territory, shall in each case be mutually agreed by I-MAB and MacroGenics. 
 (ii)    [***] shall have the initial right (but not the
obligation) to institute and direct legal proceedings against any Third Party believed to be infringing Jointly Owned Patents that claims or covers a Product sold [***]. MacroGenics agrees to discuss the foregoing in good faith with I-MAB as it pertains to the Product sold in the Territory. If [***] does not abate such violation of Jointly Owned Patents in the Territory, including by commencement of a lawsuit against the accused person if
necessary, [***] after receiving notice of such infringement of Jointly Owned Patents, then [***] shall be entitled (but shall not be obligated) to take all actions reasonably necessary to abate such violation in the Territory solely with respect to
the Product (excluding any Combination Regimen), including commencement of a lawsuit against the accused Third Party in the Territory if necessary. 

(iii)    [***] shall have the initial right (but not the obligation) to institute and direct legal proceedings against
any Third Party believed to be infringing any MacroGenics Licensed Patent that claims or covers a Product sold within the Territory. If [***] does not attempt to abate such violation [***] of receipt of notice of such infringement, [***] shall be
entitled (but shall not be obligated) to take all actions reasonably necessary to abate such violation, including commencement of a lawsuit against the accused Third Party if necessary. The Party that enforces a MacroGenics Licensed Patent in the
Territory shall have the right to pursue such proceedings with the necessary assistance, at the pursuing Party’s costs, from the non-pursuing Party. 

(iv)    All amounts recovered from enforcement of any such rights by either Party in the Territory relating to the
intellectual property licensed under this Agreement shall be first used to reimburse each Party’s costs and expenses incurred in connection with such action (“Cost Reimbursement Amounts”). For amounts, other than Cost
Reimbursement Amounts, recovered as lost profits by I-MAB for the enforcement of MacroGenics Licensed Patents, I-MAB shall pay MacroGenics any amounts that would have
been due under this Agreement if the Net Sales that correspond to such lost profits were actually made by I-MAB. All amounts, other than Cost Reimbursement Amounts, recovered from enforcement by MacroGenics of
MacroGenics Licensed Patents (whether inside or outside the Territory) and enforcement of jointly owned Patents outside the Territory shall be retained by MacroGenics. 

  
 55 

 (c)    Cooperation in Enforcement Proceedings. For any action by
a Party pursuant to subsection (b) above, in the event that such Party is unable to initiate or prosecute such action solely in its own name, the other Party shall join such action voluntarily and shall execute all documents necessary for such
Party to initiate, prosecute and maintain such action. If either I- MAB or MacroGenics initiates an enforcement action pursuant to Section 13.5(b), then the other Party shall cooperate to the extent
reasonably necessary and at the first Party’s sole expense (except for the expenses of the non-controlling Party’s counsel, if any). Upon the reasonable request of the Party instituting any such
action, such other Party shall join the suit and can be represented in any such legal proceedings using counsel of its own choice. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the
Parties reasonably the subject thereof. 
 (d)    Status; Settlement. The Parties shall keep each other informed
of the status of and of their respective activities regarding any enforcement action pursuant to Section 13.5(b). Neither Party shall settle any litigation or legal proceeding in the Territory to enforce MacroGenics Licensed Patents against a
Third Party selling a Product that [***] or MacroGenics Licensed Trademarks without the other Party’s written authorization. I-MAB will not enter into any settlement of any action described in this
Section 13.5 that admits to the invalidity, unpatentability, narrowing of scope or unenforceability of the MacroGenics Licensed Patents or the Jointly Owned Patents in any manner, incurs any financial liability on the part of MacroGenics or
requires an admission of liability, wrongdoing or fault on the part of MacroGenics, in each case without MacroGenics’ prior written consent. 
  

	 	13.6	 Defense 

(a)    Notice of Allegations. Each Party shall notify the other in writing of any allegations it receives from a
Third Party that the manufacture, production, use, development, sale, offer for sale, import or distribution of any Product or the practice of any MacroGenics Licensed Technology or I-MAB Licensed Patents or I-MAB Licensed Know-How licensed by a Party under this Agreement infringes the intellectual property rights of such Third Party in the Territory. Such notice shall be provided
promptly, but in no event [***], following receipt of such allegations. 
 (b)    Notice of Suit. In the event
that a Party receives notice that it or any of its Affiliates have been individually or collectively named as a defendant (or defendants) in a legal proceeding by a Third Party alleging infringement of a Third Party’s Patents issued in the
Territory as a result of the manufacture, production, use, development, sale or distribution of the Product or any MacroGenics Licensed Technology or I-MAB Licensed Patents or
I-MAB Licensed Know-How licensed by a Party under this Agreement, such Party shall immediately notify the other Party in writing and in no event notify such other Party later than [***] after the receipt of
such notice. Such written notice shall include a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing. Each Party shall assert and not waive the joint defense privilege with respect to all communications
between the Parties reasonably the subject thereof. In such event, the Parties shall agree how best to mitigate or control the defense of any such legal proceeding; provided however, that if either Party or any of its Affiliates have been
individually named as a defendant in a legal proceeding relating to the alleged infringement of a Third Party’s issued Patents in the Territory as a result of the manufacture, production, use, development, sale or distribution of the Product,
the other Party shall be allowed to join in such action, at its own expense. 

  
 56 

 (c)    Status; Settlement. The Parties shall keep
each other informed of the status of and of their respective activities regarding any litigation or settlement thereof initiated by a Third Party in the Territory concerning a Party’s manufacture, production, use, development, sale or
distribution of the Product in the Territory or MacroGenics Licensed Technology or I-MAB Licensed Patents or I-MAB Licensed
Know-How licensed by a Party under this Agreement; provided, however, that no settlement or consent judgment or other voluntary final disposition of a suit under this Section 13.6(c) may be undertaken by
a Party without the consent of the other Party which consent shall not be unreasonably withheld, conditioned or delayed. 
  

	14.	 DISPUTE RESOLUTION 

14.1    Exclusive Dispute Resolution Mechanism. The Parties agree that the procedures set forth in this
Section 14 shall be the exclusive mechanism for resolving any Dispute between the Parties that may arise from time to time pursuant to this Agreement relating to either Party’s rights or obligations hereunder that is not resolved through
good faith negotiation between the Parties. For the avoidance of doubt, this Section 14 shall not apply to any decision with respect to which a Party has final decision-making authority hereunder. Any Dispute, including Disputes that may
involve the parent company, subsidiaries, or Affiliates under common control of any Party, shall be resolved in accordance with this Section 14. 

14.2    Resolution by Executive Officers. Except as otherwise provided in this Section 14, in the event of any
Dispute regarding the construction or interpretation of this Agreement or the rights, duties or liabilities of either Party hereunder, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation between
themselves. In the event that such Dispute is not resolved on such basis [***] (unless otherwise agreed by the Parties) after being submitted to the JSC, either Party may, by written notice to the other Party, refer the Dispute to the Executive
Officer of each Party for attempted resolution by good faith negotiation [***] after such notice is received (unless otherwise agreed by the Parties). Each Party may, in its discretion, seek resolution of any and all Disputes that are not resolved
under this Section 14.2 in accordance with Section 14.3. 
 14.3    Arbitration. If the Parties fail to
resolve the Dispute pursuant to Section 14.2, and a Party desires to pursue resolution of the Dispute, the Dispute shall be referred to and finally resolved by arbitration administered by the Singapore International Arbitration Centre
(“SIAC”) in accordance with the Arbitration Rules of the Singapore International Arbitration Centre (“SIAC Rules”) for the time being in force, which rules are deemed incorporated by reference in this clause. The
seat of the arbitration shall be in Singapore, and the arbitration tribunal shall consist of three arbitrators, of whom each Party shall designate one in accordance with the appointment procedures provided in the SIAC Rules and the chairs shall be
selected by the tribunal in accordance the SIAC Rules. The language of the arbitration shall be English. 

  
 57 

 14.4    Costs of Dispute Resolution. Each Party shall be solely
responsible for the costs it incurs to resolve a Dispute except for the costs of engaging arbitrators which shall be shared equally by the Parties. 
  

	15.	 TERMS AND TERMINATION 

15.1    Term. Unless earlier terminated, this Agreement shall continue in effect until the expiration of the
Royalty Term as defined in Section 1.128 (“Term”), and thereafter I-MAB has no remaining payment obligations with respect to the Product pursuant to Section 7.3 above and MacroGenics
shall have no further obligations hereunder. 
 15.2    Termination for Challenge to Patent Validity. MacroGenics
may terminate this Agreement immediately upon written notice to I-MAB in the event I-MAB or any of its Affiliates: 

(a)    directly or indirectly oppose, or assist any Third Party to oppose, in any patent office proceeding, the grant of
any patent or patent application within the MacroGenics Licensed Patents, or, in any patent office proceeding, dispute or directly or indirectly assist any Third Party to dispute, the validity of any patent within the MacroGenics Licensed Patents or
any of the claims thereof, including opposing any application for amendment thereto; 
 (b)    directly or indirectly
oppose, or assist any Third Party to oppose, in any court proceeding, the grant of any patent or patent application within the MacroGenics Licensed Patents, or, in any court proceeding, dispute or directly or indirectly assist any Third Party to
dispute, the validity of any patent within the MacroGenics Licensed Patents or any of the claims thereof; or 

(c)    bring any claim or proceedings of whatever nature in relation to the MacroGenics Licensed Patents against
MacroGenics or any of MacroGenics’ Affiliates (or in respect of the foregoing their directors and officers) in respect of any activities carried out by them under any MacroGenics Licensed Patents which may be the subject of a Valid Claim of the
MacroGenics Licensed Patents. 
 15.3    Termination for Cause. This Agreement may be
terminated as a whole, or in part, at any time during the Term upon written notice by either Party if the other Party is in material breach of its obligations under this Agreement and, in each case, has not cured such breach within [***] after
notice requesting cure of the breach (other than for non-payment which shall be cured within [***]). 

15.4    Termination for Convenience. At any time after the [***], I-MAB may
terminate this Agreement in its entirety for any or no reason upon [***] written notice to MacroGenics. 

15.5    Termination for Safety or End of
Global Development. This Agreement may be terminated in its entirety or on a Product-by-Product or region-by-region basis by either Party upon [***] written notice to the other Party if it reasonably determines in good faith that there is a Major Safety Issue with respect to a Product. 

15.6    Termination for Force Majeure. This Agreement may be terminated at any time during the Term upon written
notice by either Party in accordance with Section 16.1. 

  
 58 

	 	15.7	 Effect of Termination. 

(a)    If MacroGenics terminates this Agreement pursuant to Sections 15.2, 15.3 (for cause based on material breach by I-MAB) or 15.5 or if I-MAB terminates this Agreement pursuant to Section 15.4: 

(i)    I-MAB shall pay any amounts due pursuant to Section 3.5 and
Section 7 prior to the date of termination; 
 (ii)    For the avoidance of doubt, the licenses and sublicenses
granted to I-MAB under Sections 9.1(a) and 9.3 and any agreement entered into between the Parties with respect to I-MAB’s Manufacture of the Product for or in the
Territory shall terminate; 
 (iii)    The license granted to MacroGenics under Section 9.2 shall survive and
shall automatically, without any action on the part of either Party, expand to become exclusive and worldwide; 
 (iv)    I-MAB shall return to MacroGenics or its designee all Product and all MGA012 within its possession or control and arrange for the I-MAB
Sublicensees to return to MacroGenics or its designee all Product and MGA012 within such I-MAB Sublicensees’ possession or control; 

(v)    I-MAB shall cease to Develop and Commercialize the Product, including
immediately stopping enrollment of subjects (unless otherwise directed in writing by MacroGenics) into any Clinical Trial being conducted by the Parties and at MacroGenics’ sole election either wind-down (including to cease administering the
Product to Clinical Trial subjects and conducting Clinical Trial procedures on Clinical Trial subjects, to the extent medically advisable) or transition to MacroGenics (or its designee) any Clinical Trial then be conducted by I-MAB, but in all cases in a timely manner and in accordance with all Applicable Laws and Regulations; 

(vi)    I-MAB shall cease all marketing and promotion of MGA012 as a component of
a Combination Regimen; 
 (vii)    for the Product, to the extent not already owned and possessed by MacroGenics, I-MAB shall assign and promptly transfer to MacroGenics, at no expense to MacroGenics, all of I-MAB ’s right, title and interest, if any, in and to (A) all
Regulatory Submissions (such as Regulatory Approvals, INDs, BLAs, NDAs, and drug master files) and CTAs (to the extent assignable and not cancelled) for the Product, to the extent that MacroGenics elects to continue development of the Product;
(B) all data, including clinical data, materials and information of any kind or nature whatsoever, in I-MAB’s possession or in the possession of its Affiliates or its or their respective agents
related to the Product; (C) all trademarks related to the Product (if such termination occurs after approval of such trademark by a Regulatory Authority); and (D) all material information, and any other information reasonably requested and
required by MacroGenics, relating to the manufacture of the Product; 

  
 59 

 (viii)    all sublicenses under the rights granted pursuant to
Section 9.1(b) shall terminate, unless converted to a direct license at MacroGenics’ sole option under Section 9.1(b); and 

(ix)    MacroGenics shall revoke (and I-MAB shall allow revocation of) any powers
of attorney for any MacroGenics Licensed Patents that I-MAB holds as of the time of such termination; and 

(b)    If I-MAB terminates this Agreement pursuant to Sections 15.3 (for cause
based on material breach by MacroGenics) or 15.5: 
 (i)    The provisions of Section 15.7(a) (other than
Section 15.7(a)(iii)) shall apply; 
 (ii)    I-MAB shall revoke (and
MacroGenics shall allow revocation of) any powers of attorney for any I-MAB Licensed Patents that MacroGenics holds as of the time of such termination; and 

With respect to the license granted to MacroGenics under Section 9.2, (A) if termination is by I-MAB pursuant to
Section 15.3, then such license shall terminate in its entirety or (B) if termination is by I-MAB pursuant to Section 15.5, then such license shall terminate only with respect to the Territory
and shall otherwise survive outside the Territory. 
 (c )    Return of Confidential Information.
Upon expiration or termination of this Agreement, the Parties shall comply with Section 10.1(e). 

15.8    Survival. The following provisions shall survive the termination or expiration of this Agreement for any
reason: Sections 1, 3.7, 3.8, 3.9, 4.4, 5.4 (with respect to information reasonably requested by MacroGenics to fulfill its obligations to its Third Party licensors related to activities pursuant to this Agreement after termination hereof) 6, 7, 8,
9.2, 9.4, 10, 11, 12, 13, 14, 15.7, 15.8 and 16. 
  

	16.	 MISCELLANEOUS 

16.1    Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have
defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party including
embargoes, war, acts of war (whether war be declared or not), insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental
authority or the other Party (“Force Majeure”). The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to
cure such force majeure circumstances. In the event a Party is unable to perform its obligations under this Agreement due to Force Majeure for a period of [***], the other Party shall have the option of unilaterally terminating this Agreement upon
providing [***] written notice. 

  
 60 

 16.2    Section 365(n) of the Bankruptcy Code. All rights and
licenses granted under or pursuant to any Section of this Agreement are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under
Section 101(35A) of the U.S. Bankruptcy Code. The Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. The Parties agree that a Party that is a licensee of such rights under
this Agreement shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against the licensing Party (such Party, the “Involved
Party”) under the U.S. Bankruptcy Code, the other Party (such Party, the “Noninvolved Party”) shall be entitled to a complete duplicate of or complete access to (as such Noninvolved Party deems appropriate), any such
intellectual property and all embodiments of such intellectual property, provided the Noninvolved Party continues to fulfill its payment or royalty obligations as specified herein in full. Such intellectual property and all embodiments thereof shall
be promptly delivered to the Noninvolved Party (a) upon any such commencement of a bankruptcy proceeding upon written request therefor by the Noninvolved Party, unless the Involved Party elects to continue to perform all of its obligations
under this Agreement or (b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Involved Party upon written request therefor by Noninvolved Party. The foregoing is without prejudice to any rights
the Noninvolved Party may have arising under the U.S. Bankruptcy Code or other Applicable Laws and Regulations. 

16.3    Assignment. Neither Party may assign its rights and obligations under this Agreement without the prior
written consent of the other Party, provided that either Party may assign its rights and obligations under this Agreement, without such consent from the other Party, to any successor in interest in connection with the sale of all or substantially
all of the assets of the assigning Party or a merger, acquisition or other similar transaction that involves the sale of the assigning Party’s entire business. In addition, MacroGenics may assign this Agreement without the prior written consent
of I-MAB to any MacroGenics Affiliate or any successor in interest in connection with the sale of substantially all of MacroGenics’ business related to a Product. Except in the specific circumstances set
forth in this Section 16.3, any assignment undertaken by an assigning Party without the prior written consent of the other Party in violation of this Section 16.3 shall be void. For the avoidance of doubt, the terms and conditions of this
Agreement shall be binding on the permitted successors and assignees of each Party. 
 16.4    Severability. If
any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or
impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s)
with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement. 

  
 61 

 16.5    Notices. All notices which are required or permitted
hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by
registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
  

			
	if to MacroGenics, to:	  	[***]
		  	Attention: [***]
		  	Facsimile: [***]
		
	with copy to:	  	[***]
	(which shall not constitute notice)	  	
		  	Attention: [***]
		
	if to I-MAB, to:	  	I-MAB Biopharma, Inc.
		  	[***]
		  	China Attn: [***]
		  	E-Mail: [***]
		
	with copy to:	  	Venture Partner, LLC
		  	[***]
		  	Attn: [***]
		  	E-Mail: [***]

 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. Any such notice shall be deemed to have been given upon receipt. 
 16.6    Applicable Law.
All questions of inventorship shall be determined in accordance with U.S. patent laws. In respect to all other Patent issues related to the enforceability or validity of a Patent, the laws of the jurisdiction in which the applicable Patent is filed
or granted shall govern. Except as otherwise indicated, in all other respects, the right and obligations of the Parties under this Agreement shall be governed by and construed in accordance with the laws of the State of New York, United States. 

16.7    Entire Agreement; Amendments. The Agreement contains the entire understanding of the Parties with respect
to the subject matter hereof, including the Collaboration and licenses granted hereunder. All express or implied agreements and understandings, either oral or written, with regard to the subject matter hereof, including the Collaboration and the
licenses granted hereunder, are superseded by the terms of this Agreement, including the Existing CDA. The Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both
Parties hereto. The “Existing CDA” means that certain Confidentiality Agreement between the Parties [***]. Any confidential information disclosed by the Parties pursuant to the Existing CDA shall be deemed to constitute Confidential
Information under this Agreement. 
 16.8    Headings. The captions to the several Sections hereof are not a part
of the Agreement, but are merely for convenience to assist in locating and reading the several Sections and Sections of this Agreement. 

  
 62 

 16.9    Independent Contractors. It is expressly agreed that
MacroGenics and I-MAB shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither MacroGenics nor I-MAB shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other
Party. 
 16.10    Waiver. The waiver by either Party of any right hereunder, or the failure of the other Party
to perform, or a breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. 

16.11    Cumulative Remedies. No remedy referred to in this Agreement is intended to be exclusive, but each shall
be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

16.12    Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection
with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

16.13    Counterparts. The Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
 16.14    Further Assurances.
Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and
instruments, as may be necessary or as the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and
remedies under this Agreement. 
 16.15    Construction. Any reference in this Agreement to an Article, Section,
subsection, paragraph, clause or Schedule shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause or Schedule, of or to, as the case may be, this Agreement. The captions of this Agreement are for convenience of
reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. Except where the context otherwise requires, (a) any definition of or reference to
any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth
herein or therein), (b) any reference to any Applicable Law refers to such Applicable Law including all rules and regulations thereunder and any successor Applicable Law, in each case as from time to time enacted, repealed or amended, (c) the words
“herein,” “hereof” and “hereunder,” and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof, (d) the words “include,” “includes,” and
“including” shall be deemed to be followed by the phrase “but not limited to,” “without limitation” or words of similar import, (e) the word “or” is used in the inclusive sense (and/or), (f) words in the
singular or plural form include the plural and singular form, respectively, (g) references to any gender refer to each other gender, (h) references to a particular Person include such Person’s successors and assigns to the extent not
prohibited by this Agreement, and (i) a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein shall be interpreted in a correlative manner. 

[Signature Page Follows.] 

  
 63 

 The Parties have caused this Agreement to be executed by their duly authorized
representatives as of the Effective Date. 
  

			
	    I-MAB Biopharma, US Limited	  	MacroGenics, Inc.
	/s/ I-MAB Biopharma, US Limited	  	/s/ MacroGenics, Inc.

  
 64 

 Exhibit A 

MacroGenics Licensed Patents 
 [***]

  
 65 

 Exhibit B 

MacroGenics Licensed Trademarks 
 [***]

  
 66 

 Exhibit C 

Global Development Plan 
 [***] 

  
 67 

 Exhibit D 

Territory Specific Development Plan 
 [***]

 Exhibit E 

MacroGenics-Provided Information 

MacroGenics will use Commercially Reasonable Efforts to provide the items required by the applicable Regulatory Authority to conduct the Territory Specific
Development Plan, which may include the items listed below. Such items will be provided as soon as reasonably practicable based on a format and timetable to be mutually agreed upon by the Joint Steering Committee. 

[***] 

 Exhibit F 

SAFETY MANAGEMENT PLAN COMPONENTS 
 [***]

 Exhibit G 

Product Royalty Rates 
  

			
	
Aggregate Net Sales threshold of the Product in the 
Territory:
	  	Then the Product Royalty Rate
Percentage shall be (%):
	 On that portion of aggregate Net Sales in a Calendar Year less than [***]
	  	[***]
	 On the portion of Net Sales in a Calendar Year equal to or greater than [***] but less than
[***]
	  	[***]
	 On that portion of Net Sales in a Calendar Year greater than [***]
	  	[***]

 For purposes of determining when the Calendar Year Net Sales thresholds as set forth above have been met, Calendar Quarter Net
Sales shall be converted from local currency in the Region or Country in the Territory into U.S. Dollars using the exchange rate set forth in Section 7.8 when calculating the amount of payment of royalties due and the converted Calendar Quarter
Net Sales amounts for the four Calendar Quarters in a Calendar Year will be used to determine whether the annual Net Sales thresholds have been met. 

 Exhibit H 

Form of Press Release 
 MacroGenics and
I-Mab Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Enoblituzumab in Greater China 

ROCKVILLE, MD, and SHANGHAI, China, July 9, 2019 (GLOBE NEWSWIRE) – MacroGenics, Inc. (NASDAQ: 

MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of
cancer, and I-Mab Biopharma (I-Mab), a China and U.S.-based clinical-stage biopharmaceutical company committed to the discovery and development of first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases,
announced today that the companies have entered into an exclusive collaboration and license agreement to develop and commercialize enoblituzumab. This investigational drug is an immune- optimized, anti-B7-H3 monoclonal antibody that incorporates MacroGenics’ proprietary Fc Optimization technology platform. Enoblituzumab represents one of the most advanced programs in development directed against B7-H3, a target for which no agent is currently approved. I-Mab obtains regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan. 

As part of the collaboration, I-Mab will both lead regional studies in its territories as well as participate in
global studies conducted by MacroGenics. MacroGenics intends to initiate a Phase 2 study of enoblituzumab in combination with MGA012 (also known as INCMGA0012), an investigational
anti-PD-1 antibody that MacroGenics licensed to Incyte Corporation, in first-line patients with head and neck cancer later this year. 

“We are very pleased to be partnering with I-Mab to further accelerate and broaden the development of
enoblituzumab and to support our mission of bringing innovative medicines to patients with high unmet medical needs,” said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics. “We believe that I-Mab is an ideal partner given its track record of rapidly progressing innovative immuno-oncology programs and its ability to tap into the growing pharmaceutical market in this region.” 

“MacroGenics is recognized as a leader in the development of therapeutics targeting B7-H3 and we are committed to
accelerating the development of enoblituzumab, a promising investigational drug which may represent a new treatment paradigm in immuno-oncology,” said Jingwu Zang, M.D., Ph.D., Chief Executive Officer of
I-Mab. “We believe that this program is an exciting addition to our innovative pipeline of clinical stage oncology assets.” 

MacroGenics expects to receive an upfront payment of $15 million in connection with the collaboration. MacroGenics will also be eligible to receive
additional development and regulatory milestone payments of up to $135 million. In addition, I-Mab will pay tiered double-digit royalties (ranging from mid teens to twenty percent) based on annual net
sales in its territories. 

 About Enoblituzumab Program 

Enoblituzumab is an investigational Fc-optimized monoclonal antibody that targets
B7-H3, a member of the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the
immune response to various types of cancer. 
 Encouraging data from the Phase 1 clinical study of enoblituzumab in combination with an anti-PD-1 antibody were presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2018. Based on these data, MacroGenics is planning to initiate a
Phase 2 study of enoblituzumab in combination with MGA012 in patients with squamous cell carcinoma of the head and neck (SCCHN) in the second half of 2019. 

About MacroGenics’ Fc-Optimization Technology 

MacroGenics’ Fc-Optimization platform is designed to modulate an antibody’s interaction with immune effector
cells. The Fc region of certain antibodies binds activating and inhibitory receptors, referred to as FcgRs, on immune cells found within the innate immune system. Such interactions affect killing of
cancer cells through antibody dependent cellular cytotoxicity (ADCC), among other Fc-dependent functions. 

MacroGenics’ optimized Fc region binds with increased affinity to the activating CD16A FcgR and unique to
MacroGenics’ technology, with reduced affinity to CD32B, the inhibitory FcgR. MacroGenics’ optimized Fc mediates improved effector functions, such as ADCC. To date, MacroGenics has successfully
incorporated its proprietary Fc Optimization technology in enoblituzumab, as well as margetuximab, an investigational anti-HER2 monoclonal antibody currently in Phase 3 development. 

About MacroGenics, Inc. 
 MacroGenics is a clinical-stage
biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of
next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. For more information, please see the Company’s website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks
or registered trademarks of MacroGenics, Inc. 
 About I-Mab Biopharma 

I-Mab is a dynamic and fast-growing global biotech company focusing on developing innovative biologics of first-in-class and best-in-class potential in the therapeutic areas of immuno-oncology and
autoimmune diseases. I-Mab’s pipeline of clinical and pre-clinical stage assets is driven by the company’s Fast-to-Market and Fast-to-PoC development strategies through internal R&D capabilities and global partnerships. I-Mab’s vision is to address unmet needs through drug innovation in the target therapeutic areas in China and the world. I-Mab is on track to become an end-to-end fully integrated biopharma company. The company is well-recognized by capital markets to have successfully raised approximately $370 million USD in the past
three years, with the recent $220 million USD Series C financing representing one of the largest amounts ever raised by an innovative biotech company in China. For more information, please see the company’s website at www.i-mabbiopharma.com. 

 MacroGenics’ Cautionary Note on Forward-Looking Statements 

Any statements in this press release about future expectations, plans and prospects for MacroGenics, including statements about the company’s strategy,
future operations, clinical development of the company’s therapeutic candidates, milestone or opt-in payments from the company’s collaborators, the company’s anticipated milestones and future
expectations and plans and prospects for the company and other statements containing the words “subject to”, “believe”, “anticipate”, “plan”, “expect”, “intend”, “estimate”,
“project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements
as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical
trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of MacroGenics’ product candidates and other risks described in the company’s filings with the Securities and Exchange
Commission. In addition, the forward-looking statements included in this press release represent MacroGenics’ views only as of the date hereof. MacroGenics anticipates that subsequent events and developments will cause the company’s views
to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements
should not be relied upon as representing MacroGenics’ views as of any date subsequent to the date hereof. 
 MacroGenics Contacts: 

Jim Karrels, Senior Vice President, CFO 
 Anna Krassowska, Ph.D.,
Vice President, Investor Relations & Corporate 
 Communications MacroGenics, Inc. 

1-301-251-5172, info@macrogenics.com

 I-Mab Biopharma Contacts: 

Jielun Zhu, CFO 

jielun.zhu@i-mabbiopharma.com 

Amanda Dai, Associate Director of Public 
 Relation zhenhua.dai@i-mabbiopharma.com 
 Weimin Tang, EVP and Head of Global Business 

Development Weimin.tang@i-mabbiopharma.com

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]